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Abstract 
Introduction: Robust epidemiological data on the incidence of myocardial infarction (MI) are 
hard to find, but synthesis of data from a number of sources indicates that the average 
hospital in the UK should admit about two patients with a first MI and one recurrent MI per 
1000 population per year. Although age-adjusted incidence may be declining, this may be 
offset by greater longevity in the general population. The incidence of acute coronary 
syndromes (ACS) is much higher. The incidence and outcome of both ACS and of MI will 
depend greatly on how data are collected. 
The cumulative incidence, persistence and resolution of heart failure (HF) after an MI in the 
general population are poorly described. Cardiac dysfunction subsequent to MI is a common 
cause for morbidity and mortality, however, there are few data on what proportion of long-
term survivors of MI has important cardiac dysfunction and/or HF.   
The aim of this thesis is to describe the incidence and outcome of MI in the general 
population and in different age groups, explain the natural history and prognosis of HF after 
an MI both during the index admission and long-term (6 year) follow-up in relationship to the 
presence of HF and also to determine the utility of amino-terminal pro-brain natriuretic 
peptide (NT-proBNP) alone and in conjunction with other clinical data, as a marker of left 
ventricular systolic dysfunction (LVSD) and subsequent prognosis in long-term survivors of 
MI. Subgroup data according to age and anaemia will also be reported. 
Methods: Patients with a death or discharge diagnosis of MI in 1998 were identified from 
records of hospitals providing services to a local community of 560,000 people. Records 
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were scrutinized to identify the development of HF, defined as symptoms and signs 
consistent with that diagnosis and treated with loop diuretics. HF was considered to have 
resolved if diuretics could be stopped without recurrent symptoms. Analyses were done on 
the whole population and then sub-groups by age (<65, 65-75 and >75 years) and anaemia 
status. Anaemia was defined according to WHO criteria (men haemoglobin (Hb)<13; women 
Hb<12 g/dL) and categorized as definite (>1 g below threshold), borderline (within 1g of 
threshold) and (>1g above threshold).  
In 2004, surviving patients were invited to attend for clinical assessment, an echocardiogram 
and measurement of NT-proBNP and were subsequently followed until 31st December 2009 
using medical records.  
Also in 2005, another group of patients admitted with ACS to cardiology or general medical 
wards were identified prospectively by trained nurses from 1st January to 31st December 
2005. Patients with a death or discharge code of MI were also identified by the hospital 
information department and from Myocardial Infarction National Audit Project (MINAP) 
records.  
Results: For the first cohort, 896 patients were identified of whom 54% had died by 
December 2005. During the index admission, 199 (22%) patients died, many with HF, and a 
further 182 (20%) patients developed HF that persisted until discharge, of whom 121 died 
subsequent to discharge. Of 74 patients with transient HF that resolved before discharge, 41 
had recurrent HF and 38 died during follow-up.  After discharge, 145 (33%) patients 
developed HF for the first time, of whom 76 died during follow-up. Overall, of 281 deaths 
occurring after discharge, of which 235(84%) were amongst patients who first developed HF.  
Of 896 patients, 311 were aged <65, 297 aged 65-75 and 288 aged >75 years of whom, 
respectively, 24%, 57% and 82% had died by December 2005. During the index admission, 
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by age group, 24 (8%), 68 (23%) and 107 (37%) patients died in each group, many with HF, 
and a further 37 (12%), 63 (21%) and 82 (29%) developed HF that persisted until discharge. 
After discharge, 53 (24%), 55 (40%) and 37 (47%) patients developed HF for the first time. 
Overall, of 51, 102 and 128 deaths occurring after discharge, 35 (70%), 93 (91%) and 107 
(85%) were among patients who first developed HF. 
Of 855 patients with an available hemoglobin during index admission, 103 were anaemic, 
280 were borderline and 472 were not anaemic based on the first available haemoglobin 
during the index admission. 300 patients had more than one measurement of haemoglobin, of 
which 125 (85 unchanged status from first assessment) had definite, 289 (237 unchanged) 
had borderline and 441 (424 unchanged) had no anaemia on the last available measurement. 
During the index admission, 77 patients (75%) with definite, 130 (46%) with borderline and 
196 (42%) who had no anaemia on the first available haemoglobin developed HF, of whom 
41 (53%), 50 (38%) and 60 (31%) died during the admission compared, respectively, to 7 
(27%), 14 (9%) and 9 (3%) deaths in patients who did not develop HF. During a six year 
follow-up, 543 (64%) patients developed HF and 456 (53%) died. Amongst patients with HF 
during the index admission, the six year mortality rates in those with definite, borderline and 
no anaemia (last available index admission measurement) were, 90%, 84% and 64% 
(P=0.0001). In patients without HF on the index admission, 6-year mortality rates were 62%, 
42% and 24% (P=0.0001). Anaemia (last available index admission measurement) predicted 
all-cause mortality independent of the presence of HF (p=0.055). 
451 had died by 2004 and only 414 were available for follow-up, of whom 175 patients 
attended and had NT-proBNP measured. Of these, 51 (29%) patients had LVSD, 66 (38%) 
had NT-proBNP >50pmol/L (423pg/ml), 86 (49%) had one or the other and 31 (18%) had 
both. Patients with higher NT-proBNP were more likely to have HF (and be treated with 
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diuretics), LVSD (and therefore treatment with ACE inhibitors), a dilated atrium, substantial 
mitral regurgitation and atrial fibrillation (and therefore treatment with warfarin and digoxin) 
(p=0.0001). Thirty six patients died during follow-up; 28 (42%) with an NT-proBNP 
>50pmol/L (423pg/ml) (77% of all deaths). ROC curves suggested that NT-proBNP 
56pmol/L (474pg/ml) had the highest sensitivity (78%) and specificity (77%) for predicting 
death (AUC 0.78). Echocardiography added little to the prognostic information provided by 
NT-proBNP alone. 
In 2005, the prospective survey identified 1,731 admissions (1,439 patients) with ACS, of 
which 764 (704 patients) were for MI. The hospital information department reported only 552 
admissions (544 patients) with MI and only 206 admissions (203 patients) were reported to 
MINAP. Using all three data-bases, 934 admissions (873 patients) for MI were identified, for 
which TnT was >1ug/L in 443, 0.04 to 1.0 in 435, <0.03 in 19 and not recorded in 37. A 
further 823 patients had plasma troponin T >0.03ug/L but did not have ACS ascertained by 
any survey method. Of 873 patients with MI, 146 died during admission (17% versus 22% in 
the 1998 cohort) and 218 by one year. 
Conclusion: The incidence of ACS/MI is highly dependent on the methodology for case-
ascertainment and the method used to identify cardiac damage (for instance the sensitivity of 
the troponin assay used). The development of HF precedes death in most patients who die in 
the short- or longer-term following an MI. The risk of developing HF and dying after an MI 
increases progressively with age and anaemia. In patients with a remote history of MI, 
elevated NT-BNP identifies patients with a high prevalence of LVSD. Regardless of age, 
most deaths are preceded by the development of HF. Anaemia is associated with a high 
mortality even in the absence of HF.  
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Prevention of HF, by reducing the extent of myocardial damage and recurrent MI and by 
subsequent good management could have a substantial impact on prognosis.  
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1 Chapter 1: The Development and Natural History of Heart 
Failure (HF) after Myocardial Infarction (MI) 
1.1 Introduction 
The aim of this thesis is to describe the incidence and timing of onset, persistence, resolution 
of heart failure developing after an acute myocardial infarction and its relationship to 
mortality both during and subsequent to the index admission for myocardial infarction. 
Although heart failure is a well recognised complication of myocardial infarction and one 
that is associated with a poor prognosis, very little is known about the natural history of heart 
failure after a myocardial infarction beyond these basic facts. Estimates of the incidence of 
myocardial infarction are inconsistent, depending highly on the diagnostic criteria applied 
and the method of case-ascertainment. Estimates of the incidence of heart failure after 
myocardial infarction are also inconsistent and usually confined to groups of patients who 
have survived to discharge and been managed by a cardiologist. There are few reports about 
what proportion of cases resolve or of the late development of heart failure and its 
relationship to recurrent ischaemic events. Conventionally, heart failure due to myocardial 
infarction is thought to be related to the size of the infarction. Large infarcts lead to the loss 
of a greater mass of myocardium with a reduction in ventricular contractility and greater 
adverse remodelling leading to a decline in left ventricular ejection fraction and left 
ventricular systolic dysfunction. The size of the infarct will depend on the coronary anatomy 
(patients with proximal coronary lesions subtending a large volume of myocardium are more 
likely to have large myocardial infarctions; proximal disease in the left anterior descending or 
left main coronary artery giving rise to the largest infarcts) amount of collateral blood flow, 
whether coronary artery occlusion is persistent or intermittent, reperfusion within a narrow 
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time window and the sensitivity of the cardiac myocytes to ischaemia. Factors such as left 
ventricular hypertophy may predispose to greater loss of myocytes. Anterior myocardial 
infarctions may be more likely to give rise to heart failure not only because they tend to cause 
larger infarctions but because they affect the left ventricular free wall which may be most 
likely to undergo adverse left ventricular remodelling [1]. 
However, the incidence of heart failure appears much greater than the incidence of left 
ventricular systolic dysfunction. It is unknown whether heart failure or left ventricular 
systolic dysfunction is of greater prognostic significance. Heart failure may occur subsequent 
to a myocardial infarction for many reasons. Some patients will have pre-existing cardiac 
dysfunction and heart failure. Pre-existing dysfunction may reflect prior damage from 
coronary disease leading to predominantly systolic dysfunction. However, chronic 
hypertension can lead to left ventricular hypertophy, increased myocardial collagen content 
and diastolic myocardial dysfunction. Super-imposition of damage from myocardial 
infarction may cause heart failure when there is only a modest decline in left ventricular 
systolic function. Myocardial infarction may cause papillary muscle dysfunction and mitral 
regurgitation. More rarely, myocardial infarction may cause rupture of the inter-ventricular 
septum which is usually a catastrophic event with a high mortality. 
Ventricular function probably improves more often than it declines in the aftermath of an 
acute myocardial infarction. A myocardial infarction can be considered to consist of an inner 
zone of irrecoverable myocardial necrosis and an outer zone where myocardium is ischaemic. 
This leads to myocardial stunning with loss of contractility. If ischaemia is severe and 
persists this may lead to myocardial cell death through apoptosis. If ischaemia resolves then 
stunned myocardium may recover contractility and ventricular function may improve. 
Sometimes the myocardium hangs in the balance for long periods, perhaps indefinitely, 
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without recovery of function but without cell death. Some of this is due to recurrent 
ischaemia and stunning. In other cases, myocardial hibernation may occur, either due to a 
metabolic defect in the myocardium itself or a critically low myocardial blood flow or simply 
the effects of chronic repetitive stunning[2]. One of the mechanisms by which beta-blockers 
improve ventricular function in patients with chronic heart failure is probably the relief of 
recurrent ischaemia and hibernation [2] and indeed myocardial ischaemia due to micro-
vascular disease in the absence of epicardial disease may be one cause of dilated 
cardiomyopathy and account for why these patients get such a large and consistent response 
to beta-blockers. Observational studies have suggested that revascularisation can improve the 
function of stunned and hibernating myocardium although randomised controlled trials have 
been unable to show superiority over medical treatment alone [3 4 5]. It is unknown whether 
recovery of ventricular function leads to resolution of heart failure if it has already occurred 
or whether recovery can reduce the risk of developing heart failure in the future. 
This thesis will review the literature related to the development and natural history of heart 
failure subsequent to an acute myocardial infarction and then describe, in detail, the 
development and natural history of heart failure in two large cohorts of patients drawn from a 
local population of about 560,000 patients who had a myocardial infarction either in 1998 
(cohort 1) or 2005 (cohort 2). 
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Figure  1-1Structure of Brain natriuretic peptide 
 
1.2 Literature Review 
This chapter will review three main topics, a) the incidence of myocardial infarction, b) the 
time course of the development of heart failure after an acute myocardial infarction and c) the 
use of N-terminal brain natriuretic peptide after a myocardial infarction as a means to detect 
cardiac dysfunction and to predict prognosis.  
The incidence and prevalence of heart failure and left ventricular systolic dysfunction and 
their combination after an acute myocardial infarction was extracted only from trials that 
enrolled 100 or more consecutive patients. The review was limited to English language 
papers. The electronic search for heart failure and myocardial infarction was carried out using 
Pub-med and Cochrane. This literature search was limited to publications between the 1st of 
January 1994 and 1stt of January 2008. The key words used were “myocardial infarction and 
heart failure”. A systematic review of BNP for detecting HF and LVSD after MI was carried 
out in the same way with same limitation and same period as HF and MI in Pub-med and 
Cochrane, the studies with more than 500 cases after an acute MI and more than 50 cases in 
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patients with a remote MI were reviewed. The key words used were “myocardial infarction 
and brain natriuretic peptide”.  
After applying the defined search criteria, a preliminary review of abstracts identified was 
carried out. Related abstracts were selected if they were considered relevant and their full text 
was reviewed. Only twenty full text papers & abstracts met our criteria for “heart failure and 
myocardial infarction” and only fourteen “myocardial infarction and brain natriuretic 
peptide”.  
1.2.1 The Incidence of Myocardial Infarction: 
It is probable that the incidence of MI varies around the world; although when age and sex 
matched populations are compared the differences may not be so great. MI is common in 
China, Australia, America and Europe, as evidence by large, relevant trials from each of these 
regions. Robust epidemiological data are hard to find because the majority of studies have 
restricted their interest either to certain age groups and/or only to patients with a hospital 
diagnosis and have been retrospective[6]. 
The British Heart Foundation estimates that there are about four MIs per thousand 
populations per year, but hospital discharge statistics in the UK suggest only half that 
amount. The MI National Audit Project (MINAP) for England (and Wales), which aims to 
report the outcome for all patients, not just with MI, but also other acute coronary syndromes 
either leading to hospitalisation or developing during admission, reported more than 78,000 
myocardial infarctions in 2009-2010 [7] but points out that there was disproportionate under-
reporting of myocardial infarction non ST elevation myocardial infarction, possibly because 
about half of these cases are not managed on cardiology wards. Adjusting for this MINAP 
believe there should have been about 100,000 cases in England & Wales or1.6 cases per 
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thousand population of all ages per year. However, there may well be additional under-
reporting of STEMI so the total number of cases may be between 120,000 and 150,000 per 
year. But this excludes patients who die suddenly before reaching hospital and those with no 
or atypical symptoms who do not present to hospital. Perhaps 20-30% of people suffering an 
MI will die before they reach hospital[8 9]. About 25% of patients will have no symptoms or 
symptoms that are mistaken for a less serious problem and will not seek hospital attention or 
be referred to a cardiologist[10 11 12]. Thus the total burden of myocardial infarction in 
England & Wales may be close to 300,000 cases per year or six cases per thousand 
population of all ages per year (Table 1.1). 
There are likely to be several reasons for the above discrepancies. It is unlikely that all cases 
are reported to MINAP as noted above. Cardiologists tend to focus on younger patients with a 
clear diagnosis of MI and few co-morbidities. For many years, many centres were under the 
illusion that MINAP was a register of cases who got thrombolysis – which made many 
hospitals look as though they were giving better care than was actually the case. It is likely 
that hospital statistics are an underestimate of hospital activity. We know, from a review of 
our own case records that when MI is reported on hospital death and discharge codes it is 
almost always appropriate but that a substantial number of cases with MI are not coded as 
such. The discrepancy between MINAP and the hospital discharge statistics almost certainly 
reflects selective reporting of obvious infarcts in younger patients with a typical presentation 
and relatively low co-morbidity; just the sort of patients who go into clinical trials. However, 
there is good evidence that it is the older patient with atypical presentation who is most likely 
to develop HF, has the worst prognosis but is less likely to receive effective care  [10 11 12]. 
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Table  1-1Incidence of myocardial infarction 
 
 
Study Years of data 
collection 
Age limits Population 
served 
Cases Incidence (events/ 
1000/year) 
Case fatality 
MONICAa [6] 1985-1991 35-64 years large 3,584 4.3 49% at 28 days 
OXMIS [8] 1994-1995 <80 years 568,800 1,343 2.4 39% at 28 days 
ARIC [9 13] 1987-1996 35-74 years 354,357 14,842 4.2 
 
BHF/NICE[14] Uncertain All ages 58 million 268,000 4.6 
 
Hospital Death & Discharge 
Statistics (England)[15] 
2002-2003 All ages 50 million 105,476 2.1 
 
Hospital Death & Discharge 
Statistics (England)[16] 
2005-2006 All ages 50 million 64,436 1.28 
 
Hospital Death & Discharge 
Statistics (Scotland) [17] 
1990-2000 All ages 4.8 million 96,026  
(225,512b) 
2.0 
(4.7b) 
 
Hospital Death & Discharge 
Statistics (Scotland) [18] 
2000 All ages 4.8 million ~8,000 
~27,000 
1.7 
(5.7b) 
 
MINAP[7] 2009-2010 All ages  78,574# 1.6 (>2.0#) 
 
aThe definition included definite non-fatal myocardial infarction and possible, probable or definite CHD mortality. Cities from 21 
countries were included in the study. Belfast and Glasgow represented the UK. They had a much higher than average incidence 
than the mean effect but only a slightly lower 28 day case fatality. # MINAP states that they know there is underreporting, 
especially of NSTEMI 
bCardiac chest pain including myocardial infarction and unstable angina 
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There are some serious consequences of selective reporting. Singling out a few patients and 
providing them with excellent care, while excluding patients with an intrinsically poor 
prognosis who have received less investigation and care, is the most efficient way of 
appearing to give good care when resources are limited. No doubt, as MINAP evolves and 
matures, the safe guards that have been built into the system will help prevent selective 
reporting. Using the number of events per hospital per thousand catchment population, 
together with the mean age and sex of the patients, as part of the published quality assurance 
for MINAP would be helpful. 
Synthesising data from a number of sources, it is likely that the average hospital in the UK 
should admit about two patients with an MI per thousand populations (all ages) per year of 
which about one third will be a recurrent myocardial infarction.  
Recent publications suggest that the age-adjusted risk of MI and coronary heart disease 
mortality are falling[6]. It is not clear that this has translated into an overall reduction in 
either[9 13]. As the proportion of older people in the population increases this may more than 
offset any gain in terms of a reduction in age-related morbidity. It is likely that the overall 
rate of MI in the population will increase, especially in people aged >70 years[19 20]. 
1.2.2 What Is Already Known on the Incidence of Heart Failure or LVSD During 
Admission in Patients with a Myocardial Infarction? 
LVSD and HF are not synonymous[21]. Some patients suffer major left ventricular damage 
and yet remain asymptomatic. Between 30-50% of patients who develop HF do not have 
LVSD, mitral regurgitation or arrhythmias [22 23]. LVSD can be measured fairly objectively 
but symptoms and signs of HF are subjective and the threshold for diagnosis will vary widely 
amongst clinicians. Both LVSD and HF may occur early or develop late and both may 
recover. Many patients are given loop diuretics during the course of their MI and it is likely 
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that most of these patients have exhibited signs or symptoms of HF [24].Prescription of a 
loop diuretic is associated with a worse outcome [25 26]. 
There are few data on the contemporary existing natural history of these phenomena. Surveys 
indicate that only about 60% of patients with a MI have their ventricular function 
assessed[24]. Moreover, it is clear that patients with atypical presentation of infarction, who 
are often not cared for by a cardiologists, have a higher risk of developing LVSD and HF and 
have a higher mortality[10 11 12]. Cardiology focused studies and registries are likely to 
underestimate the incidence of post-MI heart failure. It is hoped that MINAP project will 
ensure that such selective reporting is avoided. 
Perhaps the study of highest quality is the registry for the TRACE study, which underpinned 
a randomised controlled trial comparing placebo and trandolapril in Denmark, predominantly 
(76%) in patients with a first MI [21 27 28]. Of 6,526 patients in whom the wall-motion 
index was assessed, 2,606 patients (40%) developed major left ventricular systolic 
dysfunction. Amongst those who had LVSD, 74% developed features of HF and 30% of all 
patients had both LVSD and HF. However, 24% of patients had features of HF but did not 
have LVSD. Overall, about two thirds of patients had either HF or LVSD (Figures 1.2 and 
1.3). 
The VALIANT study which tested valsartan, alone or combined with the ACE-inhibitor 
(during 1999 to 2001). Of 5566 patients with MI, 27% developed LVSD. Amongst those who 
had LVSD, 30% developed HF and therefore only 8% of all patients assessed had both LVSD 
and HF. In patients who died during index admission 80%, had either HF, LVSD or both. 
However, documentation of mortality in patients with HF or LVSD alone was poor [29]. 
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Figure  1-2Proportion of patients with HF and left ventricular systolic dysfunction (LVSD) within the first 
few days after a myocardial infarction in the TRACE study [1] 
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(patients divided into 4 groups: WMI <0.8, <0.8, <1.2, <1.2, <1.6 and >1.6, approximately corresponding to LV 
ejection fraction <0.25, <0.25, <0.35, <0.35, < 0.50 and  > 0.50  respectively [28].  
WMI, wall motion index. 
Figure  1-3Proportion of patients with left ventricular systolic dysfunction (LVSD), transient or persistent heart 
failure (HF) and their outcome in TRACE study 
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In another observational study of 3166 patients with MI and LV assessment, 33% developed 
LVSD. Amongst those who had LVSD, 71% developed HF and only 23% of all patients had 
both LVSD and HF. Overall development of HF was 1464 (46%) but 15% of them was prior 
to their hospitalisation and only 10% of them developed after 24 hours of admission[23]. 
Other population studies corroborate a prevalence of major LVSD acutely after an MI of 
about 40%, although lower rates are generally reported in clinical trials that recruited patients 
selectively from cardiology services (recruiting patients from cardiology services alone will 
tend to exclude older patients who often remain under the care of geriatricians) [24 30] 
(Figure 1.2). 
Other studies have looked at Killip class or diuretic treatment only in the early days of 
admission with no further detail in other days[31]. The Worcester Heart Attack Study 
reported MI admissions during 13 annual period (from 1975 to 2001), development of HF 
during hospitalization was 37-45%, with the highest incidence of HF between 1981-1984 
with 45% compared to 40% in the last period of study (2001)[32]. 
Prior to the widespread use of thrombolysis, ACE inhibitors and beta-blockers, studies 
suggested progressive LV remodelling occurred in a substantial proportion of patients, 
leading to an increasing prevalence of LVSD over time[33]. However, others focused on the 
delayed recovery from stunning and reported recovery from LVSD after MI [34 35]. It is 
likely that more aggressive therapy of MI has reduced the risk of adverse remodelling and 
improved the chances of recovery from LVSD[35]. However, modern treatment will also 
have kept a higher proportion of patients with severe LVSD alive but had little impact on 
those without major LVSD since their prognosis was already good[36]. Overall, it appears 
that the incidence of post-infarction HF has changed little[22 36 37 38]. Obviously, the 
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complex interactions between disease, outcome, and epidemiology require study rather than 
uncertain speculation. 
The TRACE study suggested that >50% of patients having a MI would develop symptoms 
and/or signs of HF and in about one third of these cases HF will have been present prior to 
their MI [21]. This incidence of new-onset HF of about 40% is consistent with a systematic 
review of the literature[30], (Table1.2). Of patients who develop new onset symptoms of HF, 
about 70% will do so by the time of first hospital evaluation, while 30% will develop them 
later during the index admission. 
On the other hand, registries and randomised controlled trials of acute coronary syndrome 
demonstrate lower percentage of patients developing heart failure after a myocardial 
infarction as they excluded the high risk patients such as history of HF and Killip class IV 
heart failure [39]. 
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Table  1-2Prevalence and incidence of heart failure in patients with myocardial infarction 
 
Study Collection 
period 
Exclusions Number Pre-existing 
HF 
HF developing during 
index 
HF developing 
developing after 
discharge 
Total 
US National 
Registry [38] 
1994-2000 Shock or prior HF 606500  20.4% 8.6% 29.0% 
TRACE [21] 1990-1992 Shock or inadequate echo 
visualisation of LV function  
6676 17.7% 36.9% (805 within 
first 2 days) 
NA 54.6% (11.4% 
transient only) 
EHFS[24] 2000 Registry 10484 10%   ~25% NA 35% 
Olmested 
County [22 40] 
1979-1994 Registry 2171 11.8% 24.2% within 30 
days 
16.8% over 6.6 
years 
53.1% 
Framingham[37] 1950-1989 Registry 546  9.7% within 28 
days 
10 years  
Hellerman 
review 
NA Population based NA 37% (95% CI 
25% to 48%) 
  NA 
 NA Registry NA 36% (95% CI 
19% to 51%) 
  NA 
 NA Trials NA 18% (95% CI 
11% to 35%) 
  NA 
MONICA 
Project, Perth, 
Western 
Australia [41] 
1984 
&1993 
History of HF and MI, if 
patients died within 28 
daysa 
4006 none 22.4% within 28 
days 
10 years NA 
CI,confidence intervals; HF, heart failure; NA, not applicable or available; a, only age 25-64 years included; 
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Other methods of data collection, and the clinical experience of some, suggest a lower 
incidence of HF. This could reflect a higher threshold for diagnosis, failure to include 
transient events, exclusion of patients with pre-existing HF, excluding patients with 
conditions such as cardiogenic shock and excluding patients who die soon after admission. 
Cardiology focused studies and registries are likely to underestimate the incidence of HF in 
post MI patients as they tend to exclude older, higher risk patients. 
Another potential way of assessing the proportion of patients with HF after MI is to measure 
the amount of loop diuretic used, since the predominant use of these agents is for the 
management of fluid retention caused by heart or renal failure. Surveys suggest that a third or 
more of patients admitted with an acute coronary syndrome will be treated with a diuretic and 
it is likely that most of these patients have shown signs or symptoms of HF [24]. The Euro 
Heart survey of Acute Coronary syndromes suggested that about 35% of all patients with MI 
will receive in-patient diuretic therapy but did not distinguish loop from thiazide diuretic[24]. 
Estimates of the proportion of patients that have or will develop heart failure during the index 
admission vary from as low as 9% up to 55%[21 27 37]which may be transient or persist 
(Table 1.2). Overall, the literature review suggests about 40% of patients should have heart 
failure or LVSD identified during an admission for MI or about one patient per thousand 
population per year.  
1.2.3 Heart Failure Developing and Recovering after Discharge from the Index 
Myocardial Infarction Hospitalisation 
Not all patients who develop HF in the acute post-infarction period will develop chronic HF. 
The TRACE study suggested that the signs and symptoms of HF would be transient in about 
15% of patients with major LVSD and 40% of patients without major LVSD[28] (Figure 
1.2). 
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The incidence of HF developing for the first time after discharge from the index admission is 
even more uncertain. The Framingham study (population of Framingham about 65,000), 
based on rather limited evidence suggested that, although mortality had declined after an MI, 
the risk of HF had not, which the authors ascribed to improved survival amongst patients who 
had sustained major ventricular damage[37]. However, late-onset HF (>29 days after the 
event) may have been reduced by up to 50% although this analysis is based effectively on 
only 15 cases. The incidence of late-onset HF in Framingham was only 1% per year. The 
Olmsted County study, which identified 2,171 infarcts over 15 years from a population of 
about 130,000, suggested that 12% of patients had pre-existing HF and that 41% of patients 
would develop new onset HF (using the Framingham Criteria, which does not require LVSD 
to be present) over 6.6 years giving a combined total of 53% for the development of HF. 
Most new cases developed during the index hospitalisation, with an annual incidence 
thereafter of about 3%[22 36 40]. Moller demonstrated 7% of patients were hospitalized for 
new or worsening HF during 40 months follow up but they did not clarify the numbers of 
cases that were due to new onset HF[42]. Recurrent MI was not reported to be an 
independent determinant of developing HF [36 40]. However, the Framingham Criteria were 
designed to be specific rather than sensitive to a diagnosis of HF [43]and therefore the 
Framingham and Olmsted County studies may have substantially underestimated of the risk 
of developing heart failure after an MI. 
Three substantial studies of post-infarction LV systolic dysfunction that excluded patients 
with more severe heart failure developing during the index admission give some further 
insights[44 45 46 47] (Table 1.3). However, patients with ‘mild’ HF during the index 
admission were not excluded from these studies. 
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Table  1-3Progression of heart failure and mortality in randomised controlled trials of post-infarction left 
ventricular systolic dysfunction 
1.2.4 Results of the BNP Review: 
According to ESC new guideline[48] clinical skills and cardiac imaging are not the only 
measures of cardiac dysfunction after an MI. Brain natriuretic peptides (BNP) and NT-
proBNP provide an alternative simple method for detecting cardiac function, although as the 
concentration of these peptides are also dependent on renal function, they should really be 
considered a marker of cardio-renal dysfunction. Atrial fibrillation, low body mass index, left 
atrial hypertension (due to left ventricular systolic or diastolic dysfunction or mitral valve 
disease) and pulmonary hypertension may all cause a rise in NT-proBNP and are all 
associated with adverse cardiovascular outcomes. The relationship between NT-proBNP and 
this broad range of predictors of an adverse cardiovascular outcome is its strength as a tool 
with which to assess prognosis but both a strength and weakness when it comes to diagnosis. 
In health, NT-proBNP rises with age (perhaps reflecting declining renal function and reduce 
ventricular compliance) and is higher in women. These demographic trends are swamped by 
changes induced by the onset of disease and female sex. As older people are more prone 
disease it may not be intelligent to have age-corrected normal values [49]. 
Patients who have increased plasma concentrations of N terminal pro B-type natriuretic 
peptide (NT-proBNP) and BNP after an acute MI have a higher HF hospitalisation rate and 
worse prognosis (Table 1.4). Some of the studies demonstrated that NT-proBNP 
Study Year HF at 
baseline 
Diuretic use 
at baseline 
Follow up Subsequent 
HF event 
Overall 
mortality 
SAVE [46] 1987-1990 ~40% 35% 42 months 15.5 % 22.5% 
CAPRICRN[44 45] 1996-1999 NA 34% 15 months 13.1% 13.6% 
EFHESUS [47] 1999-2001 90% 60% 16 months 11.1% 15.6% 
HF, heart failure 
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concentration has negative correlation with LV EF after MI[50 51].  The ability to predict a 
poor outcome is independent and additive to that of LVSD[52 53 54]. 
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Table  1-4Prognosis of NT-BNP and BNP in patients with acute myocardial infarction 
 
Table 1-5Prognosis of NT-BNP and BNP in randomised controlled trials in patients with acute coronary syndrome. 
study Collection data Natriuretic 
peptide test 
Time of blood 
test 
number Age 
limitation 
f-up NT-proBNP 
Predicted 
Scirica[58] RCT BNP baseline 4162  24 months HF admission 
Galvani[59] Hospital registry NT-proBNP 3 hours 1756  30 days Death & severe HF 
Westerhout[60] RCT NT-proBNP baseline 7800 >21 years 30 days/1 yeara death & Death/MI  
Morrow[61] RCTb NT-proBNP baseline 1676  30 days/1 yearc Death & CHF 
James[52] RCT NT-proBNP baseline 6809  1 year death 
Omland[62] Coronary care 
unit admission 
NT-BNP 3 days 609 18-80 51 months death 
James[63] RCT BNP baseline 2525  10 months death 
aHF admission after 30days of randomisation, 30 days f-up for death and death/MI and 1 year f-up for death. bNSTE- ACCS, cnew CHF 
within 30 days and 1-year mortality. CHF, congestive heart failure. 
study Natriuretic peptide 
test 
Time of blood 
test 
number Age 
limitation 
f-up BNP & LVSD Predictor of 
Richards[54] N-BNP >median 24-96 hoursa 666 hospital admission <85 3 years 
 
Death or HF 
hospitalisation 
Khan[55 56] Log NT-proBNP 3-5 daysa 983 concecutive MIb 
 
343 days Was elevated in 
pts with LVSD 
Death and HF and  
LV EF 
Bjorklund[57] NT-BNP Before stsrting 
lysis 
782 STEMI-RCT >18y 1 year 
 
death 
aafter the onset of symptoms; bechocardiography parameters were available on 584 subjects. RCT; randomised control trial 
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Accordingly, patients who have LVSD and elevated NT-proBNP have the worst outcome, 
those with LVSD alone or elevated NT-proBNP alone have an intermediate prognosis, and 
those without LVSD and normal NT-proBNP have a good prognosis[54]. If it is accepted that 
it is important to stratify risk in patients with MI in order to identify patients who do or do not 
need intensive treatment, then a combination of cardiac imaging, natriuretic peptide, and 
stress testing for ischaemia provides a robust strategy for risk profiling. 
The studies also indicated the increase level of plasma concentrations of NT-proBNP and 
BNP provide a powerful prognostic value amongst patients with acute coronary syndrome 
and associated with higher mortality and HF hospitalisation rate (Table 1.5). 
 
In most of the previous studies BNP measurements were performed during the acute phase of 
MI or ACS, only limited surveys investigated the role of BNP in the chronic phase. An audit 
of patients with a prior history of MI conducted in primary care showed that BNP 
concentration was of some use for excluding only those patients with severe LV dysfunction, 
but was unable to discriminate between patients with lesser degree of LVSD and preserved 
LV function [64]. Another study on 418 outpatients with previous MI suggested that NT-
proBNP could be used to identify patients with a reduced LVEF (cut point of 260 pg/ml for 
EF<45% and 348pg/ml for detecting EF <35%) [65]. Another study assessed 52 stable 
patients after MI and found that NT-proBNP was independently related to LV volumes and 
LVEF [66]. Another study on 141 asymptomatic patients with previous MI showed that there 
was a correlation between LVEF and BNP concentration only in patients with a reduced 
LVEF but not in those without LVSD [67] (Table 1.6). 
 
There is a paucity of data to assess the relationship between the severity of LV dysfunction 
and NT-proBNP concentration in patients with a remote MI. The studies that investigated the 
Azam Torabi  Incidence and outcome of MI 
21 
 
prognostic value of NT-BNP were based on measurements made in the acute setting of an MI 
and there is no documentation on analysis of the prognostic power of the NT-proBNP 
measurement on the remote cases. 
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Table  1-6 Prognosis and diagnosis of NT-proBNP and BNP in patients late after myocardial infarction. 
study Collection 
data 
Natriuretic 
peptide test 
Time of 
blood test 
number Age 
limitation 
f-up BNP and LV function Multivariare-- Predictor of 
Luchner [65] MI 
registery 
NT-BNP Study time 418 <75 years 
 
Cut off value: 384pg/dl for 
detecting EF<35 and 260pg/dl for 
detecting EF<45 
in multivariate model, NT-BNP 
was independent & significant 
predictors of HF, EF, LVMI and 
GFR  
Watanabe[67] Cross 
sectional 
studya 
BNP Study time 141 
 
- Negative correlation between EF 
& BNP in low EF group, no 
correlation between EF & BNP in 
normal EF group 
 
Orn[66] RCT NT-BNP Study time, 
1months,1 
year, 
>4years 
52 
 
>4 
years 
Log BNP was related to end 
diastolic volume index 
Increasing age, no use of early 
statin therapy and LV end 
diastolic volume were 
significantly independent 
variables of NT-BNP at >4 years 
McClure[64] Primary 
care 
BNP Study time 134 
  
Low BNP can exclude severe 
LVSDb 
 
a  Outpatients with history of MI & no HF symptoms during last year. b Only can exclude severe LVSD but unable to discriminate between patients with 
moderately severe dysfunction and those with preserved LV function. MI; myocardial infarction, LV; left ventricular, HF; heart failure, EF; ejection fraction, 
GFR; glumoral filtration rate, RCT; randomised control trial, LVSD; left ventricular systolic dysfunction. 
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1.3 The Evidence Gap 
There is a paucity of data investigating the prevalence of HF and LVSD following MI in all 
patients. The percentages of patients developing HF during index admission varies amongst 
studies, many of which selectively reported from cardiology services and randomised control 
trial which tend to exclude older people, patients with prior MI, those with severe 
haemodynamic compromise and ‘fragile’ patients; all the groups at highest risk of developing 
heart failure and of dying. The development of transient and recurrent HF are poorly 
documented as is the contribution of recurrent myocardial infarction. If recurrent myocardial 
infarction rarther than ventricular remodelling is the most important factor driving the 
progression of heart failure this might require a major change in strategy. Finally, there are 
few contemporary data on the long-term development of heart failure after myocardial 
infarction and its importance as a determinant of longer term prognosis.  
It is known that the plasma concentration of BNP after acute MI provide powerful prognostic 
value and associated with higher mortality, HF hospitalisation rate and other non-fatal 
ischaemic events (MI and re admission for ACS) independent of the other factors furthermore 
the higher concentration of BNP are associated with coronary artery disease, it also has been 
reported that BNP is a useful screening test for LV dysfunction and it co-related with LV 
ejection fraction (EF). There is less data on BNP in patients with a remote MI to show the 
diagnostic value for detecting LV dysfunction and HF. The role of BNP for detecting patients 
with worse prognosis, who need more follow-up and effective treatment in patients with prior 
MI, is unclear. 
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2 Chapter 2: METHOD OF STUDY: 
2.1 Study population and process of contacting Patient 
I. This study was approved by the Local Research Ethics Committee. 
II. All patients with a death or discharge diagnosis of acute MI (International 
Classification Codes I21.0, I21.1, I21.2, I21.4, I21.9, I22.0, I22.1, I22.8 and I22.9) 
“between” the 1st of January and 31st of December 1998 were identified for us by 
the Hull & East Yorkshire Hospitals Trust Information Department (UK) that 
provide all of the acute cardiac services for about 560,000 people living in a 
geographically distinct part of the United Kingdom. Case note of all patients 
screened and follow-up data were collected until 31st December  2005. Restricting 
the cohort to cases in 1998 ensured that all patients had roughly equal duration of 
follow-up. Recruitment of consecutive cases using the hospital coding criteria 
helped to reduce ascertainment bias and increase the representativeness of the 
population. For instance inclusion only of patients cared for by a cardiologist 
would have biased the sample towards inclusion of younger patients. However, it 
is possible that some patients will have been missed by this procedure. To deal 
with this and finding out the incidence of MI between different databases, during 
2005, we compared the hospital coding criteria and Myocardial Infarction National 
Audit Project (MINAP) records, Hull Infarction Project (HIP-2005) and all 
troponin T (TnT) >0.03 ug/L reported by lab (see chapter 7). 
III. All patients who were alive by May 2004 were identified and a “Consultant Letter” 
(see appendix) sent, at the request of the ethics committee, either to the consultant 
who cared for the patient in 1998 or to a consultant who subsequently cared for the 
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patient, requesting permission for us to contact the patient asking them to attend 
the clinic at the Academic Department of Cardiology, Hull Royal Infirmary or 
Castle Hill hospital and to sign the “Consultant Letter to Patient” (see appendix) 
template. The exception to this rule was patients under the care of Professor 
Cleland, since he was supervising the project, and patients. Professor Cleland was 
designated as the cardiologist caring for the patient if none of the current 
cardiologists were or had cared for the patient. 
IV. A “patient information leaflet” and invitation letter (see appendix), which were 
approved by the local ethics committee and trust board, were sent to all patients 
who were alive by May 2004. The hospital patient administration system 
(Clinicom) was used to identify patients who had died immediately prior to 
sending the letter. 
V. Patients who responded favourably to the “Consultant Letter to Patient” were 
invited to attend Hull Royal Infirmary or Castle Hill hospital for follow up.  They 
were asked to provide consent using the “Patient Consent Form” (see appendix). 
VI. The patients’ family doctors were informed if patient(s) chose to participate and of 
any clinically relevant results by patients by using the “GP Letter” (see appendix). 
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2.2 Case Records Review 
The case records of all patients, regardless of whether they were able to attend for follow-up, 
were reviewed to identify: 
• Their usual address since only patients residing in Hull and East Yorkshire were 
included in the survey. Since Hull and East Yorkshire NHS Trust is the sole provider 
of acute care in the region this enabled tracking of recurrent hospitalisations. 
• the evidence in support of a diagnosis of acute myocardial infarction on the index 
admission 
• whether the patient developed transient or persistent heart failure during the index 
admission 
• mortality during the index admission 
• clinical course subsequent to discharge including 
• Development or resolution of heart failure 
• Readmission for acute coronary syndromes 
• Readmission for heart failure 
If no hospital record existed after January 1st 2004, the family practitioner was contacted to 
ascertain the patient’s current therapy and HF status.  
During the case note review the following data were collected: age, sex, height, weight, 
history of hypertension, history of MI, history of diabetes, history of heart failure, blood 
pressure, supra ventricular tachycardia, ventricular tachycardia, cardiology seen during index 
admission, blood test (full blood count, Urea & Electrolytes, blood glucose, cholesterol, CK 
and CK-MB), chest X-ray, electro-cardiogram, any cardiac image (echocardiography, 
angiography and radionuclide), coronary artery bypass graft, medication (thrombolysis, 
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diuretics, angiotension converting enzyme inhibitors, heparin, insulin, inothrop, nitrate, 
calcium blockers, aspirin, warfarin, oral hypoglycaemic agents, β-blockers, Digoxin, 
angiotensin-II receptor antagonists, statins and onset of diabetes (Table 2.1). Also the 
occurrence of major events, such as recurrent MI, death, LV systolic dysfunction, angina 
admission and stroke were recorded by end of December 2005 (followed six years). 
 
Azam Torabi  Incidence and outcome of MI 
28 
 
Table  2-1During the case note review the following data were collected: 
Demographi
cs 
Dates History Clinical Features Laboratory 
Values 
ECG & CX-Ray & Imaging 
Data 
Therapy Events Death data 
Age Index Admission Hypertens
ion 
Blood pressure Serum 
Creatinine 
chest X-ray PTCA Mortality Place 
Sex Index Discgarge Diabetes smoking Urea Cardiomegaly CABG HF  Mode of death 
Height Daete of LV 
measurement  
MI HF during admission Haemoglobi
n 
Upper lobe vein distension Thrombolysis Re MI Terminal HF 
Weight Date of birth HF Shock Sodium Pulmonary oedema Diuretic CVA Cardiogenic shock 
Current 
Smoking 
Onset of Diabetes LVSD supra ventricular 
tachycardia 
Potassium Pleural effusion Loop diuretic Chest pain 
admission 
Stroke 
Ex smoking Date of 1st reMI PTCA ventricular 
tachycardia 
Glucose Radionuclide Thiazide diuretic Diabetes Cardiac procedure 
Alcohol Date of any cardiac 
image 
CABG HF in discharge Cholesterol Coronary angiography Beta-blockers  Other cardiovascular 
Managed by 
cardiologist 
Last recorded as alive Family 
history 
 Peak CK electro cardiogram ACE-inhibitor  Cancer 
 Date of Death   CK-MB Rate ARB  Infection 
     Rhythm Statin  Other non-cardiovascular 
     QRS conduction Spironolactone  Autopsy 
     QRS >120 Aspirin   
     Type of MI Clopidogrel   
     LBBB, Pace Heparin   
     ST segment elevation warfarin   
     Echocardiography Calcium channel blockers   
     Major LVSD Insulin   
     Major Mitral regurgitation oral hypoglycaemic 
agents 
  
     Major other valve disease Inotropic therapy   
     Radionuclide  Nitrate   
     LVEF 35-39% Digoxin   
     LVEF <35%    
     Angiography    
     Major LVSD    
     Vessel disease    
     LMCA disease    
LV, left ventricular; MI, myocardial infarction; HF, heart failure; LVSD, left ventricular systolic dysfunction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; 
ck, creatine kinade; ECG, electro cardiogram; LBBB, left bundle brunch block; LMCA, left main coronary artery; ACE inhibitor, angiotension converting enzyme inhibitors; ARBs, angiotensin receptor 
blockers; CVA, cerebrovascular accident. 
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2.3 Tests during follow up visit 
Patients who attended for the follow up visit were asked about their medical history, 
symptoms and Current drug therapy, physical examination, blood tests including: Full blood 
count, Lipid Profile, urea, electrolytes, and blood glucose. 
The following additional tests were also performed: 
• Symptoms and quality of life using the Euro Heart Failure Questionnaire (see appendix)  
• NT-proBNP blood test as a marker for cardiac dysfunction. 
Venous blood samples for analysing NT proBNP: 
• were obtained from patients when they attended for follow up visit. Blood samples 
were immediately centrifuged at 4oC (Termo centra CL3R) for 15 minutes at 3000 
RCM (revolution per minute) within 30 minutes and pipetted plasma into small 
cryovials and stored in a –80ºC freezer until analysis. 
• Plasma NT-BNP levels were determined using a commercial assay (Elecsys 2010, 
Roche analysis). 
• 12-lead electrocardiogram (ECG). (G E Medical, Model: Mac 5000) 
• 24 hour ambulatory ECG monitoring (a few number of patients only have been offered 
this test as availability was limited). (Reynolds, Life card CF) 
• Echocardiography with Tissue Doppler Imaging (GE Medical, VIVID-5). 
• Ventricular dimensions were measured by M-mode. Two-dimentional, apical two 
and four-chamber views were taken for volume measurements and ejection fraction 
calculated by Simpson’s biplane method. Left ventricular ejection fraction (LVEF) 
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<40% or a qualitative report of moderate or severe LVSD on echocardiography. 
Left Atrial (LA) dimension was measured as the antero-septal diameter from the 
parasternal long axis view and considered as dilated if >3.8cm. Valve disease was 
assessed by colour flow Doppler from multiple echocardiographic views. Mitral 
regurgitation was graded as mild, moderate or severe.  
2.4 Inclusion Criteria 
Patients with a death or discharge code for an AMI between 1st of January and 31st of 
December 1998 identified from the Hull & East Yorkshire Hospitals NHS Trust Information 
Department. 
2.5 Exclusion Criteria for Index Admission                                          -                        
• Patients who had been transferred from outside of the Hull and East Yorkshire area or 
who were just visiting the area 
•  Patients who had missing case notes. 
•  Patients who had no confirmation of AMI in their records during 1998 and had a coding 
mistake. 
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2.6 2.6 Definitions 
2.6.1 2.6.1 Definition of Myocardial Infarction 
At least two of the following five criteria had to be identified during case note review to 
confirm a diagnosis of MI. 
1. History of prolonged cardiac chest pain. 
2. An increase in biomarkers consistent with MI, which in 1998 was usually creatinine 
kinase (CK) or CK-MB mass. These were considered abnormal if they were twice the 
upper limit of normal values. 
3. Progressive electrocardiographic changes consistent with MI or new onset left bundle 
branch block. 
4. Sudden unexpected death 
5. Autopsy evidence of MI 
2.6.2 Definition of Heart Failure 
Heart failure was defined clinically either as signs and symptoms consistent with that 
diagnosis (principally breathlessness and signs of fluid retention) resulting in treatment with 
loop diuretics or patients who died shortly after developing evidence of major cardiac 
dysfunction, such as cases of cardiogenic shock or pulmonary oedema or patients in whom 
post mortem examination definite heart failure. These patients were identified as a special 
subset so that the contribution of this group of patients to overall outcome could be identified: 
• Cardiogenic shock was defined as an arterial pressure <100mmHg due to low cardiac 
output requiring inotropic therapy or an intra-aortic balloon pump. For patients with an 
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un-recordable blood pressure, a systolic pressure of 50mmHg was entered as a default 
value for statistical purposes. 
• Patients who had evidence of HF/ LVSD and were on dialysis due to renal failure were 
counted as if they were receiving loop diuretic.  
2.6.3 Resolution of Heart Failure 
 Consistent with European Society of Cardiology Guidelines [68], resolution of HF was 
defined as the withdrawal of loop diuretics without the recurrence of symptoms.  
2.6.4 Definition for left ventricular dysfunction (LVSD) 
Criteria for LVSD were left ventricular ejection fraction (LVEF) <40% or a qualitative report 
of moderate or severe LVSD on echocardiography, first-pass radionuclide ventriculography 
or contrast angiography. Evidence of LVSD was not required for a diagnosis of heart failure. 
2.6.5 Definition of Renal Dysfunction 
Renal dysfunction was defined as estimated glomerular filtration rate (eGFR) <60 
mls/min/1.73m2, using the four-variable formula derived from the modification of diet in 
renal disease study (4V MDRD):  
GFR= 186 * [serum creatinine/88.4)-1.154 *Age-0.203 * (0.742 if female) *(1.212 if African 
Caribbean)[69]. 
2.6.6 Definition for anaemia 
Anaemia was defined according to WHO criteria as a haemoglobin concentration <13g/dL in 
men and <12g/dL in women. 
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2.6.7 Mode of Death: 
2.6.7.1 Sudden (presumed arrhythmic) cardiac death (SCD); 
Sudden cardiac death was defined as one or more of the following: 
• Unwitnessed death or witnessed sudden death in the absence of other cause of death such 
as severe heart failure, stroke, cardiac procedures, aortic dissection or aneurysm rupture, 
end stage cancer, severe infection such as septicaemia, major surgery or other end-stage 
disease 
• Resuscitated cardiac arrest in the absence of other causes of death (as above) if the patient 
died within the following 72 hours.  
• Absence of evidence of an explanation for death other than sudden (arrhythmic) death on 
autopsy. 
2.6.7.2 Heart Failure Deaths 
Patients who died at home but had persistent severe symptoms of heart failure or recurrent 
hospital admissions for worsening heart failure and patients who were admitted to hospital 
for or with worsening heart failure during and who developed cardiogenic shock, pulmonary 
oedema, or severe heart failure were considered to have died of heart failure. 
2.6.7.3 Stroke deaths 
Stroke was defined as the sudden onset of focal neurological signs that persisted for at least 
24 hours or resulting in death. Deaths within 30 days of a stroke were deemed deaths due to 
stroke unless another more proximate cause was evident. Stroke occurring within 24 hours of 
thrombolysis for myocardial infarction were deemed cardiac procedure related rather than 
deaths due to stroke. 
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2.6.7.4 Cardiovascular Procedure Related Deaths 
Patients who died during or after angiography, angioplasty, coronary artery bypass graft 
(CABG), valve surgery or vascular surgery and those who died due to stroke within 24hours 
of thrombolysis for myocardial infarction were considered cardiac procedure related deaths. 
2.6.7.5 Other cardiovascular 
This included aortic dissection and pulmonary embolism. It is recognised that a proportion of 
such events will not be clinically recognised and will often be recorded as sudden cardiac 
death. 
2.6.7.6 Cancer 
Patients who were diagnosed with advanced, incurable cancer. 
2.6.7.7 Infection 
Patients who died due to severe infection, usually bronchopneumonia or septicaemia. 
2.6.7.8 Other non cardiovascular 
Patients who died subsequent to any major non-cardiovascular surgery, end-stage renal 
failure, end-stage chronic obstructive pulmonary disease (COPD), emphysema, asbestosis, 
severe GI bleeding, bowel obstruction, general debility and pancreatitis. 
2.6.8 Place of Death 
Death was reported as in-hospital, out-of-hospital (if patients died in ambulance or sheltered 
accommodation/nursing home, we categorised as a death out-of-hospital). 
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2.7 Statistical Analysis: 
Data were entered into a Microsoft Access database and analysed using SPSS (version 13.0). 
Key outcomes were the proportion of patients who died and mortality rate. Continuously 
distributed data are presented as median and inter-quartile range. Categorical data are 
presented as percentages.  Groups of patients with and without heart failure were compared 
by the Chi-squared test. Logistic regression was used to look at relationship between HF and 
gender. The incidence rate of HF per person-year of follow-up was calculated for the first 
year and for subsequent years of follow-up[70]. This was only calculated for those discharged 
without HF or in whom HF had resolved by the time of discharge. Ninety-five percent 
confidence intervals were calculated using boot strapping with 1000 re-substitutions[71]. 
Kaplan-Meier (K-M) curves were generated to illustrate patients’ survival overall and in 
relevant subgroups.  K-M curves were compared by the log-rank test. Cox regression was 
used to look at mortality, from which hazard ratios (HRs) and 95% confidence intervals (CIs) 
were calculated. The Cox regression model is semi-parametric in the sense that no 
assumption concerning event-free survival times is necessary. The Cox regression model is 
based on the assumption that the effect of a risk factor, expressed as a hazard ratio, is 
constant over time. The purpose of this model was not to develop a risk stratification tool but 
rather to determine the extent to which a particular clinical pathway altered outcome. We 
present age-adjusted models in the text rather than adopting a formal statistical approach to 
model building (i.e., taking an epidemiological stance). The assumption of proportionality of 
the Cox model covariates was tested by plotting residuals[72 73 73]. Linearity of continuous 
data was checked by including a squared term. 
Heart Failure status was categorised into six groups:  
1. No HF at any time (this was the reference group) 
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2. Patients with HF on the index admission and persisting at follow up until death or end 
of follow-up 
3. Persistent HF on the index admission that resolved subsequent to discharge. 
4. Transient HF on the index admission that resolved prior to discharge but recurred 
during follow-up. 
5. Transient HF on the index admission that resolved prior to discharge and did not recur 
prior to death or end of follow-up 
6. Patients who did not develop HF on the index admission but who later developed HF 
during follow-up. 
Development and course of HF according to age was categorised into three groups:  
1. <70 years,  
2. 70 to 79 years 
3. > 79 years. 
Development and course of HF according to sex 
1. Women 
2. Men 
Development and course of HF according to development of ST elevation (more than 2mm in 
chest leads and more than 1mm in limb leads) was categorised into four groups:  
1. ST elevation 
2. No ST elevation. 
3. Left bundle branch block (LBBB) 
4. Unknown 
Development and course of HF and renal dysfunction according to renal function (out come 
by eGFR) was categorised into four groups: 
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1. eGFR less than 30 ml/min, 
2. 30-59 ml/min, 
3. More than 59 dl/min. 
4. Not known  
Development and course of HF and anaemia was categorised into three groups:  
1. According to WHO criteria with >1 g below WHO threshold being definite anaemia 
2. 1 g above or below WHO threshold as borderline 
3. >1g above WHO threshold as not anaemia 
Development and course of HF according to presence of diabetes was categorised into three 
groups:  
1. Any diagnosis of diabetes and the following subgroups 
• Diet only at discharge 
• Metformin at discharge 
• Other oral therapy at discharge 
• Insulin at discharge 
2. No diabetes at discharge (with blood glucose measured) 
3. No diagnosis of diabetes and no measure of glucose 
Development and course of HF according to the smoking was categorised into four groups:  
1. Current smoking 
2. Ex-smoking 
3. not smoking 
4. not known 
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Development and course of HF according to the type of MI in ECG was categorised into four 
groups:  
1. Any anterior site (V2-V4)ST elevation 
2. Other site rather than Anterior 
3. Left bundle branch block (LBBB) and Pace maker inserted 
4. No ECG report 
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3 Chapter 3: The Timing of Development and Subsequent 
Clinical Course of Heart Failure after a Myocardial 
Infarction1 
3.1 Introduction 
Heart failure (HF) is a common complication of myocardial infarction (MI), which may 
develop early or late. Once it has developed it may persist or resolve, and if it resolves it may 
re-occur. The cumulative incidence and resolution or persistence of HF after a MI is poorly 
described. 
Surveys suggest that one-third or more of patients admitted with an acute coronary syndrome 
(ACS) will be treated with a diuretic and it is likely that this will often be for signs or 
symptoms of HF [24 74]. Surveys also suggest that between 9 and 55% of patients have or 
will develop HF during admission for MI [21 27 37 74],which may be transient or persist. 
The incidence of HF developing for the first time after discharge from the index admission is 
poorly described, with incomplete data regarding numbers surviving until discharge and 
confusion about how best to present incidence rates and therefore comparison between 
studies is difficult. Despite differences in statistical presentation, these studies would seem to 
suggest that most new cases of HF in those hospitalised with an MI develop during admission 
or early after discharge [22 38 40]. Studies also suggest that patients who develop HF are at 
much greater risk of dying, whether or not they also have left ventricular systolic dysfunction 
(LVSD)[28 74]. However, few reports exist about the outcome of HF that is either transient 
or develops only subsequent to discharge. Also, it is unclear what proportion of cases 
occurring late after the index infarction is because of recurrent MI. We set out to identify the 
timing of onset, persistence, resolution, and outcome of HF developing after an MI. 
                                                 
1
 This chapter has already been published in European Heart Journal (see: Azam Torabi et al, 2008). 
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3.2 Methods 
3.2.1 Study population 
One hospital group in Hull and the East Riding of Yorkshire (UK) provide all of the acute 
cardiac services for about 560,000 people living in a geographically distinct part of the 
United Kingdom. Patients with a discharge diagnosis of acute MI during 1998 were identified 
from the Hospitals Information Department and their case notes screened. Patients who were 
transferred from another region, those with missing case notes, or in whom acute MI could 
not be confirmed from their records were excluded. 
This study was approved by the Local Research Ethics Committee. 
3.2.2 Follow-up 
This was a retrospective analysis designed in 2004. The case records of all patients were 
reviewed to identify use of loop diuretics and if so whether this was due to symptoms or signs 
of HF. Follow-up data were collected until 31st December 2005. If no recent hospital record 
existed, the family practitioners of patients or patients themselves were contacted to ascertain 
the patient’s current therapy and HF status. The occurrence of major events, such as recurrent 
MI, and stroke were recorded.  
3.2.3 Definition of Myocardial Infarction 
At least two of the following five criteria had to be identified during case note review to 
confirm a diagnosis of MI. 
1. History of prolonged cardiac chest pain. 
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2. An increase in biomarkers consistent with MI, which in 1998 was usually creatinine 
kinase (CK) or CK-MB mass. These were considered abnormal if they were twice the 
upper limit of normal values. 
3. Progressive electrocardiographic changes consistent with MI or new onset left bundle 
branch block (LBBB). 
4. Sudden unexpected death 
5. Autopsy evidence of MI 
3.2.4 Other Definitions 
HF was clinically defined either as signs and symptoms consistent with that diagnosis 
(principally breathlessness and signs of fluid retention) resulting in treatment with loop 
diuretics or patients who died shortly after developing evidence of major cardiac dysfunction, 
such as cases of cardiogenic shock or pulmonary oedema. The latter group of patients were 
identified as a special subset so that the contribution of this group of patients to overall 
outcome could be identified. Cardiogenic shock was defined as an arterial pressure 
<100mmHg because of low cardiac output requiring inotropic therapy or an intra-aortic 
balloon pump. For patients with an un-recordable blood pressure, a systolic pressure of 
50mmHg was entered as a default value for statistical purposes. Use of loop diuretics for the 
treatment of hypertension or renal failure was not included in the definition of HF. Evidence 
of LVSD was not required for a diagnosis of HF. Criteria for LVSD were left ventricular 
ejection fraction (LVEF) < 40% or a qualitative report of moderate or severe LVSD on 
echocardiography, first-pass radionuclide ventriculography, or contrast angiography. 
Azam Torabi  Incidence and outcome of MI 
42 
 
3.2.5 Resolution of Heart Failure 
Consistent with European Society of Cardiology Guidelines [68], resolution of HF was 
defined as the withdrawal of diuretics without the recurrence of symptoms. 
3.2.6 Statistical Analysis: 
Data were entered into a Microsoft Access database and analysed using SPSS version 13.0 
(UK,Ltd). Key outcomes were the proportion of patients who died and mortality rate. 
Continuously distributed data are presented as median and inter-quartile range (IQR). 
Categorical data are presented as percentages.  Groups of patients with and without HF were 
compared by the Chi-squared test. Logistic regression was used to look at the relationship 
between HF and gender. The incidence rate of HF per person-year of follow-up was 
calculated for the first year and for subsequent years of follow-up [70]. This was only 
calculated for those discharged without HF or in whom HF had resolved by the time of 
discharge. Values for 95% confidence intervals (CIs) were calculated using boot strapping 
with 1000 re-substitutions [71]. 
Kaplan-Meier (K-M) curves were generated to illustrate patients’ overall survival and in 
relevant subgroups. K-M curves were compared by the log-rank test. Cox regression was 
used to look at mortality, from which hazard ratios (HRs) and 95% CI were calculated. The 
Cox regression model is semi-parametric in the sense that no assumption concerning event-
free survival times is necessary. The Cox regression model is based on the assumption that 
the effect of a risk factor, expressed as HR, is constant over time. The purpose of this model 
was not to develop a risk stratification tool, but rather to determine the extent to which a 
particular clinical pathway altered outcome. We present age-adjusted models in the text 
rather than adopting a formal statistical approach to model building (i.e., taking an 
epidemiological stance). The assumption of proportionality of the Cox model covariates was 
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tested by plotting residuals[72 73]. Linearity of continuous data was checked by including a 
squared term. 
HF status was categorised into six groups: (i) No HF at any time (this was the reference 
group); (ii) Patients with HF on the index admission and persisting at follow-up until death or 
end of follow-up; (iii) Persistent HF (PHF) on the index admission that resolved subsequent 
to discharge; (iv) Transient HF (THF) on the index admission that resolved prior to discharge 
but recurred during follow-up; (v)THF on the index admission that resolved prior to 
discharge and did not recur prior to death or end of follow-up; (vi) Patients who did not 
develop HF on the index admission, but who later developed HF during follow-up. 
3.3 Results: 
3.3.1 Overall Results 
Of 1,012 patients with a death or discharge diagnosis of acute MI in 1998, 116 were excluded 
from further analysis (78 because they had been transferred for acute management from 
another region, 22 because of lack of relevant documents for the event, and in 16 cases 
because the diagnosis of MI could not be confirmed from the record). Of the 896 patients for 
the main analysis, 661 had no prior history of MI (Figure 3.1b). Thirty patients (3.3%) were 
lost to follow-up after the index admission. Documentation of the index event was generally 
good with little in the way of missing key data. 
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Figure  3-1Primary MI and Fist MI in 1998 and development of heart failure (HF) and mortality 
 
Flow diagram showing the sequence of development of heart failure (HF) and relationship with recurrent 
ischemic episodes and mortality over approximately 6 years in patients admitted with an acute myocardial 
infarction (MI) to the Hull and East Yorkshire Hospitals Group during 1998.  Follow-up data were incomplete 
in 30 patients. See text for details. (B) Flow diagram showing the sequence of development of HF and 
relationship with recurrent ischemic episodes and mortality over approximately 6 years in patients who had a 
first acute MI (without prior MI) in the Hull and East Yorkshire Hospitals Group during 1998. Follow-up data 
were incomplete in 20 patients (two with transient HF (THF), two with persistent HF (PHF) during the index 
admission, and 16 in patients with no HF during index admission, one of whom was reported to have died by the 
administrative system. 
 
 
 
 
Flow diagram showing the sequence of development of heart failure (HF) and relationship with recurrent 
ischemic episodes and mortality over approximately 6 years in patients admitted with an acute myocardial 
infarction (MI) to the Hull and East Yorkshire Hospitals Group during 1998.  Follow-up data were incomplete 
in 30 patients. See text for details. (B) Flow diagram showing the sequence of development of HF and 
relationship with recurrent ischemic episodes and mortality over approximately 6 years in patients who had a 
first acute MI (without prior MI) in the Hull and East Yorkshire Hospitals Group during 1998. Follow-up data 
were incomplete in 20 patients (two with transient HF (THF), two with persistent HF (PHF) during the index 
admission, and 16 in patients with no HF during index admission, one of whom was reported to have died by the 
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The median age of the patients was 70 (IQR 61-78) years and 333 (37%) were women (Table 
3.1). Of men, 141 (25%) and of women, 147 (44%), were aged >75 years. There was a prior 
history of hypertension in 300 (33%), MI in 235 (26%), HF in 134 (15%) and diabetes in 82 
(9%). In addition, 33 (4%) patients were newly diagnosed with diabetes during the index 
admission. Sixty-two percent were managed, at least in part, by a cardiologist during their 
index admission. ST-segment elevation myocardial infarction (STEMI) was present in 518 
(58%) and non-STEMI in 316 patients (35%). Forty seven patients had LBBB, five patients 
were in a paced rhythm, and 10 had no ECG recording available from the time of admission. 
During the index admission, patients with HF were more often treated with ACE-inhibitors, 
nitrates, digoxin and insulin. However, patients who developed HF on the index admission 
were less likely to receive beta-blockers (p<0.0005) (Table 3.2). 
Overall, 480 patients (54%) had died by December 2005.  Figure 3.1a describes the sequence 
of events that led to the development of HF and/or death. Figure 3.2 shows the overall 
proportion of patients who developed HF at any time during follow-up and their 
categorisation according to persistence, remission, and timing of development of HF.HF was 
present during the index admission in 417 (47%) patients and these patients were older 
(75(67-81) vs. 66(57-74) years; (p<0.0001) and more likely to be women [54% vs. 42% in 
men; (p=0.001). The median age of women with HF was 77 (IQR 71-84) and in men with HF 
was 73 (IQR range 64-79). In a logistic model, the relationship between HF and sex was no 
longer significant (p=0.46) after adjustment for age. During the index hospitalization, 161 
patients (39%) with HF died; 71 of them fulfilled the definition of cardiogenic shock. Only 
38 (8%) patients who did not fulfil the criteria for HF died during the index admission 
(Figure 3.3). HF resolved in 74 patients (18%) and therefore only 182 patients (20%) were 
discharged with PHF of whom 70 had HF prior to admission. 
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Table  3-1Patients characteristics recorded during the overall index admission overall and classified according to the development of heart failure (HF) and 
mortality during index admission [data are median (inter-quartile range) and number occurring (%)]. 
Variables (units) [missing data] Overall No HF during 
index admission 
HF during 
index 
admission 
P-value Survived index Died on Index P-value 
 896 479 417  697 199  
Age (years) [0] 70 (61-78) 66 (57-74) 75 (67-81) <0.0005 68 (59-76) 76 (71-83) <0.0005 
Women [0] 333 (37%) 153 (32%) 180 (43%) 0.001 250 (36%) 83 (42%) 0.133 
Current smoker [87] 303 (37%) 202 (44%) 101 (29%)  261 (40%) 42 (28%)  
Ex smoker 255 (32%) 126 (27%) 129 (37%) <0.0005 213 (32%) 42 (28%) <0.0005 
        
History of Hypertension [40] 300 (35%) 138 (30%) 162 (41%) 0.004 224 (33%) 76 (41%) 0.049 
History of Diabetes [3] 82+33a (13%) 42 (9%) 73 (18%) <0.0005 78 (11%) 37 (19%) <0.0005 
Prior MI [1] 235 (26%) 90 (19%) 145 (35%) <0.0005 166 (24%) 69 (35%) 0.008 
History of HF [4] 134 (15%) 4 (1%) 130 (31%) <0.0005 76 (11%) 58 (30%) <0.0005 
Prior CABG 39 (4%) 9 (2%) 30 (7%) <0.0005 29 (4%) 10 (5%) 0.598 
Prior PTCA 14 (2%) 7 (1%) 7 (2%) 0.794 10 (1%) 4 (2%) 0.564 
Managed Primarily by 
Cardiologist 
558 (62%) 317 (66%) 241 (58%) 0.01 466 (67%) 92 (46%) <0.0005 
        
Index Admission ECG        
  ST segment elevationb [10] 518 (58%) 270 (57%) 248 (60%) <0.0005 406 (59%) 112 (58%) <0.0005 
  Non ST elevation [10] 316 (36%) 192 (41%) 124 (30%)  261 (38%) 55 (29%)  
  QRS > 120 [23] 199 (22%) 58 (12%) 141 (34%) <0.0005 124 (18%) 75 (39%) <0.0005 
  Anterior site [10] 422 (48%) 195 (41%) 227 (55%) <0.0005 322 (46%) 100 (52%) <0.0005 
        
Chest X-ray        
  Pulmonary oedema [227] 160 (24%) 18 (5%) 142 (43%) <0.0005 101 (19%) 59 (45%) <0.0005 
  Cardiomegaly 156 (23%) 45 (13%) 111 (33%) <0.0005 125 (23%) 31 (24%) 0.005 
  Upper Lobe Vein Distension 159 (24%) 49 (15%) 110 (33%) <0.0005 125 (23%) 34 (26%) 0.004 
  Pleural effusion 73 (11%) 13 (4%) 60 (18%) <0.0005 50 (9%) 23 (18%) <0.0005 
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Physical Examination        
  Heart Rate [9] 78 (64-97) 72 (61-86) 87 (69-107) <0.0005 75 (63-90) 92 (72-109) <0.0005 
  Atrial fibrillation (yes/no) [2] 153 (17%) 31 (6%) 122 (29%) <0.0005 97 (14%) 56 (28%) <0.0005 
  Systolic blood pressure[5] 140 (120-160) 140 (125-160) 136 (115-160) 0.007 142 (125-162) 126 (101-142) <0.0005 
        
Blood Tests (on admission)        
  Peak creatinine kinase [49] 828 (376-1901) 880 (382-1850) 749 (348-
1941) 
0.096 888 (390-
1919) 
623 (256-
1698) 
0.721 
  Cholesterol [353]  5.5 (4.8-6.4) 5.6 (4.9-6.3) 5.4 (4.6-6.4) 0.08 5.5 (4.9-6.4) 5 (4.2-6.2) 0.27 
  Sodium [29] 137 (135-139) 137 (136-139) 137 (134-139) <0.0005 137 (135-139) 136 (134-138) <0.0005 
  Creatinine  [127] 105 (89-129) 97 (83-111) 119 (97-157) <0.0005 101 (86-120) 134 (106-198) <0.0005 
  Anaemia in first available   
haemoglobinc[41] 
206 (24%) 81 (18) 125 (31%) <0.0005 132 (20%) 74 (41%) <0.0005 
CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; MI, myocardial infarction; ECG, electrocardiogram. 
Percentages are shown are of those in whom measurements were made. 
Example interpretation: patients who had HF during the index admission had a higher heart rate compared to patients without HF; also those who died 
on the index admission had a higher heart rate than those who survived. This same patern occurred for creatinine, but the revers pattern was found for 
sodium, peak creatinine kinase, cholesterol and systolic blood pressure. 
aThirty-three cases newly diagnosed as diabetic on index admission. 
 bP-value for ST calculated between three groups [ST-elevation, no ST-elevation, and other (left bundle branch block and pace)] 
cAnaemia: WHO criteria for anaemia are used (male <13g/dL and female <12g/dL).  
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Table  3-2Treatment during index admission and any time until 31st December 2005. 
Variables (units) [missing data] All  No HF during 
index admission 
HF during index 
admission 
P-value Survived index Died on Index P-value 
n 896 479 417  697 199 
 
Revascularisation during admission       
 
  Thrombolysis [0] 372  225 (47%) 147 (35%) <0.0005 323 (46%) 49 (25%) <0.0005 
  PCI [0] 20  15 (3%) 5 (1.2%) 0.05 20 (3%)  0.016 
  CABG [0] 8 1 (0.2%) 7 (1.7%) 0.021 6 (1%) 2 (1%) 0.85 
  
    
  
Treatment at any time during 
admission 
      
 
Parenteral       
 
  Loop diuretic [7] 262 0 262 (65%) <0.0005 155 (22%) 107 (54%) <0.0005 
  Nitrates [3] 309 153 (32%) 156 (37%) 0.212 255 (37%) 54 (27%) 0.028 
  Inotropic therapy [2] 94 3 (0.6%) 93 (22%) <0.0005 29 (4%) 65 (33%) <0.0005 
  Heparin [15] 694 387 (81%) 307 (77%) 0.037 579 (85%) 115 (58%) <0.0005 
  Insulin [1] 79 30 (6.3%) 49 (11.8%) 0.008 59 (8%) 20 (10%) 0.134 
Oral       
 
  Aspirin [2] 792 455 (95%) 336 (81%) <0.0005 658 (94%) 134 (68%) <0.0005 
  Clopidogrel [2] 7 5 (1%) 2 (0.5%) 0.630 6 (1%) 1 (1%) 0.026 
  Warfarin [2] 35 3 (0.6%) 20 (4.8%) <0.0005 25 (4%) 10 (5%) 0.019 
  Statin [2] 406 281 (59%) 125 (30%) <0.0005 393 (56%) 13 (7%) <0.0005 
  ACE inhibitors [2] 354 130 (27%) 224 (54%) <0.0005 307 (44%) 47 (24%) <0.0005 
  ARBs [2] 8 1 (0.2%) 7 (1.7%) 0.065 6 (1%) 2 (1%) 0.029 
  Beta-blockers [2] 497 360 (75%) 137 (33%) <0.0005 465 (67%) 32 (16%) <0.0005 
  Nitrates [2] 320 146 (31%) 174 (42%) 0.002 260 (37%) 60 (30%) 0.006 
  Calcium-channel blockers [2] 215 104 (22%) 111 (27%) 0.227 172 (25%) 43 (22%) 0.021 
  Loop diuretic [3] 297 5 (1%) 292 (70%) <0.0005 217 (31%) 80 (41%) 0.033 
  Thiazide diuretic [1] 18 9 (2%) 9 (2%) 0.620 13 (2%) 5 (3%) 0.146 
  Spironolactone [1] 1 1 (0.2%)  0.418 1  0.150 
  Digoxin [2] 68 6 (1%) 62 (15%) <0.0005 41 (6%) 27 (14%) <0.0005 
  Oral hypoglycaemic agent [2] 21 11 (2%) 10 (2%) 0.990 17 (2%) 4 (2%) 0.028 
 
    
 
 
 
Revascularisation at Any Time     
 
 
 
  PCI [0] 94 77 (16%) 17 (4%) <0.0005 94 (13%) 0 <0.0005 
  CABG [0] 98 67 (14%) 31 (4%) 0.002 96 (14%) 2 (1%) <0.0005 
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Treatments at Any Timea        
  ACEi (seven cases prior to index   were 
on ACE-inhibitors) [2] 
496 249 (52%) 247 (59%) 0.091 449 (64%)   
  ARBs [2] 44 24 (5%) 20 (5%) 0.984 40 (6%)   
  Beta-blockers [2] 541 378 (79%) 163 (39%) <0.0005 509 (73%)   
  Loop diuretic [2] 539 151 (32%) 388 (93%) <0.0005 401 (58%)   
  Thiazide diuretic [2] 68 47 (10%) 21 (5%) 0.017 63 (9%)   
  Spironolactone [2] 64 25 (5%) 39 (9%) 0.037 64 (9%)   
  Digoxin [2] 110 30 (6%) 80 (19%) <0.0005 81 (12%)   
  Insulin [1] 93 38 (8%) 55 (13%) 0.020 73 (10%)   
  Oral hypoglycaemic agent [2] 72 46 (10%) 26 (6%) 0.111 67 (10%)   
  Aspirin [2] 805 461 (96%) 345 (83%) <0.0005 671 (96%)   
  Statin [2] 530 367 (77%) 163 (39%) <0.0005 517 (74%)   
 PCI, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; ARBs, angiotensin receptor blockers;  
aLData on patients who died during the index admission treatment is not shown since it could not have changed. 
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In patients who’s HF persisted until discharge, only 27 had their diuretics discontinued 
subsequently. Two of these patients developed renal failure and progressed to dialysis. 
Diuretics were stopped in three patients because of hypotension and electrolyte disturbances 
with a recurrence in symptoms and subsequent death. In the remaining 22 patients, diuretics 
were withdrawn without a recurrence of HF symptoms. Of the 182 patients with PHF at the 
time of discharge, 121 (66%) died within 6 years. 
Figure  3-2The proportions of patients developing different categories of heart failure (HF) 
 
Pie-chart showing the proportions of patients developing different categories of heart failure (HF) according to 
early mortality, timing of onset and persistence. See methods for definitions of transient, persistent, remission 
and recurrence. 
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Figure  3-3Mortality during index admission according to the development of HF during the index 
admission (transient or persistent). 
 
Of 74 patients with THF during the index admission, 41 (55%) had recurrence of HF (THF in 
eight), which occurred during admission for ACS or within 30 days of discharge in 18 
patients. Thirty eight (51%) of these patients died during follow-up, of which 29 were after 
the recurrence of HF (five after THF). 
Of 441 patients discharged without any occurrence of HF, follow-up data were available for 
417, of whom 145 (35%) subsequently developed HF, 58 of these in the year after the index 
admission. HF was transient during follow-up in 26 patients (18%). Late onset HF occurred 
in 46 (32%) cases during admission for ACS or within 30 days of discharge. Of the 145 
patients who developed HF after discharge, 76 (52%) died (six after transient HF) compared 
with 46 (16%) among the 296 patients who never developed HF at any time.  
Thus, of 278 deaths occurring subsequent to discharge following an MI, 235 (84%) occurred 
subsequent to the development of THF or PHF (Figures 3.4 and 3.5). In those patients who 
did not have HF at the time of discharge and in whom follow-up records were available 
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(n=489), the incidence of HF was 0.194 (95% CI 0.154 – 0.239) per person-year within the 
first year and 0.048 (95% CI 0.039 – 0.057) per person-year thereafter. 
Figure  3-4Kaplan-Meier curves showing prognosis amongst patients discharged after the index 
myocardial infarction with and without persistent or transient heart failure (HF). 
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Figure  3-5Pie-chart showing the proportion of patients who died with or without preceding evidence of 
heart failure (HF) subsequent to discharge from index admission. 
 
A report on left ventricular function during or shortly after the index admission was available 
in 507 (77%) surviving patients and 71 patients who died during the index admission (Table 
3.3). Of 255 (30%) patients reported to have LVSD during or within 90 days of admission, 46 
(18%) died during the index admission, 82 (32%) developed PHF, 30 (12%) developed THF, 
50 (20%) developed HF only after discharge, eight (3%) died after discharge without 
documented HF (one with no follow-up data), and 34 (14%) survived without documentation 
of HF (four with no follow-up data). A further 26(3%) patients had a prior diagnosis of 
LVSD without any imaging during index or within 90 days of index admission of whom 16 
(62%) died during the index admission and seven after discharge. Overall, 108 (49%) patients 
with documented LVSD died after discharge, 98 (91%) of whom also had HF. Of 297 
patients documented not to have major LV systolic dysfunction, nine (3%) died during the 
index admission, 34 (11%) developed PHF, 25 (8%) developed THF, 54 (18%) developed HF 
only after discharge, 20 (7%) died after discharge but without developing HF (one with no 
follow-up data), and 142 (50%) survived without developing HF (12 with no follow-up data). 
Died after 
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(84% of death)
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Overall, 67 (38%) patients who were documented not to have LVSD died after discharge, 46 
(69%) of whom had HF. 
Of 283 (33%) patients for whom no report of LV function was identified, 128 (45%) died 
during the index admission, 49 (17%) developed PHF, 13 (5%) developed THF, 29 (10%) 
developed HF only after discharge, 14 (5%) died after discharge without documented HF 
(one with no follow-up data), and 44 (16%) survived without documentation of HF (five with 
no follow-up data). Overall, 85 (49%) patients, who had no assessment of LV function 
reported in their records, died after discharge; 80 (94%) of them also had HF. 
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Table  3-3Imaging evidence of left ventricular (LV) function during index admission or shortly thereaftera 
Images [missing data] All 
 
No HF during 
index admission 
HF during 
index admission 
P-value Survived 
index 
Died on 
Index 
P-value 
 861 458 403  662 199 
 
Contrast angiography 93 60 33  87 6  
 
  Left main coronary artery [2] 10 6 (10%) 4 (12%) 0.551 10 (11%) 1 (16%) 0.837 
 Three-vessel diseaseb 42 27 (45%) 15 (47%)  41 2 (33%) 
 
Two-vessel disease 25 17 (28%) 8 (25%)  23 2 (33%) 
 
 One-vessel disease 24 15 (25%) 9 (28%)  22 2 (33%) 
 
  NVD 1 1 0 0.824 1 0 0.926 
  LVSD (LV assessed n=59) [33] 13 7 (16%) 6 (38%) 0.048 13 0 0.034 
 
 
    
 
 
Echocardiography 283 106 177  226 57 (29%) 
 
  Major LVSD [4] 141 31 (29%) 110 (63%) <0.0005 96 (43%) 45 (83%) <0.0005 
  Moderate or severe mitral regurgitation [12] 39 3 (3%) 36 (20%) <0.0005 24 (11%) 15 (29%) 0.001 
  Moderate or severe other valve disease[6] 11 1 (1%) 10 (6%) 0.118 8 (4%) 3 (5%) 0.818 
 
 
    
 
 
Radionuclide 357 251 106  249 2   
  LVEF 35-39% 42 27 (11%) 15 (14%)  42 (17%) 0  
  LVEF <35% 110 51 (20%) 59 (57%) <0.0005 108 (43%) 2 (100%) 0.105 
        
LVSD Prior to indexc 26 1 15  9 16  
  LV assessment by any technique ∆ 578 329 (72%) 249 (62%) 0.002 507 (77%) 71 (36%) <0.0005 
  Moderate or severe LVSD by any technique [283] 281 100 (30%) 181 (73%) <0.0005 219 (43%) 62 (87%) <0.0005 
aThe imaging test indicating the most severe left-ventricular impairment on index admission or first available within 90 days after index 
admission (excluding 35 cases with recurrent acute myocardial infarction within 90 days, since the image may not reflect the damage 
from their index infarction). Percentages shown are of those in whom measurements were made. 
bFour cases had graft occlusion, six cases had ventricular septal defect, and one had mitral valve rupture during index admission. Two 
patients had prior valve replacement and aortic regurgitation or stenosis or mitral stenosis.  
cLeft ventricular systolic dysfunction (LVSD) Prior to index admission without imaging during index admission or shortly after. ∆ LV 
assessed in 578 cases of which 26 cases had LVSD prior to index admission and LVSD on index admission in 392 cases, 500 cases 
within 30 days, 37 cases within 31-60 days, and 15 cases within 61-90 days. Two cases had angiography done privately with no result in 
case note. 
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3.3.2 Mode of Death 
Of 199 patients who died during the index admission, the mode of death was considered to be 
sudden cardiac death (SCD) in 55 cases (14 after arrhythmia), HF in 114, stroke in two, 
cardiac procedure-related in four, other cardiac in eight, infection in four, cancer in one, and 
other non-cardiac in 11 patients. 
Of 281 patients who died after the index admission, 168 died during a re-admission to 
hospital and 113 died out of hospital. Out of hospital deaths were usually poorly documented 
but were probably sudden because of arrhythmias or vascular events. Fifteen patients had 
severe HF, one died of self-poisoning, nine had advanced cancer, one had severe pulmonary 
hypertension, and two had stroke.  Among patients who died out of hospital, 83 (73%) had 
either THF or PHF, 48 of whom had documented LVSD, 19 documented absence of 
important LVSD at last cardiac imaging prior to death. Sixteen had no assessment of LV 
function. 30 (27%) had no HF, seven of whom had asymptomatic LVSD, 13 had documented 
absence of LVSD at last cardiac imaging prior to death and also ten had no assessment of LV 
function. Of those who died on re-admission, nine were attributed  to SCD, 68to HF of whom 
39 fulfilled the definition of cardiogenic shock prior to death, 11 to stroke, two to cardiac 
procedures, four to other cardiac causes, 22 to infection, 24 to cancer and 27 to other non-
cardiac causes. One patient had missing notes. 
3.3.3 Cox Model 
The age-adjusted models are presented in Table 3.4.  Patients with PHF at follow-up had a 
high mortality when compared with those having no HF. Adjusting for other factors such as 
creatinine, anaemia, beta blockers, smoking, diabetes, prior MI, history of HF, gender, ST-
Azam Torabi  Incidence and outcome of MI 
58 
 
elevation and non ST-elevation, SVT, PTCA, CABG and Q wave in discharge did not alter 
the nature of these relationships (though obviously the HRs were different). 
 
Table  3-4Cox-regression models; for mortality in patients unadjusted and age-adjusted subsequent to 
discharge (n=667). 
  Univariable Age Adjusted 
Variable Name N HR P-value HR P-value 
HF Statusa 272     
PHF-persistent at follow-
up 
156 7.822 (5.497-11.131) <0.0005 4.732 (3.270-6.848) <0.0005 
PHF-resolved at follow-up 22 0.753 (0.352-1.613) 0.466 0.677 (0.316-1.450) 0.315 
THF-redevelop HF  41 2.4444 (1.550-3.854) <0.0005 2.409 (1.527-3.798) <0.0005 
THF-remission at follow-
up 
31 0.656 ( 0.329-1.309) 0.232 0.775 (0.388-1.549) 0.471 
No HF-developed HF 145 1.434 (1.046-1.967) 0.025 1.499 (1.093-2.057) 0.012 
MI after discharge 145 2.655 (2.075-3.398) <0.0005 2.011 (1.565-2.584) <0.0005 
Angina admission 111 0.395(0.260-0.601) <0.0005 0.419 (0.275-0.637) <0.0005 
HF, heart failure; MI, myocardial infarction; HR, hazard ratio; THF, transient HF during index 
admission; PHF, persistent HF during the index admission. 
awith reference to no HF any time (index admission and follow-up). 
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3.4 Discussion 
This report suggests that the prognosis of MI is much worse than many contemporary clinical 
trials suggest, and that death is usually preceded by the development of HF. Of 896 patients 
with a hospital diagnosis of acute MI in 1998, 562 (62.7%) had or developed HF in the 
following 6 years. The high proportion of patients who develop HF after an MI might seem 
surprising, as ischaemic heart disease is common and the prevalence of HF only about 1%. 
This reflects the poor prognosis of HF, often a short-lived illness usually terminated by death, 
and suggests that the burden of HF may be better described by its incidence rather than 
prevalence[75]. HF is also often under-represented in health-care statistics, because events 
such as death or hospitalization are ascribed to the cause of HF rather than its presence. Death 
is usually a complex process and attributing death to only one reason is often inappropriate. 
For instance, a patient could die of a lethal arrhythmia in the setting of worsening HF induced 
by a recurrent ischaemic event. This patient died as a consequence of a constellation of 
events. What is important is to identify which interventions might produce worthwhile 
benefit for patients. 
A systematic review suggested that the crude incidence of HF for any reason in the overall 
population is 1.3/1,000/year[76]. Extrapolating from our data, the population incidence of HF 
related to MI may be about 0.7/1,000/year. As population studies suggest that only about half 
the cases of HF are preceded by an MI [77 78], our data appear consistent with the overall 
situation but provide a rather different perspective. New-onset HF after discharge was more 
common than in previous reports [22 38 40], perhaps reflecting the intensity of surveillance 
or the definition used in our study. However, effective treatment of MI is likely to reduce 
mortality to a greater extent in patients with large MIs who are then likely to survive to 
develop HF. Therefore, our study provides some support for the widely held suspicion that 
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good post-infarction care will increase rather than decrease the incidence and prevalence of 
HF [74]. 
Understanding the natural history of patients who have had an MI with and without HF may 
help inform therapeutic choices. Amongst patients who had HF, it was present in 23.1% prior 
to the index infarct, many of whom had had a previous MI, it developed for the first time 
during the index hospital admission in 51.1% and within 30 days of a further coronary event 
in 6.1%. Only 19.4% of patients developed HF more than 30 days after the index infarction 
without a further hospitalization for MI. Not all MIs present with typical symptoms and may 
manifest as worsening HF or sudden death[79 80 81 82]. Thus, most cases of HF observed in 
this cohort occurred in close proximity to an acute coronary event. This has two important 
implications. Firstly, it challenges the concept that HF is often because of progressive LV 
remodelling with a long prodrome. Most cases of HF may have a sudden and rather 
unpredictable onset because of MI or arrhythmias, which would account for why most first 
diagnosis of HF occurs in hospital[83]. Secondly, it reinforces the view that treatment 
directed at reducing the extent of acute myocardial damage and prevention of re-infarction 
might have important effects on the development of HF[84 85 86 87 88 89].Trials of 
statins[90 91], ACE-inhibitors[15 92], aldosterone antagonists[93] and beta-blockers[94] , 
although not aspirin [95], appear to reduce the risk of HF after MI, which is partly mediated 
by reducing further coronary events. It is widely believed that these treatments can also 
reduce the risk of recurrent MI in patients with HF, thereby improving survival [96]. 
However, a recent large study suggested that rosuvastatin could reduce non-fatal vascular 
events but not mortality, perhaps because vascular events were not an important driver of 
outcome [97]. Similarly, anti-thrombotic agents have failed, so far, to reduce mortality in HF 
[98]. Other treatments, such as ACE-inhibitors, aldosterone antagonists, and beta-blockers, 
appear more effective at reducing mortality than coronary events in patients with established 
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HF, although it has been argued that this reflects their ability to prevent some patients with 
MI from dying suddenly [96]. Treatment directed solely at preventing progressive LV 
remodelling in the years after MI might have only a minor role in the prevention of HF in this 
population, as few patients who developed HF did so remote from an acute coronary event. 
However, treatments aimed predominantly at ventricular remodelling may have an important 
role in slowing the progression of HF once it has developed. 
About 40% of the deaths that occur within approximately six years after a MI occur during 
the index admission and 35% during a subsequent re-admission. Most of these deaths were 
associated with severe HF. About one-quarter of patients died out of hospital. Most of these 
patients had developed HF prior to death, although only about 10% reported deteriorating 
symptoms in the month before death. Little information could be obtained on the mode of 
death in these patients but adjudication committees of clinical trials, that often obtain more 
detailed data, assign most of these to sudden death and assume that arrhythmias rather than 
recurrent vascular events are the cause [96]. Accordingly, widespread implantation of a 
defibrillator theoretically might reduce mortality amongst discharged patients by about 30%. 
However, the Defibrillator in Acute Myocardial Infarction Trial (DINAMIT) [99] showed 
that implantation of a defibrillator early after MI did not reduce mortality, perhaps because 
this intervention cannot reduce the commonest mode of death in these patients which is 
worsening HF. More aggressive pharmacological therapy [47] may be the best way to 
manage the risk of both sudden death and worsening HF. Whether early implantation of a 
device that also provides bi-ventricular pacing could improve prognosis awaits the outcome 
of further trials[100]. 
The prognosis of HF in this study was worse than suggested by either randomized controlled 
trials [101 102]or many surveys of MI [24]. However, using the GRACE registry score, the 
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predicted in-hospital mortality for our patients was 22%[103]. The lower mortality observed 
in other cohorts most likely represents case-selection, with preference being given to 
recruitment of younger patients, who tend to be managed by cardiologists, in trials and 
surveys and the exclusion of cardiogenic shock and severe HF. Age was a powerful 
determinant not only of prognosis but also of the likelihood of being referred to a cardiologist 
in our study.  
As reported by others[21], LVSD and clinical evidence of HF carried independent prognostic 
information. Patients who had both did worse than those who had either alone. Potential 
markers of the metabolic stress of a large infarction and the development of HF, including 
renal dysfunction and hyponatraemia were also independent predictors of an adverse outcome 
and each a potential target for therapy. 
3.5 Study limitations 
Patients with THF developing either during or after the index admission that subsequently 
resolved permanently had a HR <1 which may seem surprising (Table 3.4). There were few 
such patients in these cohorts, the CIs around the HR were wide and overlapped that of 
patients who never developed HF. Patients with THF had to survive long enough to permit 
HF to resolve and this may have introduced methodological bias favouring outcome in 
patients with THF. A similar potential bias towards an over-optimistic assessment of survival 
exists for patients with late-onset HF who had a poor outcome when compared with those 
who never developed HF. Also, exclusion of patients with recurrent or late-onset HF and a 
poor prognosis from the groups with only THF will bias outcome favourably in the latter 
groups. A less likely explanation for the lower mortality in patients with THF is that their 
intrinsic risk is similar to patients who never had HF, but that they received the prognostic 
Azam Torabi  Incidence and outcome of MI 
63 
 
benefits of treatment for HF. We also acknowledge a potential pessimistic bias in assessing 
outcome in patients with PHF, as patients who die early have less opportunity to recover and 
therefore less opportunity to be labeled as THF[104]. Ultimately, this analysis is descriptive 
and not designed to show whether one group does better than another but rather the outcome 
in each individual clinical group of patients. 
Our study will have missed patients who died of their MI before reaching hospital and 
patients who, if they had symptoms, were not recognized as having had an MI. 
Epidemiological studies suggest that about one-third of patients with MI die before they 
reach hospital[6], and that about one-quarter of patients who survive an MI do not have 
symptoms that lead to urgent hospital referral[26 105 106]. It is likely that the hospital 
records system failed to code some infarcts, although false-positive coding was rare. For 
these reasons, this study substantially underestimates the true incidence of MI in the 
community. The survey was of patients managed in 1998. Significant changes in prevention 
and management have occurred and may have altered outcome. In 2005, 704patients had a 
death or discharge diagnosis MI reported in our hospital of which78 died (11% compared to 
22% in 1998). We defined HF as HF symptoms that led to treatment with loop diuretics but 
some patients may have been managed with thiazides. Not all patients had LV function 
assessed. Also, as systematic attempts were not made to withdraw diuretics, we may have 
under-estimated the transitory nature of HF in some cases. A simple, robust definition of HF 
remains elusive. However, patients who receive loop diuretics and who have cardiovascular 
disease clearly have a poor prognosis whether or not they have a low EF [26]. Ultimately, HF 
is a clinical syndrome that relies on a doctor’s skill in assessing a patient in the light of 
appropriate investigations. 
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The prevalence of diabetes mellitus was similar to that reported in another large trial from the 
same county in England, but is towards the lower end of the spectrum reported in the 
literature [38 41]. This may reflect under-reporting of milder cases of diabetes, as it was not 
routine practice to obtain fasting blood glucose in these patients. However, surveys reporting 
high levels of diabetes have generally included large numbers of patients from North 
America, where the prevalence of diabetes is probably, genuinely higher than in our region. 
Another potential limitation of our analysis is that patients who died early had less 
opportunity to recover or to develop late-onset HF. It is unclear how useful attempts at 
adjusting for this problem would be. Ultimately, our study is not trying to build a risk model, 
but to establish the proportion of patients who develop HF after an MI, to describe its time of 
onset, whether it resolves and the consequences of each in terms of mortality. 
3.6 Conclusion: 
The development of THF or PHF precedes death in the great majority of patients who die 
within 6 years of an MI. Most patients who develop HF after an MI do so shortly after an 
initial or recurrent coronary event suggesting that reducing infarct size and recurrent events 
rather than ventricular remodelling may be a more successful strategy to prevent HF. 
Improved management of HF and its important co-morbidities such as renal dysfunction and 
diabetes may slow the rate of progression and improve quality of life and prognosis in such 
patients.  
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4 Chapter 4: The development and course of Heart Failure after 
a Myocardial Infarction in different age groups 
4.1 Introduction 
Heart failure (HF) is a common complication of myocardial infarction (MI), which may 
develop early or late and once it has developed it may persist or resolve, and if it resolves it 
may re-occur [107].A growing proportion of patients with MI are aged >65 years and older 
patients are at greater risk of developing HF and have a poorer prognosis[108 109 110]. 
Surprisingly, the complex pattern and timing of the development and resolution of HF and 
the importance of such distinctions has never been quantified in relationship to age [109 111].  
Understanding the drivers of morbidity and mortality after MI is important, given the large 
gap between mortality rates reported in clinical trials of MI compared to those reported in 
epidemiological studies. Improved understanding of which patients are at risk and the nature 
of the risk could help focus attention on patients at greater need, to ensure that they receive 
appropriate therapy and that they are targeted for recruitment into clinical trials, which are 
currently struggling to show substantial differences in outcome partly because their event 
rates are so low. Treatment can only help patients who are at risk of the problem you are 
trying to prevent.  
4.2 Methods 
4.2.1 Study population 
One hospital group in Hull and the East Riding of Yorkshire (UK) provides all of the acute 
cardiac services for about 560,000 people living in a geographically distinct part of the 
United Kingdom. Patients with a discharge diagnosis of acute MI during 1998 were identified 
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from the Hospitals Information Department and their case notes screened. Patients who were 
transferred from another region, those with missing case notes or in whom acute MI could not 
be confirmed from their records were excluded. The study was approved by the Local 
Research Ethics Committee. 
4.2.2 Follow-up 
This was a retrospective analysis designed in 2004. The case records of all patients were 
reviewed to identify use of loop diuretics and if so whether this was due to symptoms or signs 
of HF. Follow-up data were collected until 31st December 2005. If no recent hospital record 
existed, the family practitioners of patients or patients themselves were contacted to ascertain 
the patient’s current therapy and HF status. The occurrence of major events, such as recurrent 
MI, and stroke were recorded.  
4.2.3 Definition of Myocardial Infarction 
At least two of the following five criteria had to be identified during case note review to 
confirm a diagnosis of MI. 
1. History of prolonged cardiac chest pain. 
2. An increase in biomarkers consistent with MI, which in 1998 was usually creatinine 
kinase (CK) or CK-MB mass. These were considered abnormal if they were twice the 
upper limit of normal values. 
3. Progressive electrocardiographic changes consistent with MI or new onset left bundle 
branch block. 
4. Sudden unexpected death 
5. Autopsy evidence of MI 
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4.2.4 Other Definitions 
Heart failure was clinically defined either as signs and symptoms consistent with that 
diagnosis (principally breathlessness and signs of fluid retention) resulting in treatment with 
loop diuretics or patients who died shortly after developing evidence of major cardiac 
dysfunction, such as cases of cardiogenic shock or pulmonary oedema. Cardiogenic shock 
was defined as an arterial pressure <100mmHg because of low cardiac output requiring 
inotropic therapy or an intra-aortic balloon pump. For patients with an un-recordable blood 
pressure, a systolic pressure of 50mmHg was entered as a default value for statistical 
purposes. Use of loop diuretics for the treatment of hypertension or renal failure was not 
included in the definition of HF. Criteria for left ventricular systolic dysfunction (LVSD) 
were left ventricular ejection fraction (LVEF) < 40% or a qualitative report of moderate or 
severe LVSD on echocardiography, first-pass radionuclide ventriculography or contrast 
angiography. Patients according to their age were categorised into three groups: (i) <65 years 
old; (ii) 65-75 years old and (iii) >75 years old. 
4.2.5 Resolution of Heart Failure 
Consistent with European Society of Cardiology Guidelines[68], resolution of heart failure 
was defined as the withdrawal of diuretics without the recurrence of symptoms.  
4.2.6 Statistical Analysis: 
Data were entered into a Microsoft Access database and analysed using SPSS Inc, version 
13.0 (UK, Ltd). Key outcomes were the proportion of patients who died and all-cause 
mortality. Continuously distributed data are presented as median and inter-quartile range 
(IQR). Categorical data are presented as percentages.  Groups of patients with and without 
HF were compared by the Chi-squared test. Kaplan-Meier (K-M) curves were generated to 
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illustrate patients’ overall survival, and in subgroups.  K-M curves were compared by the log-
rank test on the appropriate degrees-of-freedom. Cox regression was used to look at 
mortality, from which hazard ratios (HRs) and 95% CIs were calculated. The Cox regression 
model is semi-parametric in the sense that no assumption concerning event-free survival 
times is necessary. The Cox regression model is based on the assumption that the effect of a 
risk factor, expressed as a HR, is constant over time. The assumption of proportionality of the 
Cox model covariates was tested by plotting residuals[72 73]. Linearity of continuous data 
was checked by including a squared term. We did not build a model using automated 
selection methods. Models explained survival on the basis of their biological relevance to 
heart failure[112]. Hence, we adopted an epidemiological approach to model building. 
Heart failure status was categorised into six groups: (i) No HF at any time (this was the 
reference group for statistical comparisons); (ii) Patients with HF on the index admission and 
persisting at follow up until death or end of follow-up; (iii) Persistent HF on the index 
admission that resolved subsequent to discharge; (iv) Transient HF on the index admission 
that resolved prior to discharge but recurred during follow-up; (v)Transient HF on the index 
admission that resolved prior to discharge and did not recur prior to death or end of follow-
up; (vi) Patients who did not develop HF on the index admission but who later developed HF 
during follow-up. 
4.3 Results: 
4.3.1 Overall results: 
Of 1,012 patients with a death or discharge diagnosis of acute MI in 1998, 116 were excluded 
from further analysis because they were transfered from another region or due to a lack of 
confirmation of MI in the patient-record. This left 896 patients for analysis, of whom 311 
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(35%) were aged <65 years, 297 (33%) were aged 65-75 years and 288 (32%) were aged >75 
years (Table 4.1). Of these patients,16, 8 and 6 from each group respectively were lost to 
follow-up after the index admission. About one third of patients were women, with the 
proportion increasing with age. About 25% of patients had a prior history of MI and about 
15% had a history of HF preceding the index event, rising from 7% in those aged <65 years 
to 25% in those aged >75 years. ST-segment elevation myocardial infarction (STEMI) was 
present in 193 (62%), 174 (59%) and 151 (53%). Fewer older patients were managed 
primarily by a cardiologist. 
During the index admission, younger patients were more often treated with aspirin, statin, 
beta-blockers, intravenous nitrate and heparin. Older patients were more likely to receive 
loop diuretics and digoxin (p=0.0005) (Table 4.2). Primary angioplasty was not done in this 
hospital group in 1998. 159, 127 and 86 patients received thrombolysis in aged <65 years 65-
75 years and aged >75 respectively. 
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Table 4-1 Patients Characteristics recorded during the Index Admission overall and classified according to the three different age group: >65 years old, 65-75 years 
old and > 75 years old (data are median (inter-quartile range) and number occurring (%)). 
Variables (units) Missing data All <65 years old 65-75 years old >75 years old P  value 
n  896 311(35%) 297 (33%) 288 (32%)  
Age (years) 0 70 (61-78) 58(51-61)  71 (68-73) 81 (78-85) 0.0001 
Women 0 333 (37%) 66 (21%) 120 (40%) 147 (51%) 0.0001 
Current smoker 87 303 (37%) 166 (55%) 97 (35%) 40 (17%) 0.0001 
Ex smoker  255 (32%) 85(30%) 96 (35%) 74 (32%)  
History of Hypertension 40 300 (35%) 81 (27%) 105 (37%) 114 (42%) 0.006 
History of Diabetes 3 82 + 33a (13%) 33 (11%) 45 (15%) 37 (13%) 0.290 
Prior MI 1 234 (26%) 73 (24%) 73 (25%) 89 (31%) 0.153 
History of HF 4 134 (15%) 22 (7%) 39 (13%) 73 (25%) 0.0001 
Prior CABG  39 (4%) 19 (6%) 14 (5%) 6 (2%) 0.051 
Prior PTCA  14 (2%) 10 (3%) 4 (1%) 0 0.006 
Managed Primarily by Cardiologist  558 (62%) 233 (75%) 186 (63%) 139 (48%) 0.0001 
Index Admission ECG       
ST segment elevation	 10 518 (58%) 193 (62%) 174 (59%) 151 (53%) 0.001 
Non ST elevation 10 316 (36%) 110 (36%) 104 (35%) 102 (36%)  
ARS >120 23 199 (23%) 41 (13%) 70 (24%) 88 (31%) 0.0001 
Anterior site 10 422 (47%) 132 (43%) 151 (52%) 139 (49%) 0.052 
Chest X-ray       
Pulmonary oedema 227 160 (24%) 33 (14%) 54 (24%) 73 (33%) 0.0001 
Cardiomegaly  156 (23%) 42 (18%) 47 (21%) 67 (30%) 0.018 
Upper Lobe Vein Distension  159 (24%) 50 (22%) 51 (23%) 58 (26%) 0.388 
Pleural effusion  73 (11%) 15 (7%) 23 (10%) 35 (16%) 0.014 
Physical Examination       
Heart Rate 9 78 (64-97) 73 (61-88) 76 (64-98) 85 (68-101) 0.0001 
Atrial fibrillation (yes/no) 2 153 (17%) 19 (6%) 56 (19%) 78 (27%) 0.0001 
Systolic blood pressure 5 140 (120-160) 132 (121-142) 140 (120-160) 140 (120-160) 0.610 
HF during index  417 (47%) 82 (29%) 143 (48%) 192 (67%) 0.0001 
Discharged with HF  182 (20%) 37 (12%) 63 (21%) 82 (28%) 0.0001 
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Died during index admission  199 (22%) 24 (8%) 68 (23%) 107 (37%) 0.0001 
Blood Tests (on admisssion)  828 (376-1901)     
Peak CK 49 828 (376-1901) 1062(418-2262) 767 (369-1779) 684 (318-1651) 0.018 
Cholesterol 353 5.5 (5-6.4) 5.5(4.9-6.3) 6 (5-6) 5 (5-6) 0.591 
Sodium 29 137 (135-139) 137(136-139) 137 (135-139) 137 (135-138) 0.001 
Creatinine 127 105 (89-129) 95(83-108) 108 (90-132) 117 (96-149) 0.0001 
Anaemia in 1st available Hb 41 206(24%)  67 (24%) 105 (38%) 0.0001 
CABG, coronary artery bypass; PTCA, percutaneous transluminal coronary angioplasty; ECG, electrocardiogram. Percentages are shown are of those in whom measurements were made. CK = 
creatine kinase. Example interpretation: older patients hadhigh creatinine levels compare to younger patients. Many of these associations show dose-response. The differences for Na are 
exaggerated because of the relative large sample sizes between the three groups, and the relatively low standard deviations ( in other words, this is a statistical quirk). 
aThirty-two cases newly diagnosed as diabetic on index admission. 
bP-value for ST calculated between three groups (STE, No STE and other (LBBB and pace).  
cHeart failure during index admission. Of deaths during the index admission, in age <65, 65-75 and >75 years respectively 12, 27, and 33 patients developed cardiogenic shock.  d Anaemia: 
WHO criteria for anaemia are used  (male <13 dg/dL; female <12 g/dl) 
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Table  4-2Treatment during index admission and any time until 31st December 2005. 
 
 
Variables (units)  missing 
data 
All  <65 years old 
 
65-75 years old 
 
>75 years old P value 
n  896 311 (35%) 297 (33%) 288 (32%)  
Revascularisation during 
admission 
      
    Thrombolysis 0 372  159 (51%) 127 (43%) 86 (30%) 0.0001 
    PCI 0 20  16 (0.05%) 4 (0.01%) 0(%) 0.0001 
    CABG 0 8 4 (0.01%) 3 (0.01%) 1 (<0.01%) 0.459 
Treatment During Admission       
  Parenteral       
    Loop diuretic 7 262 49 (16%) 91 (31%) 122 (42%) 0.0001 
    Nitrates 3 309 125 (40%) 103 (35%) 81 (28%) 0.019 
    Inotropic therapy 2 94 22 (0.07%) 34 (11%) 38 (13%) 0.121 
    Heparin 15 694 264 (86%) 234 (80%) 196 (70%) 0.0001 
    Insulin 1 79 28 (0.09%) 34 (11%) 17 (0.06) 0.104 
  Oral       
    Aspirin 2 792 302 (97%) 251 (85%) 239 (83%) 0.0001 
    Clopidogrel 2 7 3 (1%) 4 (1%) 0 0.321 
    Warfarin 2 35 7 (2%) 14 (5%) 14 (5%) 0.332 
    Statin 2 406 214 (69%) 141 (48%) 51 (18%) 0.0001 
    ACE inhibitors 2 354 126 (41%) 120 (41%) 108 (38%) 0.782 
    ARBs 2 8 2 (1%) 2 (1%) 4 (1%) 0.689 
    Beta-blockers 2 497 236 (76%) 163 (55%) 98 (34%) 0.0001 
    Nitrates 2 320 90 (29%) 107(36%) 123 (43%) 0.008 
    Calcium channel blockers 2 215 70 (23%) 82 (28%) 63 (22%) 0.364 
    Loop diuretic 3 297 58 (19%) 94 (32%) 145 (50%) 0.0001 
    Thiazide diuretic 1 18 4 (1%) 7 (2%) 7 (2%) 0.495 
    Spironolactone 1 1  1   
    Digoxin 2 68 6 (2%) 22 (7%) 40 (14%) 0.0001 
    Oral hypoglycaemic agent 2 21 4 (1%) 6 (2%) 11 (4%) 0.241 
Revascularisation at Any Time       
    PCI 0 94 72 (23%) 20 (8%) 2 (1%) 0.0001 
    CABG 0 98 58 (19%) 35 (12%) 5 (2%) 0.0001 
Treatments at Any Time       
    ACE-inhibitors  2 496 197 (63%) 170 (57%) 129 (45%) 0.0001 
    ARBs 2 44 26 (8%) 11 (4%) 7 (2%) 0.009 
    Beta-blockers 2 541 256 (82%) 173 (58%) 99 (35%) 0.0001 
    Loop diuretic 2 539 130 (42%) 187 (63%) 222 (77%) 0.0001 
    Thiazide diuretic 2 68 30 (10%) 20 (8%) 18 (6%) 0.287 
    Spironolactone 2 64 28 (9%) 20 (8%) 17 (6%) 0.301 
    Digoxin 2 110 16 (5%) 38 (13%) 56 (20%) 0.0001 
    Insulin 1 92 33 (11%) 39 (13%) 20 (7%) 0.083 
    Oral hypoglycaemic agent 2 67 26 (8%) 24 (8%) 17 (6%) 0.499 
    Aspirin 2 805 304 (98%) 256 (86%) 245 (85%) 0.0001 
    Statin 2 530 269 (86%) 189 (64%) 72 (25%) 0.0001 
PCI, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; ARBs, angiotensin receptor-
blockers. 
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Overall, 75 (24%) patients <65 years, 170 (57%) 65-75 years and 235 (82%) >75 years had 
died by December 2005.  Figure 4.1a, b and c describes the sequence of events that led to the 
development of HF and/or death. Figure 4.2 shows the overall proportion of patients who 
developed HF at any time during follow-up and their categorisation according to persistence, 
remission and timing of development of HF in different age groups. During the index 
hospitalization, 82 patients (26%) <65 years, 143 (48%) patients 65-75 years and 192 patients 
(67%) >75 years developed HF. Twenty four patients (8%) <65 years died, of whom 19 
(79%) had HF, 68 (23%) patients 65-75 years died, of whom 53 (78%) also had HF and 107 
patients (37%) >75 years died, of whom 89 (83%) died after developing HF. Heart failure 
resolved in 26 (32%)patients <65 years, in 27 (19%) patients 65-75 years and in 21 (11%) 
patients >75 years and therefore only 37 (12%) patients <65 years, 63 (21%) patients 65-75 
years and 82 (28%) patients >75 years were discharged with persistent heart failure of whom 
13, 26 and 31 respectively had HF prior to admission. 
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19 Died During Index
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(n= 37)
Discharged with No HF
(n= 26)
Discharged No HF
(n=224)
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(n=28)
Alive 14 / Dead 14
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(n= 9)
Alive 8 / Dead 1
Without recurrent 
ischaemic episode
(n= 6)
Alive 5 / Dead 1
No HF at FU (n= 13)
Alive 12 / Dead 1
1 Not Known 15 Not Known
After recurrent 
ischaemic episode
(n=6)
Alive 2 / Dead 4
Redeveloped HF
(n= 12)
No HF any time
(n=156)
Alive 141 / Dead 15
Developed HF
(n= 53)
Without recurrent 
ischaemic episode
(n= 43)
Alive 31 / Dead 12
After recurrent 
ischaemic episode
(n= 10)
Alive 8 / Dead 2
Age 65-75 years (n= 297)
Age <65 years (n= 311)
 
Fig 4.1.a:Flow diagram showing the sequence of development of heart failure (HF) and relationship with recurrent 
ischemic episodes and mortality over approximately 6 years in patients less than 65 years old which admitted with an 
acute myocardial infarction (MI) to the Hull and East Yorkshire Hospitals Group during 1998.  Follow-up data were 
incomplete in 16 patients. See text for details.  
Figure  4-1Flow diagram showing the sequence of development of heart failure and mortality over approximately 6 years in 
different age group 
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(n=139)
HF Persisted
(n= 56)
Alive 14 / Dead 42
HF Resolved
(n= 5)
Alive 3 / Dead 2
Without recurrent 
ischaemic episode
(n= 11)
Alive 3 / Dead 8
No HF at FU (n= 11)
Alive 8 / Dead 3
1 Not Known 5 Not Known
After recurrent 
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No HF any time
(n=79)
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(n= 36)
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After recurrent 
ischaemic episode
(n= 19)
Alive 6 / Dead 13
Age 65 years (n= 311)
Age 65-75 years (n= 297)
2 Not Known
 
Fig 4.1.bFlow diagram showing the sequence of development of heart failure and relationship with recurrent ischemic 
episodes and mortality over approximately 6 years in patients 65 to 75 years oldwhich admitted with an acute myocardial 
infarction to the Hull and East Yorkshire Hospitals Group during 1998.  Follow-up data were incomplete in 8 patients. See 
text for details. 
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2 Not Known
 
Fig 4.1.cFlow diagram showing the sequence of development of heart failure and relationship with recurrent ischemic 
episodes and mortality over approximately 6 years in patients more than 75 years oldwhich admitted with an acute 
myocardial infarction to the Hull and East Yorkshire Hospitals Group during 1998.  Follow-up data were incomplete in 6 
patients. See text for details. 
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Figure  4-2The proportions of patients developing different categories of heart failure according
age groups. 
Pie chart showing the proportions of patients developing different categories of h
mortality, timing of onset and persistence according to different age group (>65 years, 65
years). See methods for definitions of transient (THF), persistent (PHF), remission and recurrent heart failure 
(HF). 
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4.3.2 Long-Term Follow-up 
Amongst 37, 63 and 82 patients <65, 65-75 and >74 years with persistent heart failure at 
discharge, crude mortalities at six years were 41%, 70% and 76% respectively (two patients 
aged 65-75 years and two aged>75 years lost follow-up). Amongst 26, 27 and 21 patients 
with transient heart failure during the index admission in the three age groups during, 
46%,56% and 67% had recurrence of HF and 23%, 56% and 81% died. Of 224, 139 and 78 
patients in the three age groups who were discharged without developing HF, 15 were lost to 
follow-up and, of the remainder, 25%, 41% and 50% subsequently developed HF, which 
usually persisted. Of 53, 55 and 37 patients who developed HF after discharge, 26%, 62% 
and76% died in each age group respectively, compared to 10%, 12% and 51% in patients 
who never developed HF at any time. Thus of 271, 221 and 175 patients aged <65, 65-75 and 
>75 years who were discharged and followed-up, 115, 142 and 138 had or developed 
transient or persistent HF and 50 (18%), 102 (46%) and 126 (72%) subsequently died, of 
whom 35 (70%), 93 (91%) and 107 (85%) respectively occurred subsequent to the 
development of HF (Figures 4.3a, b and 4.4).  
A report on LV function during or shortly after the index admission was available in 228 
(83%), 175 (81%) and 104 (60%) surviving patients in the above mentioned patient groups 
and in 16, 24 and 31 patients who died during the index admission (Table 4.3). The outcome 
of these patients is shown in detail in Table 4.3. Overall, stratified by age, 26 (31%), 48 
(59%) and 34 (63%) patients with documented LVSD (including LVSD prior to the index 
admission) died after discharge, of whom 20 (77%), 46 (96%) and 32 (94%) also had heart 
failure. 
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Figure  4-3.a &b a and b:prognosis amongst patients discharged after the index myocardial infarction 
a: 
 
 
 
 
 
 
 
 
Kaplan-Meier curves showing prognosis amongst patients discharged after the index myocardial infarction in 
different age groups (>65 years, 65-75 years and >75 years) with any HF (persistent or transient) and those who 
never developed HF.  
 
Group ID 2 3 4 5 6 
 sig sig sig sig sig 
2 0.0001     
3 0.650 0.002    
4 0.0001 0.0001 0.0001   
5 0.0001 0. 019 0.0001 0.88  
6 0.0001 0.0001 0.0001 0.49 0.003 
1 
2 
3 
4 
5 
6 
KEY: 
1: <65 years- Never HF (n=156) 
2: <65 years- HF any time (n=115) 
3: 65-75 years- Never HF (n=79) 
4: 65-75 years- HF any time (n=142) 
5: >75 years- Never HF (n= 37) 
6: >75 years- HF any time (n= 138) 
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B: 
 
 
Kaplan-Meier curves showing prognosis amongst patients discharged after the index myocardial infarction with 
and without transient or persistent heart failure according to different age group (>65 years, 65-75 years and >75 
years). For statistical comparisons see Table 5.6. Numbers in table are numbers of patients. 
 
KEY <65 years 65-75 years >75 years 
----HF at Index- Persistent at Follow-Up 28 56 72 
---HF at Index- Remission at Follow-Up 9 5 8 
----Transient HF at Index- Recurrent at Follow-Up 12 15 14 
----Transient HF at Index- Remission at Follow-Up 13 11 7 
---5No HF at Index- Incident at Follow-Up 53 55 37 
----No HF at any time 156 79 37 
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Pie-chart showing the proportion of patients in different age groups (>65 years, 65-75 years and >75 years) who 
died, subsequent to discharge from index admission, with or without preceding evidence of heart failure.  
 
Figure  4-4 Mortality after index admission, with and without Heart failure any time and 
15% 85%
>75 years
Never HF (n= 19)
Development of HF (n= 107)
9% 91%
65-75 years
Never HF (n= 9)
Development of HF (n= 93)
30% 70%
<65 years
Never HF (n= 15)
Development of HF (n= 35)
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Of 51, 102 and 128 patients aged <65, 65-75 and >75 years who died after the index 
admission, 23 (45%), 67 (66%) and 78 (61%) patients died during a re-admission to hospital 
(Table 4. 4). Little detailed information was available for out-of-hospital deaths but review of 
existing data suggested that most were unexpected and probably sudden. 
4.3.3 Cox Model 
Patients who had or developed HF during the index admission had the poorest survival across 
all age groups Figure 4.3a and 4.3b a. Univariate age-stratified models are presented in Table 
4.5.  Patients with persistent HF had the highest mortality.  This effect was most marked for 
those patients in the middle-aged group (65-75 years old) and less pronounced for patients 
aged >75 years, most of whom developed HF and who had a poor outcome whether or not 
they developed HF.   
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Table  4-3Imaging evidence of left ventricular function during index admission or shortly after 
 Missing 
Data 
All Age<65 years Age 65-75 years Age>75 years p-value 
n  861 296 284 281  
Contrast angiography  93 64 24 5  
    Left main coronary artery 2 10 6 (10%) 3 (13%) 1 (20%) 0.855 
    Three-vessel diseaseb  42 25 (39%) 13 (54%) 4 (80%) 0.539 
    Two-vessel disease  25 20 (31%) 5 (21%)   
    One-vessel disease  25 18 (28%) 6 (25%) 1 (20%)  
    LVSD (LV assessed n=59) 33 13 11 (25%) 2 (13%) 0 0.210 
Echocardiography  283 96 100 87  
    Major LVSD 4 141 44 (46%) 51 (51%) 46 (55%) 0.029 
    Moderate or severe mitral regurgitation 12 39 9 (9%) 14 (14%) 16 (18%) 0.519 
    Moderate or severe other valve disease 6 11 1 (1%) 5 (5%) 5 (6%) 0.329 
Radionuclide  357 176 123 58  
    LVEF 35-40%  42 46 (26%) 39 (32%) 25 (43%) 0.087 
    LVEF <35%  110 18 (10%) 18 (15%) 6 (10%)  
LV assessment by any technique 319 552 237 (80%) 192 (68%) 123 (44%)  
Moderate or severe LVSD (any technique)c  281 98 101 82  
   Died index admission  62 15 (15%) 19 (19%) 28 (34%) 0.006 
   Discharged with persistent HF   91 24 (26%) 33 (33%) 34 (41%)  
   Discharged after transient HF  30 12 (13%) 13 (14%) 5 (7%)  
   Developed HF after discharge  50 21 (23%) 23 (24%) 6 (9%)  
Died after discharge-transient or persistent HF 
 
99 19 (19%) 48 (48%) 32 (39%)  
Survived despite transient or persistent HF 
 
72 8 (8%) 21 (21%) 13 (16)  
   Died after discharge without developing HF 1 10 6 (6%) 2 (2%) 1 (1%)  
   Survived without developing HFe 4 38 20 (20%) 11 (11%) 8 (10%)  
Total Deaths 1 170 40 (41%) 69 (69%) 61 (74%)  
 No Major LVSD (any technique)  297 146 98 53  
   Died index admission  9 1 (1%) 5 (5%) 3 (6%) 0.0001 
   Discharged with persistent HF   34 5 (3%) 14 (14%) 15 (28%)  
   Discharged after transient HF  25 10 (7%) 9 (9%) 6 (11%)  
   Developed HF after discharge  54 24 (16%) 19 (19%) 11 (21%)  
Died after discharge-transient or persistent HF  46 4 (3%) 22 (22%) 20 (38%)  
Survived despite transient or persistent HF 3 67 35 (24%) 20 (21%) 12 (23%)  
   Died after discharge without developing HF 2 21 7 (5%) 5 (5%) 9 (17%)  
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   Survived without developing HF 11 154 99 (71%) 46 (48%) 9 (17%)  
Total Deaths 2 76 12 (8%) 32 (33%) 32 (60)  
No Report of LV function by any technique  283 52 85 146  
   Died index admission 
 
128 8 (15%) 44 (52%) 76 (52%) 0.0001 
   Discharged with persistent HF  
 
49 6 (12%) 13 (15%) 30 (21%)  
   Discharged after transient HF 
 
13 2 (4%) 3 (4%) 8 (5%)  
   Developed HF after discharge 
 
29 3 (6%) 8 (9%) 18 (12%)  
Died after discharge-transient or persistent HF 
 
70 6 (12%) 16 (19%) 48 (33%)  
Survived despite transient or persistent HF 
 
21 5 (10%) 8 (9%) 8 (5%)  
   Died after discharge without developing HF 
 
15 5 (10%) 2 (2%) 8 (5%)  
   Survived and did not develop HF 
 
49 28 (54%) 15 (18%) 6 (4%)  
Total Deaths 
 
213 19 (37%) 62 (73) 132 (90%)  
aThe imaging test indicating the most severe left-ventricular impairment on index admission or 1st available within 90 days after index admission 
(excluding 35 cases with recurrent acute myocardial infarction within 90 days since the image may not reflect the damage from their index infarction). 
Percentages are shown are of those in whom measurements were made. 
bFour cases had graft occlusion, one cases had no vessel disease, six cases had ventricular septal defect, one cases had mitral valve rupture during index 
admission and two patients had prior valve replacement.  caortic regurgitation or stenosis or mitral stenosis. 
cTwentypatientshad prior LVSD without any LV assessment during or shortly after index admission. 
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Table  4-4 Mode of death in patients who died during index admission (n=199) and subsequent to 
discharge (n=281) 
 All Age<65 years Age 65-75 years Age>75 years 
 896 311 (35%) 297 (33%) 288 (32%) 
Died during index admission 
Total 199 24 68 107 
SCD 55 6 18 31 
HF 114 16 38 60 
Stroke 2 0 0 2 
Cardiac procedures related 4 0 1 3 
Other cardiac 8 1 3 4 
Infection 4 0 2 2 
Cancer 1 0 0 1 
Other non cardiac 11 1 6 4 
     
Died after the index admission 281 51 102 128 
Died during a re-admission 
Total 168a 23 67 78 
   SCD 9 2 3 4 
   HF 68 8 (35%) 30 (45%) 30 (39%) 
   Stroke 11 1 4 6 
   Cardiac procedures related 2 0 2 0 
   Other cardiac 4 1 1 2 
   Infection 22 2 7 13 
   Cancer 24 6 8 10 
   Other non cardiac 27 3 12 12 
Died out of hospitalb 
Total 113 28 35 50 
   Severe HFc 16 7 5 4 
   Advanced cancer 9 2 2 5 
   Stroke 2 1 0 1 
Any transient or persistent HF 83 17 29 37 
     Any HF with LVSD prior to deathd 48 12 20 16 
     Any HF with no LV assessment  16 2 3 11 
     Any HF with No LVSD 19 3 6 10 
  Never HF  30 11 6 13 
     Never HF but LVSD prior to death 7 5 2 0 
     Never HF with no LV assessment  10 2 2 6 
Never HF and No LVSD 13 4 2 7 
aone patient with age >75 years had missing data during last admission. 
bwith age 65-75 years one patients died of self-poisoning, with age <65 years one patient had three vessel disease and was 
waiting for CABG , one patient had three vessel disease and was waiting for PTCA and another had LAD disease but were not 
suitable for surgery and one patient 65-75 year old  had severe pulmonary hypertension. 
cSevere HF during one month prior to death of whom two had missed HF(chest X-rays report were pulmonary oedema after 
death). 
dLVSD in last cardiac imaging prior to death 
P-values not calculated owing to small cell numbers. 
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Table  4-5Cox-regression models; unadjusted and multivariate-adjusted procedures of mortality in patients subsequent to discharge (n=667). 
   Univariate  Multivariable Adjusted 
Variable Name N  HR P value  HR P value 
<65 years old 271       
Heart Failure Status* 156 30.559   24.632   
    PHF-persistent at f/up 28 26.103 6.701 (3.230-13.902) <0.0005 20.904 5.889 (2.754-12.593) <0.0005 
    PHF-resolved at f/up  9 0.618 0.450 (0.061-3.301) 0.432 0.436 0.507 (0.068-3.802) 0.509 
    THF-redevelop HF  12 2.667 2.543 (0.830-7.793) <0.102 2.378 2.420 (0.787-7.439) <0.123 
    THF-remission at f/up 13 1.203 0.319 ( 0.042-2.456) 0.273 1.160 0.326 (0.042-2.508) 0.281 
    No HF-developed HF 53 1.035 1.512 (0.682-3.351) 0.309 0.915 1.478 (0.664-3.287) 0.339 
Re-admission with MI 39 9.474 2.638 (1.422-4.893) 0.002 2.607 1.747 (0.888-3.437) <0.106 
Re-admission with angina 51 0.019 0.950 (0.462-1.955) 0.890 0.027 0.938 (0.435-2.022) <0.870 
65-75 years old 221       
Heart Failure Status* 79 49.172   46.855   
    PHF-persistent at f/up 56 44.738 11.798 (5.724-24.315) <0.0005 42.600 11.408 (5.492-23.697) <0.0005 
    PHF-resolved at f/up  5 0.136 1.309 (0.313-5.483) 0.712 0.225 1.416 (0.337-5.960) 0.635 
    THF-redevelop HF  15 6.317 2.683 (1.243-5.791) 0.012 4.199 2.143 (1.036-4.856) 0.040 
    THF-remission at f/up 11 0.796 0.578 (0.173-1.929) 0.372 1.089 0.526 (0.157-1.758) 0.297 
    No HF-developed HF 55 4.398 1.753 (1.037-2.962) 0.036 2.433 1.525 (0.897-2.592) 0.119 
Re-admission with MI 47 21.711 2.660 (1.763-4.015) <0.0005 3.718 1.522 (0.993-2.334) 0.054 
Re-admission with angina 39 11.348 0.267 (0.124-0.576) 0.001 8.644 0.305 (0.138-0.673) 0.003 
>75 years old 175       
Heart Failure Status* 37 14.914   12.452   
    PHF-persistent at f/up 72 11.415 2.452 (1.457-4.127) 0.001 7.580 2.114 (1.241-3.603) 0.006 
    PHF-resolved at f/up  8 1.572 0.523 (0.190-1.441) 0.210 2.580 0.434 (0.157-1.202) 0.108 
    THF-redevelop HF  14 3.293 1.872 (0.951-3.684) 0.070 3.266 1.869 (0.948-3.682) 0.071 
    THF-remission at f/up 7 0.463 1.381 (0.545-3.504) 0.496 1.184 1.689 (0.657-4.338) 0.277 
    No HF-developed HF 37 0.335 1.152 (0.713-1.861) 0.563 0.328 1.151 (0.711-1.863) 0.567 
Re-admission with MI 59 7.351 1.641 (1.147-2.349) 0.007 1.516 1.269 (0.868-1.855) 0.218 
Re-admission with angina 21 9.641 0.321 (0.157-0.658) 0.002 7.531 0.357 (0.171-0.745) 0.006 
*with reference to No HF any time (index admission and follow up). 
THF, transient HF during the index admission; PHF, persistent heart failure during the index admission; MI, myocardial infarction. 
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4.4 Discussion 
This analysis shows that the development of heart failure after a myocardial infarction 
increases steeply with age, that most patients who die subsequent to a myocardial infarction 
will first develop heart failure and that heart failure is a powerful adverse prognostic factor. 
Patients aged <65 years were least likely to develop heart failure but nonetheless, over six 
years of follow-up, 50% developed heart failure and 70% of deaths in this age group occurred 
subsequent to the development of HF. For patients aged 65-75 years, 73% developed heart 
failure during follow-up and 91% of deaths in this age group occurred subsequent to the 
development of HF. In patients aged >75 years, 87% developed heart failure but the 
prognosis was poor even amongst patients who did not develop overt heart failure. Few 
patients (only 34 of 281 or 12% of those evaluated) who had substantial LVSD after 
myocardial infarction escaped death or the development of heart failure over the subsequent 
six years. However, about half of patients who did not have substantial LVSD still went on to 
develop heart failure, of whom a large proportion died. Thus the prevention and management 
of heart failure rather than of LVSD may be the most important therapeutic target in patients 
with heart failure. 
This cohort of patients was enrolled prior to the widespread adoption of primary angioplasty 
and before national audits were introduced to improve the quality of care. Treatments to 
restore coronary perfusion were suboptimal. Studies show that thrombolysis and primary 
percutaneous angioplasty can reduce myocardial damage[113 114 115] leading to improved 
long-term recovery of cardiac function [116 117 118] and reduced mortality [119 120 121 
122]. This should lead to a reduction in the incidence of heart failure, although evidence in 
support of this hypothesis is scant. Use of ACE inhibitors [123], angiotensin receptor 
blockers[124 125], aldosterone receptor antagonists[93], beta-blockers [45]  and statins 
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[126]were not used optimally by contemporary standards. Greater use might have assisted 
recovery in ventricular function, reduced the development of heart failure and improved 
prognosis. Aspirin was used widely but was rarely used in combination with clopidogrel. The 
need for long-term anti-platelet therapy after MI is now under question, especially in patients 
who have developed HF [48 127 128]. Studies of patients with heart failure and coronary 
disease suggest no survival advantage [48 98 129 130] from aspirin in patients with heart 
failure but a substantial increase in admissions with exacerbations of HF.  
Hopefully, improvements in care have improved the prognosis of patients with myocardial 
infarction [131]. However, a repeat survey in our hospital conducted in 2005, with much 
higher uptake of guideline-indicated therapy, revealed a three year mortality which was still 
in excess of 30%, suggesting that the prognosis of heart failure in epidemiologically 
representative cohorts of patients, not just those who get to the catheter laboratory, remains 
poor. Overall, our cohort of patients was most unlike that observed in clinical trials. The 
median age in our cohort in 1998 was 70 years and 35% were women [107]. This had 
changed little by 2005 and is similar to that reported by the Myocardial Infarction National 
Audit Programme (MINAP) in the UK in 2003-2005 (mean age 69 years and 36% women 
[132]. The Euro Heart Survey of Acute Coronary Syndromes reported a mean age of just 63 
years and 29% women amongst patients with an ST elevation MI and 66 years and 36% in 
those with MI but not ST elevation [24]. In contemporary clinical trials, such as the Platelet 
Inhibition and Patient Outcomes (PLATO) study, the median age was only 62 years and only 
28% were women[133]. One year mortality, including in-patient deaths, was only 6% 
compared to in-patient and one year mortalities of 22% and 31% in 1998 and 11% and 19% 
in 2005 in our epidemiological cohort. The TRITON-TIMI 38 study was a randomized 
controlled trial comparing a new thienopyridine, prasugrel, to one of the first agents in this 
class, clopidogrel conducted between 2004 and 2007. Prasugrel has a faster and more 
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consistent effect on the inhibition of platelet activation than clopidogrel, the activity of which 
may be dependent on genetic factors. TRITON-TIMI 38 included very few patients aged >75 
years (only 13%). Patients aged >75 years were more likely to reach the primary end-point 
(cardiovascular death, MI or stroke) than the majority of patients who were aged <65 years 
(18.3% versus 10.6% over a median follow-up of 15 months for those assigned to 
clopidogrel. The relative and absolute gain of those assigned to prasugrel were lower in the 
older age group but with a substantial increase in the risk of haemorrhagic complications 
leading the regulators to the conclusion that the risks outweighed benefit in patients aged >75 
years with a low body weight (<60kg) [134].As low body weight indicates, in general, a 
worse prognosis in patients with cardiovascular disease [135] this should be a very high risk 
population but at 15 months only 16.0% of those assigned to clopidogrel had reached a 
primary endpoint compared to a one year mortality of 19% in the overall population in our 
2005 cohort. This could be reflect differences in care but more likely reflects differences in 
case ascertainment and selection. Old, frail and sick patients may either decline to participate 
in trials or investigators, for a variety of reasons including compassion, may avoid enrolling 
them. Moreover, patients in TRITON-TIMI 38 had to be eligible for PCI to participate and 
many multi-morbid, older patients may be deemed unfit for such a procedure. A low 
threshold for the detection of MI with the use of more sensitive troponin assays may also lead 
to an apparent improvement in prognosis, as small MIs will generally have a better prognosis 
than large ones. 
The patients with the worst prognosis, those aged >75 years are poorly represented in clinical 
trials (only 15% in the PLATO trial with a 1.4% absolute reduction in mortality from 5.9% 
with copidogrel to 4.6% with ticagrelor; p<0.001) and may well receive an inferior quality of 
care. Clinical trials amongst older patients with acute coronary syndromes could highlight the 
needs of this patient group and also provide a group at high risk of a poor outcome that would 
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allow the benefits of an effective therapy to be clear. The prognosis of patients enrolled in 
many contemporary trials of acute coronary syndrome is now so good it is difficult to make 
any improvement. However, older patients may also be at greater risk of side effects such as 
bleeding and renal dysfunction making the challenge of finding effective therapy greater. It is 
also possible that outcome in older patients is more resistant to change with therapy. 
The problem may not be so much chronological as biological age. Older patients had more 
co-morbid conditions such as atrial fibrillation, conducting system disease, respiratory 
disease, renal dysfunction, anaemia and, worst of all, heart failure. In a sense, age is a 
surrogate for the drivers of an adverse outcome. Investigation and management of these co-
morbidities could be an important pathway to improved outcomes. Patients aged 65-75 years 
are at intermediate risk and it is in patients at intermediate risk where the greatest therapeutic 
gains may occur. It is difficult to reduce risk in a group already at low risk, whereas in 
patients at high risk, an effective therapy may still not be effective enough to make a 
meaningful difference in outcome [136]. Identifying and managing modifiable risk is key and 
it may be best to target the intermediate age group at intermediate risk to achieve the greatest 
benefit. 
4.5 Study limitations 
The survey was of patients managed in 1998. Substantial changes in management have 
occurred and should have altered outcome. New cohorts of patients should be recruited but 
must inevitably reflect practice from a previous era if long follow-up is required. Not all 
patients had LV function assessed. Since systematic attempts were not made to withdraw 
diuretics, we may have under-estimated the transitory nature of heart failure in some cases. A 
simple, robust definition of heart failure remains elusive. However, patients who receive loop 
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diuretics and who have cardiovascular disease clearly have a poor prognosis whether or not 
they have a low ejection fraction[26]. Ultimately, heart failure is a clinical syndrome that 
relies on a doctor’s skill in assessing a patient in the light of appropriate investigations. 
The prevalence of diabetes mellitus was similar to that reported in another large trial from the 
same county in England but is towards the lower end of the spectrum reported in the literature 
(15, 16). This may reflect under-reporting of milder cases of diabetes, as it was not routine 
practice to obtain fasting blood glucose [137]. However, surveys reporting high levels of 
diabetes have generally included large numbers of patients from North America, where the 
prevalence of diabetes is probably, genuinely higher than in our region. 
4.6 Conclusions: 
In conclusion, the development of transient or persistent HF precedes death in the great 
majority of patients who die within six years of an MI in all age groups. Improved 
management of cardiac dysfunction and HF and its important co-morbidities such as anaemia 
and renal dysfunction may slow the rate of progression and improve quality of life and 
prognosis in such patients.  
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5 Chapter 5: Anaemia after a Myocardial Infarction and Its 
Relationship to the Development of Heart Failure and 
Mortality 
5.1 Introduction 
Anaemia is common in patients who have had an acute myocardial infarction (AMI), predicts 
a high 1-year [138] and 30-day all-cause and cardiovascular mortality [139 140] and is 
associated with the development of  heart failure (HF) [140 141].Anaemia is also common in 
patients with heart failure, may exacerbate its symptoms [142]and is also associated with 
poor prognosis[143]. Not surprisingly, patients who develop heart failure with or without 
LVSD as a consequence of AMI are also commonly anaemic and this also predicts an 
adverse prognosis [144].  Interestingly, there is little evidence of a dose effect with mild and 
moderate anaemia predicting a similarly poor outcome. However, the interplay between 
anaemia and heart failure after AMI and their relative prognostic significance is uncertain.  
We set out to explore these relationships and their association with short- and long-term 
prognosis after AMI. 
5.2 Methods 
5.2.1 Study population 
One hospital group in Hull and the East Riding of Yorkshire (UK) provide all of the acute 
cardiac services for about 560,000 people living in a geographically distinct part of the 
United Kingdom. Patients with a discharge diagnosis of acute MI during 1998 were identified 
from the Hospitals Information Department and their case notes screened. Patients who were 
transferred from another region, those with missing case notes or in whom AMI could not be 
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confirmed from their records were excluded. The study was approved by the Local Research 
Ethics Committee. 
5.2.2 Follow-up 
This was a retrospective analysis designed in 2004. The case records of all patients were 
reviewed to identify use of loop diuretics and if so whether this was due to symptoms or signs 
of heart failure. Follow-up data were collected until 31st December 2005. If no recent hospital 
record existed, the family practitioners of patients were contacted to ascertain the patient’s 
current therapy and heart failure status. The occurrence of major events, such as recurrent MI, 
and stroke were recorded.  
5.2.3 Definition of Myocardial Infarction 
At least two of the following five criteria had to be identified during case note review to 
confirm a diagnosis of MI. 
1. History of prolonged cardiac chest pain. (n = 657) 
2. An increase in biomarkers consistent with MI, which in 1998 was usually creatinine 
kinase (CK) ratio or CK-MB mass. These were considered abnormal if they were 
twice the upper limit of normal values. (CK >200 n = 737)  
3. Progressive electrocardiographic changes consistent with MI or new onset left bundle 
branch block. (n = 539) 
4. Sudden unexpected death (n = 46) 
5. Autopsy evidence of MI (n = 10) 
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5.2.4 Other Definitions 
Heart failure was defined clinically either as signs and symptoms consistent with that 
diagnosis (principally breathlessness and signs of fluid retention) resulting in treatment with 
loop diuretics or patients who died shortly after developing evidence of major cardiac 
dysfunction, such as cases of cardiogenic shock or pulmonary oedema. For patients with an 
un-recordable blood pressure, a systolic pressure of 50mmHg was entered as a default value 
for statistical purposes. Use of loop diuretics for the treatment of hypertension or renal failure 
was not included in the definition of heart failure. Evidence of LVSD was not required for a 
diagnosis of heart failure. Criteria for LVSD were left ventricular ejection fraction (LVEF) < 
40% or a qualitative report of moderate or severe LVSD on echocardiography, first-pass 
radionuclide ventriculography or contrast angiography. The World Health Organization 
(WHO) criteria for anaemia is a haemoglobin (Hb) <12g/dL in women and <13g/dL in men. 
Mean Hb values for healthy men and women in the report on which this was based were 
13.3+/-0.9g/dL for women and 15.2+/-0.9g/dL for men [145]. We categorised patients 
according to the first available Hb reported during the index admission into those who had 
definite anaemia (>1 g below threshold), borderline anaemia (within 1g above or below the 
threshold) or who were not anaemic (>1g above threshold). 
5.2.5 Statistical Analysis: 
Data were entered into a Microsoft Access database and analysed using SPSS (version 13.0). 
Key outcomes were the proportion of patients who died and mortality rate. Continuously 
distributed data are presented as median and inter-quartile range. Categorical data are 
presented as percentages. Groups of patients with and without anaemia and/or heart failure 
were compared by the Chi-squared test on 2 degrees-of-freedom. 
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Kaplan-Meier (K-M) curves were generated to illustrate patients’ survival overall, and in 
relevant subgroups.  K-M curves were compared by the log-rank test. Cox regression was 
used to look at mortality, from which hazard ratios (HRs) and 95% confidence intervals (CIs) 
were calculated. The Cox regression model is semi-parametric in the sense that no 
assumption concerning event-free survival times is necessary. The Cox regression model is 
based on the assumption that the effect of a risk factor, expressed as a hazard ratio, is 
constant over time.  
The assumption of proportionality of the Cox model covariates was tested by plotting 
residuals[72 73]. Linearity of continuous data was checked by including asquared term.  
We present age-adjusted models and looked at the relationship between all-cause mortality 
and the following variables: sex, HF, LVSD, creatinine and anaemia (according to last Hb 
during index admission).  We adopted an epidemiological approach to model building rather 
than a more formal statistical approach.  Hence, models were built that explained survival on 
the basis of their biological relevance to heart failure [112]. 
HF status was categorised into four groups: (i) No HF during index admission as a reference 
group; (ii) patients with HF prior to index; (iii) persistent HF (PHF) during the index 
admission; (iv) transient HF (THF) during index admission. Anaemia status was categorised 
into three groups as described in the method section but we used the last Hb during index 
admission. 
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5.3 Results: 
5.3.1 Overall Results 
Of 896 patients with confirmed myocardial infarction during 1998, no report of Hb during the 
index admission could be found in 41 cases. This left 855 patients for analysis, of which 103 
had definite, 280 had borderline and 472 had no anaemia based on the first available 
haemoglobin during the index admission. Of these patients, 2, 8 and 18 from each group 
respectively were lost to follow-up after the index admission. The distribution of Hb in men 
and women with and without heart failure is shown in figure 5.1. 300 patients had more than 
one measurement of haemoglobin, of which 125 had definite, 289 had borderline and 441 had 
no anaemia on the last available measurement. Changes between first and last available 
measurement are shown in Table 5.1. The median (IQR) haemoglobin changed from 
13.70(13.70-14.80) to 13.50 (13.50-14.60) and the prevalence of definite anaemia rose from 
12% to 15%. 
Table  5-1 Anaemia groups Changes between first and last available measurement 
Baseline  
Follow-up 
None Borderline Definite Total 
None 424 17 0 441 
Borderline 34 237 18 289 
Definite 14 26 85 125 
Total 472 280 103 855 
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The characteristics of the patients according to first available haemoglobin are shown in 
Table 5.2.The median age of the patients was 70 (interquartile range 61-78) years and 321 
(38%) were women. There was a prior history of hypertension in 284 (33%), MI in 223 
(26%), heart failure in 130 (15%) and diabetes in 78 (9%). Additionally, 22 (3%) patients 
were newly diagnosed with diabetes during the index admission. Sixty-two percent were 
managed, at least in part, by a cardiologist during their index admission. ST segment 
elevation myocardial infarction (STEMI) was present in 495 (58%) and non-STEMI in 301 
patients (35%). Forty seven patients had Left Bundle Branch Block (LBBB), five patients 
were in a paced rhythm, and seven had no ECG recording available from the time of 
admission. Patients without anaemia were, on average, younger (p<0.0001) (Table 5.2) but, 
using a sex-specific threshold for the definition of anaemia, the prevalence was similar in 
men and women. Patients with anaemia were less likely to receive aspirin (p<0.0001) 
compared to those with borderline or no anaemia (Table 5.3). Older patients (>75 years old) 
were less likely to be treated with aspirin compared to younger patients (<65 years old). 
Of855 patients, 103 had definite, 280 had borderline and 472 had no anaemia based on the 
first available haemoglobin during the index admission.Figures5.2a, 5.2b and 5.2c describe 
the sequence of events that led to the development of heart failure and/or death in these 
groups. During the index admission, 77 patients (75%) with definite, 130 (46%) with 
borderline and 196 (42%) who had no anaemia developed HF, of whom 41 (53%), 50 (38%) 
and 60 (31%) died during the index admission compared, respectively, to 7 (27%), 14 (9%) 
and 9 (3%) deaths in patients who did not develop HF. (Figure 5.3a). 
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Figure  5-1Prevalence of Heart Failure during index admission Y/N according to gender (men and 
women) 
A: Numbers of men and women with definite, borderline or no anaemia.
B1 and B2: Prevalence of Heart Failure Y/N according to gender (men and women)
(Expressed as percentages of the Population with a Measurement of Haemoglobin n = 855)
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Panel A 
 Data are expressed as a number of the whole population (n=855) stratified by gender and anaemia status 
determined by the first measurement of haemoglobin during the index admission 
Panel B1 and B2 
Prevalence of index admission heart failure and no heart failure reported only during the index admission in 
relationship to gender and to anaemia status determined by the first measurement of haemoglobin during the 
index admission. 
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Table  5-2Patients Characteristics recorded during the Index Admission classified according to Anaemia 
status 
 
  
 missi
ng  
data 
 Anaemia a  
Variables (units)  Overall Definite  Borderline None P value 
N   855 103 280 472  
Age (years) 0 70 (61-78) 78 (71-82) 76 (68-83) 72 (65-79) 0.0001 
Patients Aged <65 years 0 296 (35%) 13 (13%) 69 (25%) 214 (45%) 0.0001 
Patients Aged >75 years 0 275 (32%) 55 (53%) 115 (41%) 105 (22%)  
Women 0 321 (38%) 42 (41%) 113 (40%) 166 (35%) 0.281 
Current smoker 76 304 (39%) 19 (23%) 85 (33%) 200 (46%) 0.0001 
Ex smoker  234 (30%) 27 (33%) 89 (35%) 118 (27%)  
History of Hypertension 37 284 (35%) 41(41%)  105 (39%) 138 (31%) 0.029 
History of Diabetes 3 78+32b  (13%)
 
14 (14%) 34 (12%) 62 (13%) 0.607 
Prior MI 0 223 (26%) 33 (32%) 75 (27%) 115 (24%) 0.261 
History of HF 4 130 (15%) 33 (32%) 45 (16%) 52 (11%) 0.0001 
Prior CABG  36 (42%) 3 (3%) 13 (5%) 20 (4%) 0.755 
Prior PTCA  14 (2%) 2 (2%) 4 (1%) 8 (2%) 0.930 
Managed Primarily by 
Cardiologist 
 532 (62%) 51 (50%) 163 (58%) 318 (67%) 0.001 
Index Admission ECG       
   ST segment elevationc 7 495 (58%) 52 (52%) 160 (57%) 283 (60%) 0.592 
   Non ST elevation 7 301 (35%) 40 (40%) 101 (36%) 160 (34%)  
   QRS >120 18 192 (23%) 30 (31%) 64 (23%) 98 (21%) 0.120 
   Anterior site 7 406 (48%) 46 (46%) 101 (48%) 226 (48%) 0.923 
Chest X-ray       
   Pulmonary oedema 202 157 (24%) 30 (37%) 48 (22%) 79 (22%) 0.014 
   Cardiomegaly  155 (24%) 25 (31%) 59 (27%) 71 (20%) 0.044 
   Upper Lobe Vein Distension  158 (24%) 26 (32%) 51 (23%) 81 (23%) 0.205 
   Pleural effusion  73 (11%) 18 (22%) 26 (12%) 29 (8%) 0.001 
Physical Examination       
   Heart Rate (b/min) 6 78 (64-97) 86 (66-102) 78 (65-96) 77 (64-96) 0.466 
   Atrial fibrillation (yes/no) 1 148 (17%) 30 (29%) 51 (18%) 67 (14%) 0.001 
HF during indexd  403 (47%) 77 (75%) 130 (46%) 196 (42%) 0.0001 
Systolic BP (mm/Hg) 4 140 (120-160) 130 (110-150) 140 9120-160) 140 (123-160) 0.003 
Blood Tests (on admission)       
   Peak CK 33 828(374-1902) 595 (312-1225) 700 (327-1705) 1011 (411-
2130) 
0.008 
   Cholesterol (mmol/L) 326 6 (5-6) 5 (4-6) 6 (5-6) 6 (5-6) 0.560 
   Sodium 11 137 (135-139) 137 (134-139) 137 (135-139) 137 (135-139) 0.011 
   Creatinine 103 105 (89-128) 124 (96-165) 106 (87-129) 103 (87-121) 0.0001 
CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; ECG, electrocardiogram. 
Percentages are shown are of those in whom measurements were made. CK = creatine kinase. Example interpretation: patients who 
had anaemia had a lower ck compared to patients with no anaemia. Also patients who had anaemia had a higher creatinine during the 
index admission compared to patients with borderline and no anaemia.  The differences for Na are exaggerated because of the relative 
large sample sizes between the three groups, and the relatively low standard deviations ( in other words, this is a statistical quirk). 
aAnaemia: WHO criteria for anaemia are used(men<13 dg/dL; women<12 g/dL), Definite anaemia is defined as >1g below these 
thresholds Borderline is within 1g above or below these thresholds 
bThirty-two cases newly diagnosed as diabetic on index admission. 
cP-value for ST calculated between three groups (STE, No STE and other (LBBB and pace).  
dHeart failure during index admission. 
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Table  5-3Treatment during index admission and any time until 31st December 2005. 
   Anaemia  
Variables (units)  missingd
ata 
Overall Definite* Borderline* None* P value 
n 855  103 280 472  
Revascularisation during admission       
  Thrombolysis 0 354  22 (21%) 108 (39%) 255 (54%) 0.0001 
  PCI 0 18  2 (2%) 4 (1%) 12 (3%) 0.585 
  CABG 0 8  2 (2%) 1 5 (%) 0.331 
Treatment at any time during 
admission 
      
Parenteral       
  Loop diuretic  6 257 50 (49%) 81 (29%) 126 (27%) 0.0001 
  Nitrates  2 300 37 (36%) 93 (33%) 170 (36%) 0.676 
  Inotropic therapy 1 88 18 (17%) 25 (9%) 45 (10%) 0.116 
  Heparin 13 673 72 (71%) 217 (78%) 384 (83%) 0.091 
  Insulin 1 77 7 (7%) 21 (8%) 49 (10%) 0.506 
Oral       
  Aspirin 1 757 75 (73%) 255 (91%) 427 (91%) 0.0001 
  Clopidogrel 1 6 2 (2%) 4 (1%) 0 0.074 
  Warfarin 1 35 4 (4%) 14 (5%) 17 (4%) 0.792 
  Statin 1 388 17 (17%) 112 (40%) 259 (55%) 0.0001 
  ACE inhibitors 1 341 38 (37%) 110 (39%) 193 (41%) 0.832 
  ARBs 1 7 1 (1%) 3 (1%) 3 (1%) 0.869 
  Beta-blockers 1 478 35 (34%) 149 (53%) 294 (62%) 0.0001 
  Nitrates 1 308 53 (51%) 108 (39%) 147 (31%) 0.002 
  Calcium channel blockers 1 205 30 (30%) 63 (23%) 112 (24%) 0.617 
  Loop diuretic 0 291 59 (57%) 98 (35%) 134 (28%) 0.0001 
  Thiazide diuretic 0 17 2 (2%) 5 (2%) 10 (2%) 0.951 
  Spironolactone 0 1 0  0 1 0.666 
  Digoxin 1 65 16 (16%) 20 (7%) 29 (6%) 0.021 
  Oral hypoglycaemic agent 1 19 2 (2%) 8 (3%) 9 (2%) 0.813 
Revascularisation at any time       
  PCI 0 90 (11%) 2 (2%) 24 (9%) 64 (14%) 0.001 
  CABG 0 94 (11%) 5 (5%) 24 (9%) 65 (14%) 0.009 
Treatments at any time       
  ACE inhibitor 1 477 46 (45%) 152 (54%) 279 (59%) 0.074 
  ARBs 1 41 1 (1%) 15 (5%) 25 (5%) 0.334 
  Beta-blockers 1 522  39 (38%) 166 (59%) 317 (67%) 0.0001 
  Loop diuretic 1 523 83 (81%) 183 (65%) 257 (55%) 0.0001 
  Thiazide diuretic 1 66 5 (5%) 21 (8%) 40 (8%) 0.660 
  Spironolactone 1 64 6 (6%) 23 (8%) 35 (7%) 0.837 
  Digoxin 1 106 18 (17%) 38 (14%) 50 (11%) 0.289 
  Insulin 0 91 7 (7%) 26 (9%) 59 (13%) 0.175 
  Oral hypoglycaemic agent  1 72 2 (2%) 17 (6%) 51 (11%) 0.016 
  Aspirin 1 770 77 (75%) 259 (93%) 434 (92%) 0.0001 
  Statin 1 506 24 (23%) 151 (54%) 331 (70%) 0.0001 
PCI, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; ARBs, angiotensin receptor-
blockers. 
*For definitions see foot note of table 5.2 
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Of patients who did not have HF during the index admission, a further 9 (47%), 58 (43%) and 
73 (27%) patients with, respectively, definite, borderline and no anaemia subsequently went 
on to develop HF. Amongst patients with persistent heart failure at discharge, crude 
mortalities at six years were 23 (77%), 43 (75%) and 53 (58%) in those with definite, 
borderline or no anaemia. Of patients who developed HF after discharge, 7 (78%), 38 (66%) 
and 29 (40 %) died respectively in those with definite, borderline or no anaemia, compared to 
4 (40%), 14 (18%) and 26 (13%) patients who never developed HF at any time. 
Of 53, 208 and385 patients with, respectively, definite, borderline or no anaemia based on the 
first haemoglobin who survived to discharge, 39 (74%), 106 (51%) and 127 (33%) 
subsequently died and of these 35 (90%), 92 (87%) and 102 (80%) occurred after developing 
transient or persistent HF. Overall, 86 (83%) patients with definite, 188 (67%) with 
borderline and 269 (57%) without anaemia developed HF, of which 87 (84%), 172 (61%) and 
197 (42%) had died by December 2005.  Based on the last, rather than first haemoglobin, of 
125, 289 and 441 patients with, respectively, definite, borderline or no anaemia, 87 (70%), 
172 (60%) and 197 (45%) subsequently died and of these 76 (87%), 144 (84%) and 162 
(82%) occurred after developing transient or persistent HF. Overall, 101 (81%) patients with 
definite, 200 (69%) patients with borderline and 242 (55%) patients without anaemia 
developed HF, of which 89 (88%), 155 (76%) and 138 (57%) had died by December 2005. 
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Flow diagram showing the sequence of development of heart failure and relationship with recurrent ischemic 
episodes and mortality over approximately 6 years in patients admitted with an acute myocardial infarction and 
Hb >1g/dL below WHO criteria for anaemia to the Hull and East Yorkshire Hospitals Group during 1998.  
Follow-up data were incomplete in 2 patients. See text for details.  
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Hb >1g/dL below WHO criteria for anaemia to the Hull and East Yorkshire Hospitals Group during 1998.  
Follow-up data were incomplete in 2 patients. See text for details.  
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Figure  5-2Flow diagram showing the sequence of development of heart failure and mortality over approximately 6 
years in patients with (a) anaemia, (b) Borderline, (c) No anaemia according to first haemoglobin during admission. 
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Flow diagram showing the sequence of development of heart failure and relationship with recurrent ischemic 
episodes and mortality over approximately 6 years in patients admitted with an acute myocardial infarction and 
Hb 1g above or below WHO threshold as borderline to the Hull and East Yorkshire Hospitals Group during 
1998.  Follow-up data were incomplete in 8 patients. See text for details. 
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Flow diagram showing the sequence of development of heart failure and relationship with recurrent ischemic 
episodes and mortality over approximately 6 years in patients admitted with an acute myocardial infarction and 
Hb >1g/dL above WHO criteria for anaemia to the Hull and East Yorkshire Hospitals Group during 1998.  
Follow-up data were incomplete in 2 patients. See text for details.  
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Figure  5-3Prevalence & Mortality according to anaemia groups and (a) heart failure and (b) LVSD. 
5-3-a : Prevalence & Mortality in patients according to anaemia groups with Heart Failure 
during Index Admission 
(Expressed as percentages of the Population with a Measurement of Haemoglobin n = 855)
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Panel A 
Overall mortality in relationship to heart failure reported during the index admission only and to anaemia status 
determined by the first measurement of haemoglobin during the index admission. 
Panel B1 and B2 
Index admission and post-discharge mortality in relationship to heart failure reported during the index admission 
only and to anaemia status determined by the first measurement of haemoglobin during the index admission. 
 
Azam Torabi  Incidence and outcome of MI 
106 
 
5-3-b:Prevalence & Mortality in Patients with and without LVSD During index Admission or Shortly after
(Expressed as percentages of the Population with a Measurement of Haemoglobin  n= 855)
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b:  
Panel A:  
Overall mortality in relationship to LVSD reported during the index admission or shortly after and to anaemia 
status determined by the first measurement of haemoglobin during the index admission (n=456). 
Panel B1 and B2: 
Index admission and post-discharge mortality in relationship to LVSD reported during the index admission or 
shortly after and to anaemia status determined by the first measurement of haemoglobin during the index 
admission. 
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Table  5-4Imaging evidence of left ventricular function during index admission or shortly after and 
relationship to development of heart failure or death 
 missi
ng  
data 
 Anaemia  
Variables (units) [missing data] Overall Definite
* 
Borderlin
e* 
None* P 
value 
n 820 101 267 452  
Contrast angiography  88 4  26 58  
   Left main coronary artery 2 8 0 2 (8%) 6 (11%) 0.792 
   Three-vessel diseaseb  39 2 (50%) 10 (38%) 27 (47%) 0.979 
   2VD  25 1 (25%) 8 (31%) 16 (28%)  
   1VD  23 1 (25%) 8 (31%) 14 (24%)  
   LVSD (LV assessed n=57) 31 13 1 (33%) 4 (25%) 8 (21%) 0.861 
Echocardiography  281 34 90 157  
   Major LVSD  4 139 23 (70%) 43 (49%) 73 (47%) 0.055 
   Moderate or severe mitral  
regurgitation 
12 37 9 (29%) 10 (11%) 18 (12%) 0.031 
   Moderate or severe other valve 
disease 
6 10 1 (3%) 7 (8%) 2 (1%) 0.031 
Radionuclide  340 21 102 217  
   LVEF 35-39%  40 2 (10%) 13 (13%) 25 (12%) 0.116 
   LVEF <35%  105 10 (48%) 37 (36%) 58 (27%)  
LV assessment by any technique 264 556 53 169 334  
 Moderate or severe LVSD (any 
technique) c 
 271 38 
(72%) 
89 (53%) 144 
(43%) 
 
   Died index admission  59 18 (47%) 17 (19%) 24 (17%) 0.002 
   Discharged with persistent HF   90 14 (37%) 25 (28%) 51 (35%)  
   Discharged after transient HF  29 3 (10%) 10 (12%) 16 (12%)  
   Developed HF after discharge  48 2 (6%) 21 (25%) 25 (19%)  
   Died after discharge without 
developing HF 
1 8 0 1 (1%) 7 (5%)  
   Survived without developing HF e 3 37 1 (3%) 15 (17%) 21 (15%)  
       
Died after discharge - transient or 
persistent HF 
 96 14 (37%) 35 (39%) 47 (33%) 0.19 
Survived despite transient or persistent 
HF 
1 71 5 (13%) 27 (30%) 45 (31%)  
Total Deaths 2 163 32 (84%) 53 (60%) 78 (54%)  
 No Major LVSD (any technique)  285 15 80 190  
   Died index admission  9 3 (20%) 1 (1%) 5 (3%) 0.005 
   Discharged with persistent HF   33 3 (20%) 13 (16%) 17 (9%)  
   Discharged after transient HF  25 0 6 (8%) 19 (10%)  
   Developed HF after discharge  51 3 (20%) 18 (23%) 30 (16%)  
   Died after discharge without 
developing HFg 
2 21 2 (13%) 6 (8%) 13(7%)  
   Survived without developing HFh 11 146 4 (27%) 36 (47%) 106 (56%)  
       
Died after discharge - transient or 
persistent HF 
 46 3 (20%) 22 (28%) 21 (11%) 0.023 
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Survived despite transient or persistent 
HF 
 63 3 (20%) 15 (19%) 45 (24%)  
Total Deaths 2 76 8 (53%) 29 (36%) 39 (21%)  
No Report of LV function by any 
technique  
 264 48 98 118  
   Died index admission  113  27 (65%) 46 (47%) 40 (34%) 0.004 
   Discharged with persistent HF   48 12 (25%)  17 (17%) 19 (16%)  
   Discharged after transient HF  13 3 (6%) 3 (3%) 7 (6%)  
   Developed HF after discharge  29 3 (6%) 14 (14%) 12 (10%)  
   Died after discharge without 
developing HF 
1 14 2 (4%) 6 (6%) 6 (5%)  
   Survived without developing HFj 5 47 1 (2%) 12 (12%) 34(29%)  
       
Died after discharge - transient or 
persistent HF 
 69 16 (33%) 27 (28%) 26 (22%) 0.21 
Survived despite transient or persistent 
HF 
 21 2 (42%) 7 (7%) 12 (10%)  
Total Deaths 1 196 45 (94%) 79 (81%) 72 (61%)  
*
 For definitions see foot note of table 5.2 
aThe imaging test indicating the most severe left-ventricular impairment on index admission or 1st 
available within 90 days after index admission. Percentages are shown are of those in whom 
measurements were made. 
bFour cases had graft occlusion, six had ventricular septal defect and one had mitral valve rupture during 
index admission. Two patients had prior valve replacement and aortic regurgitation or stenosis or mitral 
stenosis. 
cTwenty patients had prior LVSD without any LV assessment during or shortly after index admission. 
#LV assessed in 556 cases of whom LVSD reported only prior to admission in 25 cases, on index 
admission in 193 cases, a further 41 cases within 30 days, 8 cases within 31-60 days and 4 cases within 
61-90 days.  
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A report on left ventricular function during or shortly after the index admission was available 
in 32 (58%), 151 (70%) and 305 (76%) surviving patients in the above mentioned patient 
groups and in 21, 18 and 29 patients who died during the index admission (Table 5.4). 
Overall, stratified by Hb, 14 (70%), 36 (51%) and 54 (45%) patients with documented LVSD 
died after discharge, of whom 14 (100%), 35 (97%) and 47 (87%) also had heart failure 
(Figure 5.3b).  Of patients in whom LVSD was excluded, 5 (42%), 28 (41%) and 34 (18%) 
died of whom 3 (60%), 22 (79%) and 21 (62%) also had heart failure. 
Of 275 deaths that occurred subsequent to discharge, 231 (84%) were preceded by the 
development of transient or persistent heart failure. Of these 275 deaths, 39, 108 and 128 
patients had, respectively, definite, borderline and no anaemia on the first haemoglobin 
during the index admission and of these 35 (90%), 94 (87%) and 102 (80%) also had 
transient or persistent HF (Figures 5.3b and 5.4). Based on the last, rather than first 
haemoglobin, 42, 123 and 110 patients had, respectively, definite, borderline and no anaemia 
on the first haemoglobin during the index admission and of these 39 (93%), 107 (87%) and 
85 (77%) also had transient or persistent HF. 
5.3.2 Mode of death 
Of 181 patients who died during the index admission, 165 cases were cardiac related. Of 275 
patients who died after the index admission, 166 died during a re-admission to hospital and 
109 died out of hospital. In patients who died out of hospital, 16 had severe heart failure, one 
died of self-poisoning, nine had advanced cancer and two had a stroke and one had three 
vessel diseases and was waiting for PCI (Table 5.5). Information on the precise cause of 
death was lacking in 79 cases and in most cases appeared to be sudden. 
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Table  5-5Mortality and mode of death during index admission (N=181) and subsequent to discharge 
(n=275) according to anaemia status. 
 
 Anaemia 
 Overall Definite* Borderline* None* 
n 820 101 267 452 
Died during index admission 
Total 181 48 64 69 
Sudden cardiac death 46 9 16 21 
HF 106 24 39 43 
Stroke 2 1 1 0 
Cardiac procedures related 3 1 1 1 
Other cardiac 8 4 3 1 
Infection 4 2 2  
Cancer 1 1 0 0 
Other non cardiac 11 6 2 3 
Died after the index admission 275 39 108 128 
Died during a re-admission 
Total 166 28# 67 71 
   SCD 9 3 3 3 
   HF 66 5 30 31 
   Stroke 11 2 4 5 
   Cardiac procedures related 2 0 1 1 
   Other cardiac 4 1 1 2 
   Infection 22 7 9 6 
   Cancer 24 5 10 9 
   Other non cardiac 27 4 9 14 
Died out of hospital 
Total 109 11 41 57 
   Severe HF 16c 1 5 10 
   Advanced cancer 9 1 4 4 
   Stroke 2 1 1 0 
  Any transient or persistent HF 81 19 40 31 
     Any HF with LVSD prior to deatha 46 4 18 24 
     Any HF with no LV assessment  16 2 3 11 
     Any HF with No LVSD 19 2 7 10 
  Never HF  28 1 10 17 
     Never HF but LVSD prior to death 6 0 2 4 
     Never HF with no LV assessment  9 1 3 5 
     Any HF and No LVSD 13 0 5 8 
*
 For definitions see foot note of table 5.2 
#Missing data for the last admission for one cases   
a LVSD in last cardiac imaging prior to death 
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Figure  5-4Kaplan-Meier curves showing prognosis among patients discharged after the index 
hospitalisation 
 
Kaplan-Meier curves showing prognosis among patients discharged after the index myocardial infarction with 
anaemia, borderline and no anaemia according to last recorded Hb during index admission with and without 
heart failure at any time (persistent or transient) (N=646). 
5.3.3 Cox Models 
Patients with anaemia were more likely to die (Table 6). This relationship was mostly 
retained after further adjustment for sex, HF, LVSD, GFR and the other variables listed in 
table 6.  (HR=1.379, 95% CI=0.982, 1.935, p=0.055).  Substituting, the last available with the 
first available haemoglobin the link was slightly weakened. 
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Table  5-6Cox-regression models; for mortality in patients subsequent to discharge (n=646). 
  
 Univariable  Age Adjusted 
Variable Name N Wald HR P value Wald HR P value 
No anaemia* 360 49.743  0.0001 5.794  0.055 
Borderline 223 30.996 2.090 (1.612-2.708) 0.0001 3.252 1.291 (0.978-1.704) 0.071 
Anaemia 63 19.873 2.115 (1.521-2.940) 0.0001 2.876 1.339 (0.956-1.876) 0.090 
HF statusa 397 105.586  0.0001 21.964  0.0001 
New PHF during index admission 111 42.306 2.703 (1.998-3.657) 0.0001 6.820 1.528 (1.112-2.101) 0.009 
New THF during index admission 67 1.216 1.224 (0.847-1.770) 0.282 1.519 1.266 (0.870-1.843) 0.218 
Prior HF 71 44.198 2.779 (2.054-3.760) 0.0001 10.191 1.673 (1.220-2.295) 0.001 
LV function status 275 57.164  0.0001 19.895  0.0001 
LVSDb 224 45.111 2.957 (2.148-4.072) 0.0001 12.058 1.809 (1.295-2.527) 0.001 
Not reported LV 275 15.077 1.598 (1.257-2.031) 0.0001 8.899 1.459 (1.138-1.869) 0.003 
Sex (Female, n= 239) 
 
19.847 0.582 (0.458-0.738) 0.0001 2.422 1.233(0.947-1.605) 0.120 
Glomerular filtration Ratec 646 51.387 0.969 (0.960-0.977) 0.0001 4.053 0.991 (0.981-1.000) 0.044 
Age (as a continues variable) 646 149.183 1.073 (1.061-1.085) 0.0001 44.007 1.048 (1.033-1.062) 0.0001 
HR, hazard ratio; HF, heart failure; LV, left ventricular; THF, transient HF during index admission; PHF, persistent HF during index 
admission 
*Anaemia status was according to last Hb available during index admission. 
awith reference to No HF during index admission; bWith reference to no left ventricular systolic dysfunction during index admission. 
cfour-variable formula derived from the modification of diet in renal disease study (4V MDRD): [GFR= 186* (Creat/88.4)-1.154 
*Age-0.203* 0.742 if female *1.212 if African Caribbean] were used to calculate glomerular filtration rate, In patients with no 
creatinine report during index admission (74 cases) median creatinine were used. 
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5.4 Discussion 
This report confirms that anaemia is common in patients with AMI and is associated with the 
development of heart failure. Anaemia predicts a worse prognosis, largely because of its 
association with heart failure and renal dysfunction. Indeed, anaemia was rare in the absence 
of heart failure and, since ascertainment heart failure. The development of clinical heart 
failure rather than anaemia was the more powerful predictor of an adverse outcome but 
anaemia had some additional, independent prognostic value.   In the absence of heart failure, 
anaemia had relatively little influence on prognosis, although very few patients had definite 
anaemia but not heart failure. In patients with heart failure, the presence of ‘definite’ anaemia 
indicated a poor one-year mortality and the prognosis of ‘borderline’ anaemia was as poor as 
that of ‘definite’ anaemia in the longer term. Patients with definite anaemia were older and 
presumably frailer with more co-morbidities which may account for why a higher proportion 
of deaths were non-cardiac (59%), including due to cancer (19%), in this group.  
Anaemia may just be associated with and a marker of heart failure, but the two conditions 
could also be causally linked. The cardiovascular system is designed, amongst other things, to 
supply enough oxygen to the metabolising tissues. Anaemia reduces the oxygen carrying 
power of the blood. The cardiovascular system can adapt first by extracting a higher 
proportion of oxygen, leading to a reduction in mixed venous oxygen saturation, and then by 
raising cardiac output. In an already damaged heart this may lead to heart failure. Anaemia 
may also be a sign of iron deficiency and iron deficiency can impair metabolism of both 
cardiac and skeletal muscle and other metabolic processes requiring iron [146]. Widespread 
use of aspirin could be responsible for an epidemic of mostly subclinical duodenal ulceration 
[26 147] leading to iron deficiency amongst patients with known coronary artery disease [26 
127]. Chronic cardiac dysfunction is associated with anaemia. This is often due to iron 
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deficiency and again may be aspirin related or related to reduced absorption in the gut either 
due to mucosal dysfunction or hepcidin overproduction [148] that prevents iron transport. 
Heart failure is also linked to cytokine activation that may lead to bone marrow resistance to 
the effects of erythropoietin. Heart failure is also associated with renal dysfunction which 
may lead to inadequate production of erythropoietin [149]. Thus, heart failure and anaemia 
may reflect yet another set of ‘vicious cycles’ where worsening of one condition begets 
worsening of the other. 
A further possible cause of anaemia in the setting of AMI is cardiac dysfunction causing salt 
and water retention leading to plasma volume expansion and a reduction in haemoglobin 
concentration without a reduction in red blood cell mass [150]. This might be expected to 
progress as heart failure develops and might improve with plasma volume contraction in 
response to diuretic therapy. Anaemia appears more prevalent around the time of 
decompensation of heart failure [151] and haemoglobin often rises after re-compensation 
after discharge. Treatments given for AMI, including ACE inhibitors [152] and carvedilol 
[153] will often cause a modest fall in Hb and yet improve prognosis rather than make it 
worse. The reasons why these agents cause a fall in Hb is controversial but may simply due to 
arterial and, more importantly, venous relaxation leading to plasma volume expansion[154]. 
ACE inhibitors may also interfere with erythropoietin production [155]. Major haemorrhage 
due to the use of anti-thrombotic and thrombolytic interventions is associated with an adverse 
prognosis [156]. 
5.5 Study limitations 
The survey was of patients managed in 1998. Significant changes in prevention and 
management have occurred and may have altered outcome. Not all patients had LV function 
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assessed. Patients with less severe heart failure may not have received loop diuretics and it is 
possible that not all patients who received a loop diuretic were identified. Also, since 
systematic attempts were not made to withdraw diuretics, we may have under-estimated the 
transitory nature of heart failure in some cases. A simple, robust definition of heart failure 
remains elusive. However, patients who receive loop diuretics and who have cardiovascular 
disease clearly have a poor prognosis whether or not they have a low ejection fraction[26]. 
Ultimately, heart failure is a clinical syndrome that relies on a doctor’s skill in assessing a 
patient in the light of appropriate investigations. 
We obtained measurements of Hb predominantly from only one time-point. Only a minority 
of patients had a second measurement of Hb (Table 5.1). Hb may vary with the progression 
of heart failure, the impact of cardiovascular therapies, the availability of haematinics and 
changes in plasma volume. Serial measurement of Hb during admission  and subsequent 
follow-up may have demonstrated a stronger link between anaemia and prognosis [157]. 
Another potential limitation of our analysis is that patients who died early had less 
opportunity to recover or to develop late-onset heart failure. It is unclear how useful attempts 
at adjusting for this problem would be.  
We did not collect information on haematinic deficiencies, although in patients with 
cardiovascular disease and anaemia, iron deficiency is common as is a normochromic 
normoytic anaemia without associated deficiency in iron or vitamin B12 or folic acid. The 
latter is often associated with renal dysfunction and an increase in inflammatory markers such 
as C-reactive protein and termed ‘anaemia of chronic disease’.  Neither did we collect serial 
information on medical therapy to investigate changes over time that might have been 
associated with anaemia. Such analyses are complex to do and even more complex to 
interpret. For instance, a patient with anaemia may be more likely to be taking aspirin, which 
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can cause blood loss and iron deficiency, but may also be more likely to stop aspirin because 
they have become anaemic. Sorting out which is the ‘chicken’ and which is the ‘egg’ may be 
impossible in an observational study.  
5.6 Conclusion: 
In conclusion, in patients with AMI, anaemia is associated with a greater risk of developing 
HF. Most patients who die in the six years subsequent to an MI first develop HF. Whether 
treatment for anaemia would alter the risk of developing heart and/or improve outcome 
awaits investigation.  
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6 Chapter 6: Utility of NT-proBNP to Identify Left Ventricular 
Dysfunction and Adverse Prognosis in Patients with a Prior 
Myocardial Infarction 
6.1 Introduction 
Myocardial infarction is a common cause of cardiac dysfunction, which is a major 
determinant of subsequent prognosis. Patients with severe myocardial damage often die in 
the acute phase or go on to develop heart failure. Ventricular dysfunction and heart failure 
may resolve if myocardial stunning rather than necrosis is extensive. On the other hand, 
ventricular dysfunction and heart failure may develop as a late complication of myocardial 
infarction either due worsening ventricular function due to recurrent ischaemic damage or 
adverse ventricular remodelling or due to the development of other complications such as 
atrial fibrillation or renal dysfunction. These complex and competing risks make it difficult 
to predict the prevalence of chronic left ventricular systolic dysfunction (LVSD) or heart 
failure amongst long-term survivors of a myocardial infarction.  
Amino-terminal pro-brain natriuretic peptide (NT-proBNP) is a powerful predictor of an 
adverse prognosis in the setting of an acute myocardial infarction partly reflecting it’s strong 
association with LVSD [50 51]. Patients with both LVSD and an elevated NT-proBNP in the 
setting of an acute myocardial infarction are reported to have a worse outcome compared to 
those with either LVSD or an elevated NT-proBNP alone [54].Several studies have shown 
that measurement of natriuretic peptides are of limited value in identifying patients with left 
ventricular systolic dysfunction remote from the time of myocardial infarction, although 
normal values generally exclude severe LVSD[64 65]. Natriuretic peptides may reflect other 
factors including LV diastolic dysfunction, atrial fibrillation, cardiac valve disease and renal 
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dysfunction. Also, assessment of cardiac function is prone to large observer errors[67]. None 
of these reports provide information on the utility of measuring NT-proBNP in long-term 
survivors of myocardial infarction as a convenient and inexpensive means of monitoring 
cardiovascular risk. We set out to determine the utility of NT-proBNP alone and in 
conjunction with other clinical data, as a marker of cardiac dysfunction and prognosis in 
patients who had survived a myocardial infarction for approximately 6 years. 
6.2 Method 
6.2.1 Study population 
The Hull and East Yorkshire Hospitals (UK) serve a population of approximately 560,000 
people. Patients with a discharge diagnosis of acute myocardial infarction during 1998 were 
identified from the Hospitals Information Department. All patients who were alive by May 
2004 and lived in Hull were invited for assessment during 2004 and 2005 for: 
• Medical history  
• Symptom and quality of life assessment using the Euro Heart Failure Questionnaire[158] 
• Physical examination 
• Blood tests for standard haematology, biochemistry and lipid profiles, glucose and NT-
proBNP. Venous blood was drawn after 15 min at rest and either sent to the hospital 
routine laboratory or, for NT-proBNP, immediately centrifuged at 4oC (Termo centra 
CL3R) for 15 minutes at 3000 RPM (revolution per minute) and supernatant plasma 
stored within 30 minutes in 1.5ml cryovials at –80ºC until analysis. Plasma NT-BNP 
levels were determined using a commercial assay (Elecsys 2010, Roche analysis) with 
units given as pmol/L (1pmol/L = 8.457pg/ml). 
• Electrocardiogram (ECG) 
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• Echocardiogram with Tissue Doppler Imaging (GE Medical, VIVID-5). Ventricular 
dimensions were measured by M-mode. Two-dimensional, apical two-and four-chamber 
views were taken for volume measurements and ejection fraction calculated by Simpson’s 
biplane method. Left ventricular systolic dysfunction (LVSD) was defined as a left 
ventricular ejection fraction (LVEF) <40% or a qualitative report of moderate or severe 
LVSD on echocardiography[107]. Left atrial (LA) dimension was measured as the antero-
septal diameter from the parasternal long axis view and considered as dilatated if >3.8cm. 
Valve disease was assessed by colour flow Doppler from multiple echocardiographic 
views. Mitral regurgitation was graded as mild, moderate or severe. 
The case records of all patients were reviewed and followed-up until December 31st 2005. 
All-cause mortality was subsequently followed through the regional medical records system 
until 31st December 2009. Out of hospital deaths are automatically reported to the hospital. 
Survival was confirmed using patient centre (hospital electronic records) during 2010. The 
study was approved by the Local Research Ethics Committee. Patients who attended for 
review provided written informed consent. 
6.2.2 Definition of Myocardial Infarction 
At least two of the following five criteria had to be identified during case note review to 
confirm a diagnosis of MI. 
1. History of prolonged cardiac chest pain.  
2. An increase in biomarkers consistent with MI, which in 1998 was usually creatinine 
kinase (CK) or CK-MB mass. These were considered abnormal if they were twice the 
upper limit of normal values.   
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3. Progressive electrocardiographic changes consistent with MI or new onset left bundle 
branch block.  
4. Sudden unexpected death  
5. Autopsy evidence of MI  
6.2.3 Heart failure, LVSD, LA dilatation and valve disease 
Heart failure was defined clinically either as signs and symptoms consistent with that 
diagnosis (principally breathlessness and signs of fluid retention) resulting in treatment with 
loop diuretics or patients who died shortly after developing evidence of major cardiac 
dysfunction, such as cases of cardiogenic shock or pulmonary oedema. Use of loop diuretics 
for the treatment of hypertension or renal failure was not included in the definition of heart 
failure. LVSD was not required for a diagnosis of heart failure. Patients who moved out of 
the region were excluded.  Body mass index (BMI) was calculated weight/height2. 
6.2.4 Adjudication of Mode of Death 
Death was ascribed to only one of the following primary modes: sudden cardiac death, heart 
failure, stroke, cardiovascular procedure related deaths, other cardiovascular, cancer, 
infection or other non-cardiovascular. Each mode other than the primary mode could also be 
reported as contributory. So, a patient with metastatic prostate cancer and heart failure but 
who had a high probability of survival for more than a year who then died suddenly would be 
reported as having a primary mode of sudden death but with heart failure and cancer as 
contributory factors. 
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6.2.5 Statistical Analysis: 
Data were entered into a Microsoft Access database and analysed using SPSS (version 17.0). 
Continuously distributed data are presented as median and inter-quartile range. Categorical 
data are presented as percentages. Patients were classified according to the NT-BNP quartile 
during follow-up clinic and were compared by the Chi-squared test on 3 degrees-of-freedom. 
Key outcomes were the proportion of patients who had LVSD and all-cause mortality. 
Receiver operating characteristic (ROC) curves [159] were calculated for NT-proBNP.  Cox 
regression was used to look at the relationships between all-cause mortality and a limited 
subset of the variables (age, sex, diabetes, NYHA, quality of life (QOL), systolic BP, AF, 
body mass index (BMI), haemoglobin (Hb), urea, NT-proBNP, left ventricular systolic 
dysfunction (LVSD), left atrial dilatation (LAD) and mitral regurgitation (MR).  Serum urea, 
serum creatinine and eGFR were highly collinear and therefore only serum urea, which was 
most strongly associated with an adverse outcome on univariate analysis, was entered in the 
multi-variable model. All variables were included in the Cox model. The proportionality of 
hazards assumption was checked for all variables by residual inspection[72]. Follow-up time 
was censored at 31 December 2009.  Goodness-of-fit was measured by the Wald Chi-squared 
statistic. Given the few deaths (n=36) QOL was considered as a continuous variable in the 
Cox models.  Missing values for continuous variables were imputed by the median; for 
categorical variables inclusion of an additional category.  An arbitrary level of 5% statistical 
significance (2-tailed) was assumed.  
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6.3 Results 
6.3.1 Overall results 
Of 896 patients with a confirmed myocardial infarction during 1998, 451 had died and 31 had 
moved out of the region leaving414who were alive and potentially available to participate in 
May 2004. These patients were invited to attend for follow-up. Overall, 189 patients (47%) 
attended but through administrative or laboratory errors measurement of NT-proBNP was 
obtained in only 175 patients. The median [and interquartile (IQR) range] of NT-proBNP was 
35pmol/L [13 to 86pmol/L] (Figure 6.1 and Table 6.1).  
 
 
NT-BNP not available(n=14) 
3 died by 31st Dec. 2009) 
Died by 31st Dec. 2009 
(n=36) (21%) 
Primary MI in 1998 HRI/CHH 
(n=896) 
Alive & Local in May 
2004(n=414) 
NT-BNP 
available(n=175) 
Assessed 2004-
2005(n=189) 
Alive on 31st Dec. 2009 
(n=139) 
Not Assessed (n=227) 
Died by 31st Dec. 2009 
(n=61) (27%) 
Alive on 31st Dec. 2009 
(n=166) 
Known Deaths by May 2004 
(n= 451)  
378 developed HF, 33 died 
suddenly without HF, 21 died 
of cancer, 59 died of other non 
CV cause 
Moved out of region 
(n=31) 
Figure  6-1NT pro-BNP test in patients with myocardial infarction 
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Table  6-1Patients Characteristics classified according to the NT-proBNP quartile 
data are median (inter-quartile range) and number occurring (%). Assessments were conducted blind to NT-proBNP values. 
Variables (units) [patients with 
missing data] 
Overall 1st Quartile 
<13 pmol/L 
2nd Quartile 
13-35 pmol/L 
3rdQuartile 
>35-86 pmol/L 
4thQuartile>86 
pmol/L 
p-value 
n 175 43 44 44 44  
Age (years) [0] 68 (63-75) 64 (58-68) 67 (65-77) 69(65-75) 72 (67-77) 0.0001 
Women [0] 42 (24%) 7 (16%) 13 (30%) 11 (25%) 11 (25%) 0.533 
Current smoker [3] 31 (18%) 7 (17%) 9 (21%) 8 (19%) 7 (16%) 0.662 
Ex-smoker 103 (60%) 29 (69%) 22 (52%) 26 (59%) 26 (59%)  
Non smoker 38 (22%) 6 (14%) 11 (26%) 10 (23%) 11 (25%)  
History of Hypertension 105 (60%) 17 (40%) 23 (52%) 35 (80%) 30 (68%) 0.001 
History of Diabetes 32 (18%) 6 (14%) 4 (9%) 11 (25%) 11 (25%) 0.128 
History of heart failure 73 (42%) 9 (21%) 13 (30%) 18 (41%) 33 (75%) 0.0001 
History of SVT 35 (20%) 1 (2%) 3 (7%) 8 (18%) 23 (52%) 0.0001 
Prior CABG 46 (26%) 4 (9%) 10 (23%) 13 (30%) 19 (43%) 0.004 
Prior PTCA 49 (28%) 17 (40%) 12 (27%) 10 (23%) 10 (23%) 0.225 
Clinic ECG       
Heart Rate 61 (54-70) 61 (56-68) 59 (51-69) 60 (53-68) 65 (54-82) 0.039 
AF (yes/no) 19 (11%) 0 0 6 (14%) 13 (30%) 0.0001 
Any Anterior Q-wave 28 (16%) 4 (9%) 9 (20%) 7 (16%) 8 (18%) 0.524 
Other pathological Q-wave 52 (30%) 12 (28%) 16 (36%) 10 (23%) 14 (32%) 0.548 
LBBB/Pace/ICD 24 (14%) 1 (2%) 3 (7%) 8 (19%) 12 (27%) 0.003 
No Q-wave 71 (41%) 27 (63%) 16 (36%) 19 (43%) 10 (23%) 0.004 
QRS >120 [23] 29 (17%) 3 (7%) 4 (9%) 7 (16%) 15 (34%) 0.002 
Physical Examination       
NYHA I 94 (54%) 34 (79%) 27 (61%) 24 (55%) 9 (20%) 0.0001 
NYHA II 60 (34%) 6 (14%) 13 (30%) 17 (39%) 24 (55%)  
NYHA III/IV 21 (12%) 3 (7%) 4 (9%) 3 (7%) 11 (25%)  
Body mass index [2] 27 (24-31) 28 (26-32) 28 (25-31) 27 (24-32) 25 (22-29) 0.066 
Systolic blood pressure 139 (126-154) 140 (126-157) 138 (130-154) 141 (130-165) 133 (117-153) 0.578 
Quality of life       
Overall health (Poor) # 38 (56%) 7 (16%) 8 (19%) 8 (19%) 16 (40%) 0.038 
Overall quality of life (Poor) # 27 (16%) 4 (9%) 3 (7%) 5 (12%) 15 (37%) 0.001 
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Blood Tests       
Cholesterol [6]  4.2 (3.8-4.8) 4.4 (3.9-4.8) 4.3 (3.7-4.9) 4 (3.8-4.7) 4.2 (3.7-4.9) 0.881 
Sodium [2] 140 (139-141) 140 (138-141) 140 (139-142) 140 (139-141) 140 (137-143) 0.954 
Potassium [5] 4.3 (4.1-4.6) 4.2 (3.9-4.6) 4.4 (4.1-4.5) 4.4 (4-4.6) 4.4 (4.1-4.7) 0.143 
Creatinine  [2] 98 (85-118) 93 (81-101) 95 (84-106) 101 (81-117) 120 (100-144) 0.0001 
Haemoglobin [1] 14.2 (13-15) 14.9 (14-15.5) 14.2 (12.9-14.9) 13.9 (13.5-14.7) 13.2 (12.2-14.7) 0.001 
Anaemia [1] 34 (19%) 2 (5%) 10 (23%) 6 (14%) 16 (36%) 0.001 
Urea [2] 5.8 (4.7-7) 5.2 (4.2-6) 6 (4.9-6.7) 5.6 (4.8-7) 6.9 (5.8-9.8) 0.0001 
Glucose [6] 5.7 (5.2-6.6) 5.7 (5.2-6.9) 5.7 (5.2-6.6) 5.8 (4.9-6.7) 5.8 (5.4-7.4) 0.338 
Outcome       
Death 36 (21%) 3 (7%) 4 (9%) 6 (14%) 23 (52%) 0.0001 
Death if in Sinus Rhythm 25 (14%) 3 (7%) 4 (9%) 4 (9%) 14 (32%) 0.0019 
Death within 12 months 8 (5%) 0 2 (5%) 0 6 (14%) 0.006 
Death >12 to 36 months 15 (9%) 2 (5%) 1 (2%) 3 (7%) 9 (20%) 0.011 
Cardiovascular Death 19 (11%) 1 (2%) 1 (2%) 6 (14%) 11 (25%) 0.0011 
Heart Failure Death 8 (5%) 0 0 0 8 (18%) 0.0001 
Sudden Death 12 (7%) 1 (2%) 1 (2%) 5 (11%) 5 (11%) 0.13 
Non-cardiovascular death 17 (10%) 2 (5%) 3 (7%) 0 12 (27%) 0.026 
Cancer Deaths 8 (5%) 2 (5%) 3 (7%) 0 3 (7%) 0.37 
SVT, Supra ventricular tachycardia; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; LBBB/ Pace/ ICD, left bundle 
branch block or pace maker or intra cardiac device. 
# Patients ranked quality of life on a seven-point scale with the worst three ranks (quite poor, poor and very poor) counted as poor.  
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The median (IQR) age of 70 (61-78) years for the whole population at the time of the index 
myocardial infarction in 1998 was and 37% were women. The median (IQR) age of the 175 
patients at the time of assessment was 68 (63-75) years and 42 (24%) were women. Prior 
histories of hypertension (n = 105; 60%), of transient or persistent heart failure (n = 73; 42%) 
and of diabetes (n = 32; 18%) were common. Q-waves were present on the ECG in 80 (46%) 
and left bundle brunch block (LBBB) in 18 patients, four patients were in a paced rhythm and 
two had implantable cardiac defibrillators (ICD).Patients in the highest quartile of NT-
proBNP were, on average, older (p=0.0001) (table 6.1) and more often had a history of heart 
failure (p=0.0001), paroxysmal or persistent atrial fibrillation (AF) (p=0.0001) and CABG 
(p=0.005). These patients were more likely to receive warfarin, ACE-inhibitors, loop 
diuretics and digoxin (Table 6.2) and to have LVSD, left atrial dilatation and moderate or 
severe mitral regurgitation (Table 6.3). Indeed, 38 (88%) of patients in the highest quartile of 
NT-proBNP had one or more echocardiographic features of cardiac dysfunction or atrial 
fibrillation versus only 28% (mainly left atrial dilatation) amongst patients in the lowest 
quartile. In a logistic regression model the relationship between NT-proBNP quartile and 
LVSD and LA dilatation remained significant after adjustment for age and creatinine. 
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Table  6-2Treatment during follow-up clinic. 
 
Table  6-3Imaging evidence of left ventricular function during follow-up clinic 
Variables (units) [missing data] Overall 1st 
Quartile<
13 
Pmol/L 
2nd 
Quartile 
13-35 
Pmol/L 
3rdQuarti
le>35-86 
Pmol/L 
4thQuartil
e>86 
Pmol/L 
p-value 
for trend 
N 175 43 44 44 44  
Echocardiography       
Major LVSD  51 (29%) 3 (7%) 9 (21%) 17 (39%) 22 (50%) 0.0001 
Left atrial (LA) dilatation [9] 73 (44%) 9 (21%) 15 (38%) 22 (54%) 27 (63%) 0.0001 
Moderate or severe mitral 
regurgitation [2] 
20 (11%) 0 1 (2%) 2 (5%) 17 (36%) 0.0001 
Moderate or severe disease of other 
valve[2] 
14 (8%) 1 (2%) 3 (7%) 3 (7%) 7 (16%) 0.03 
LVSD or Moderate or Severe Valve 
Disease [2] 
63 (36%) 4 (9%) 12 (27%) 19 (45%) 28 (64%) 0.0001 
LVSD or LA dilatation [6] 93 (57%) 11 (26%) 19 (48%) 29 (67%) 34 (79%) 0.0001 
Any of the Above [6] 97 (57%) 12 (28%) 19 (48%) 29 (67%) 37 (86%) 0.0001 
Any of the Above or AF 99 (59%) 12 (28%) 19 (48%) 30 (70%) 38 (88%) 0.0001 
LVSD = left ventricular systolic dysfunction. Major is LVEF <40% either measured or semi-quantitatively. 
Other valve disease: moderate or severe tricuspid or pulmonary valve disease. 
 
 
 
Variables (units) [missing 
data] 
Overall 1st 
Quartile<13 
Pmol/L 
2nd Quartile 
13-35 
Pmol/L 
3rdQuartile
>35-86 
Pmol/L 
4thQuartile>
86 Pmol/L 
p-
value 
N 175 43 44 44 44 
 
Treatments at f-up       
Aspirin  137 (79%) 38 (86%) 38 (84%) 37 (86%) 26 (59%) 0.003 
Clopidogrel  16 (9%) 3 (7%) 5 (11%) 5 (11%) 3 (7%) 0.786 
Warfarin [2] 16 (9%) 1 (2%) 1 (2%) 1 (2%) 13 (30%) 0.0001 
Statin  149 (85%) 39 (91%) 40 (91%) 38 (86%) 32 (73%) 0.055 
ACE inhibitors 86 (49%) 10 (23%) 19 (43%) 25 (57%) 32 (73%) 0.0001 
ARBs##  14 (8%) 4 (9%) 5 (11%) 3 (7%) 2 (5%) 0.666 
Beta-blockers  108 (62%) 22 (51%) 31 (71%) 30 (68%) 25 (57%) 0.197 
Nitrates  38 (22%) 10 (23%) 8 (18%) 8 (18%) 12 (27%) 0.681 
Nicorandil 18 (10%) 4 (9%) 3 (7%) 3 (7%) 8 (18%) 0.244 
Calcium channel blockers  29 (17%) 10 (23%) 5 (11%) 5 (11%) 9 (21%) 0.309 
Loop diuretic 53 (30%) 6 (14%) 8 (18%) 13 (30%) 26 (59%) 0.0001 
Thiazide diuretic 13 (7%) 6 (14%) 2 (5%) 3 (7%) 2 (5%) 0.290 
Digoxin 11 (6%)  1 (2%) 3 (7%) 7 (16%) 0.012 
Oral hypoglycaemic agent 14 (8%) 4 (9%) 2 (5%) 6 (14%) 2 (5%) 0.331 
ARBs, angiotensin–II receptor antagonists. 
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6.3.2 Long-Term Follow-up 
Median follow-up time was 1759 days (IQR 1548-1963). Of the 227 eligible patients who 
failed to attend the clinic or in whom no NT-proBNP value was obtained, 61 (27%) 
subsequently died. Of the 175 patients who had a measurement of NT-proBNP, 36 (21%) 
subsequently died prior to the 31st December 2009, of whom 23 (52%) were in the highest 
quartile of NT-proBNP (Figure 6.2). Twelve patients died suddenly, of whom 8 had heart 
failure, although this was severe in only one case. Five patients died primarily of progressive 
heart failure and it was contributory in a further four (one sudden death, one COPD deaths, 
one chest infection and one stroke death). Two patients died of stroke, six of infection 
(mainly pulmonary), eight of cancer and two died of other non-cardiac causes (dementia-
related). All of the heart failure deaths occurred in patients in the highest quartile of NT-
proBNP, while eleven of the twelve sudden deaths occurred in those with above median NT-
proBNP. However, non-cardiovascular deaths were also more common in the highest quartile 
of NT-proBNP. 
 
 
 
 
 
 
 
 
Figure  6-2Mortality within 12 month, 36months and by 31st December 2009 according to quartile of NT-
proBNP (Median and IQR 35 (13-86) pmol/L) 
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Fifty one patients had LVSD of whom 31 (61%) also had an NT-proBNP >50 pmol/L 
(median and IQR 100 (80-367)pmol/L) and 20 did not (median and IQR 28 (19-37)pmol/L) 
(Table 6.4). Of 124 patients with no LVSD, thirty five patients (28%) had an NT-proBNP 
>50pmol (median and IQR 124 (66-199)pmol/L) and 89 did not (median and IQR (14 (8-
27)pmol/L). Patients with an NT-proBNP >50pmol/L had a high mortality whether LVSD 
was present (42%) or not (43%). Patients with an NT-proBNP <50pmol/L had a lower 
mortality whether LVSD was present (10%) or not (7%). Indeed, only two of 109 patients 
with NT-proBNP <50pmol/L died within one year of assessment, compared to seven (11%) 
of 66 with NT-proBNP >50pmol/L. Echocardiography added little to the prognostic 
information provided by NT-proBNP alone (figure 6.3a, b and 6.4a, b). 
6.3.3 ROC curve 
Receiver-operator curves (ROC) suggest that 56pmol/L (474pg/ml) had the optimal 
sensitivity (78%) and specificity (77%) for predicting death (AUC 0.78, 95% CI=0.69, 0.87) 
(Figure 6. 4a).  If only patients (n = 152) in sinus rhythm (25 deaths) were included, the cut-
point was unchanged but sensitivity improved to 84% with some loss of specificity 68%. 
(Figure 6.4b). 
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Table  6-4Patients Characteristics recorded during follow-up clinic overall and classified according to the LVSD Y/N and NT-proBNP >50 
Variables (units) [missing data] Overall No LVSD with  
proBNP<25 
NoLVSD with 
proBNP25-50 
LVSD with 
proBNP<50  
No LVSD 
&proBNP>50 
LVSD & 
proBNP >50 
P-value 
n 175 64 25 20 35 31  
Age (years) [0] 68 (63-75) 66 (60-70) 70 (66-77) 65 (61-72) 72 (67-80) 70 (66-75) 0.005 
Women [0] 42 (24%) 15 (23%) 8 (32%) 4 (20%) 7 (20%) 8 (26%) 0.840 
Current smoker [3] 31 (18%) 12 (19%) 3 (12%) 5 (26%) 4 (11%) 7 (23%) 0.607 
Ex-smoker 103 (60%) 39 (63%) 16 (64%) 11 (58%) 23 (66%) 14 (45%)  
Non smoker 38 (22%) 11 (18%) 6 (24%) 3 (16%) 8 (23%) 10 (32%)  
History of Hypertension 105 (60%) 30 (47%) 16 (62%) 13 (65%) 27 (77%) 19 (61%) 0.055 
History of Diabetes 32 (18%) 6 (9%) 3 (12%) 5 (25%) 12 (34%) 6 (19%) 0.102 
History of heart failure 73 (42%) 18 (20%) 13 (28%) 11 (55%) 18 (51%) 25 (81%) 0.0001 
History of SVT 35 (20%) 4 (6%) 2 (8%) 1 (5%) 17 (49%) 11 (35%) 0.0001 
Prior CABG 46 (26%) 11 (17%) 3 (12%) 4 (20%) 14 (40%) 14 (45%) 0.005 
Prior PTCA 49 (28%) 20 (31%) 5 (20%) 7 (35%) 11 (31%) 6 (19%) 0.593 
Clinic ECG        
Heart Rate [1] 61 (54-70) 60 (55-64) 57 (51-68) 66 (54-72) 65 (56-74) 64 (58-81) 0.076 
AF (yes/no) 19 (11%) 0 0 0 12 (34%) 7 (23%) 0.0001 
Any Anterior Q-wave 28 (16%) 4 (6%) 6 (24%) 8 (40%) 2 (6%) 8 (26%) 0.0001 
Other pathological Q-wave 52 (30%) 21 (33%) 7 (28%) 5 (25%) 14 (40%) 5 (16%) 0.282 
LBBB/Pace/ICD 24 (14%) 2 (3%) 1 (4%) 5 (25%) 3 (9%) 13 (42%) 0.0001 
No Q-wave 71 (41%) 37 (58%) 11 (44%) 2 (10%) 16 (46%) 5 (16%) 0.0001 
QRS >120 [23] 29 (17%) 4 (6%) 2 (8%) 4 (20%) 7 (20%) 12 (39%) 0.0001 
Physical Examination        
NYHA I 94 (54%) 52 (81%) 16 (62%) 7 (35%) 14 (40%) 5 (16%) 0.0001 
NYHA II 60 (34%) 10 (16%) 8 (32%) 9 (45%) 16 (46%) 18 (58%)  
NYHA III/IV 21 (12%) 2 (3%) 1 (4%) 4 (20%) 5 (14%) 8 (26%)  
Body mass index [2] 27 (24-31) 28 (26-31) 28 (24-31%) 28 (25-32) 27 (25-30) 24 (22-28) 0.166 
Systolic blood pressure 139 (126-
154) 
143 (130-154) 141 (132-165) 131 (113-144) 144 (133-159) 121 (115-151) 0.004 
Blood Tests        
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Cholesterol [6]  4.2 (3.8-4.8) 4.4 (3.9-4.9) 4 (3.7-4.6) 4.2 (4.1-4.8) 4.2 (3.8-5) 4.2 (3.7-4.8) 0.768 
Sodium [2] 140 (139-
141) 
140 (139-141) 140 (140-142) 139 (138-141) 140 (139-142) 140 (138-141) 0.713 
Potassium [5] 4.3 (4.1-4.6) 4.2(4-4.5) 4.4 (4.1-4.6) 4.4 (4.1-4.8) 4.4 (4.1-4.6) 4.4 (4.1-4.6) 0.313 
Creatinine  [2] 98 (85-118) 92 (82-1100) 96 (85-108) 104 (88-113) 113 (91-143) 114 (100-126) 0.0001 
Haemoglobin[1] 14.2 (13-15) 14.6 (13.8-15.3) 13.9 (12.8-14.8) 13.8 (13.2-
14.4) 
13.6 (12.1-14.7) 14.2 (12.7-14.7) 0.010 
Anaemia [1] 34 (19%) 4 (6%) 6 (24%) 5 (25%) 13 (38%) 6 (19%) 0.013 
Urea [2] 5.8 (4.7-7) 5.4 (4.3-6.2) 5.8 (4.6-7.4 5.5 (5.1-6) 6.6 (5-9.4) 6.8 (5.7-7.8) 0.0001 
Glucose [6] 5.7 (5.2-6.6) 5.6 (5.2-6.5) 5.8 (5.4-6.5) 5.9 (5.2-6.9) 6.2 (5.5-8.9) 5.6 (5.1-6.3) 0.162 
Outcome        
Death 36 (21%) 4 (6%) 2 (8%) 2 (10%) 15 (43%) 13 (42%) 0.0001 
Death within 12 months 9 (5%) 0 0 2 (10%) 4 (11%) 3 (10%) 0.068 
Death >12 to 36 months 23 (13%) 3 (4%) 0 0 7 (20%) 5 (16%) 0.009 
Death if in Sinus Rhythm 25 (14%) 4 (6%) 2 (8%) 2 (10%) 9 (26%) 8 (26%) 0.02 
CV Death 19 (11%) 1 (2%) 1 (4%) 1 (5%) 10 (29%) 6 (19%) 0.002 
Heart Failure Death 9 (5%) 0 0 0 5 (14%) 4 (13%) 0.0034 
Sudden Death 12 (7%) 1 (2%) 1 (4%) 1 (5%) 6 (17%) 3 (10%) 0.051 
Non-CV death 16 (9%) 3 (5%) 1 (4%) 1 (5%) 4 (11%) 7 (23%) 0.045 
Cancer 8 (5%) 3 (5%) 1 (4%) 1 (5%) 0 3 (10%) 0.46 
SVT, Supra ventricular tachycardia; CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; LBBB/ Pace/ ICD, left bundle 
branch block or pace maker or intra cardiac device. CV = cardiovascular 
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Mortality within 12 months, 36months and by end of 2009 according to LVSD and NT-proBNP >50 pmol/L 
(423 pg/ml) 
 
 
 
 
 
 
Mortality within 12 months, 36months and by end of 2009 according to left atrial (LA) dilatation and NT-
proBNP>50 pmol/L (423 pg/ml) 
  
Figure  6-3Mortality within 12 months, 36months and by end of 2009 
according to (a) LVSD and (b) Lent atrial dilatation. 
10%
26%
42%
11%
29%
45%
10% 10% 10%
0% 3%
7%
-10%
0%
10%
20%
30%
40%
50%
60%
12 mths 36 mths Died by 2010
LVSD & NT-proBNP≥50 (N=31)
No LVSD & NT-proBNP≥50 (N=35)
LVSD & NT-proBNP<50 (N=20)
No LVSD & NT-proBNP<50 (N=89)
15%
33%
49%
0%
23%
41%
3% 3%
7%
3% 6%
7%
-10%
0%
10%
20%
30%
40%
50%
60%
12 mths 36 mths Died by 2010
LA Dil & NT-proBNP≥50 (N=39)
No LA Dil & NT-proBNP ≥50(N=22)
LA Dil & NT-proBNP<50 (N=34)
NoLA Dil & NT-proBNP<50 (N=72)
Azam Torabi  Incidence and outcome of MI 
132 
 
Figure  6-4 ROC Curve for all-cause mortality by 2010 
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Table  6-5Cox-regression models predicting mortality in patients attended for follow-up clinic during 2004 and 2005 (n=175). 
 
Variables ranked according to Wald χ2 value on univariate analysis 
 Univariate Multivariable with BNP Multivariable without BNP 
Variable Name HR Wald P value HR Wald P 
value 
HR Wald P- 
value 
NT-proBNP 
(pmol/L) 
1.004 (1.003-1.005) 44.178 0.0001 1.003 (1.000-1.005) 4.397 0.036    
NYHA III  7.572 (3.682-
15.573) 
30.278 0.0001 4.497 (1.359-14.878) 6.065 0.014 4.636 (1.450-
14.827) 
6.688 0.010 
Quality of life 1.807 (1.462-2.232) 30.024 0.0001 1.628 (1.137-2.331) 7.079 0.008 1.770 (1.240-2.524) 9.912 0.002 
Urea (mmol/L) 1.157 (1.079-1.241) 16.642 0.0001 1.052 (0.912-1.214) 0.492 0.483 0.981 (.867-1.111) 0.087 0.768 
Haemoglobin (g/dl) 0.672 (0.554-0.816) 16.183 0.0001 0.708 (0.538-.933) 6.026 0.014 0.669 (0.509-.881) 8.212 0.004 
Mitral regurgitation 4.282 (2.051-8.943 14.988 0.0001 0.582 (0.145- 2.336) 0.582 0.445 1.174 (.389-3.539) 0.081 0.776 
Age (years) 1.070 (1.031-1.111) 12.803 0.0001 1.077 (1.018-1.140) 6.646 0.010 1.083 (1.026-1.142) 8.451 0.004 
Atrial fibrillation 3.713 (1.717-8.028) 11.118 0.001 0.319 (0.065-1.577) 1.964 0.161 0.780 (0.228-2.669) 0.157 0.692 
NYHA II 3.653 (1.489-8.962) 8.006 0.005 1.895 (.539-6.659) 0.993 0.319 1.767 (.499-6.254) 0.779 0.377 
Left atrial dilatation 2.316 (1.174-4.569) 5.874 0.015 1.917 ( 0.795- 4.622) 2.098 0.147 1.854 (.773-4.444) 1.914 0.167 
LVSD* 1.951 (1.005-3.787) 3.902 0.048 1.037 (0.423- 2.539) 0.006 0.937 1.054 (0.442-2.515) 0.14 0.905 
Systolic BP 
(mm/Hg) 
0.985 (0.970-1.001) 3.549 0.060 0.993 (.975-1.011) 0.641 0.423 0.993 (.976-1.010) 0.670 0.413 
Sex (Men) 1.197 (0.543-2.635) 0.198 0.656 3.052 (1.146-8.130) 4.984 0.026 3.106 (1.162-8.306) 5.100 0.024 
Diabetes 1.074 (0.470-2.452) 0.029 0.886 1.780 (.726-4.366) 1.589 0.208 1.685 (.691-4.107) 1.318 0.251 
BMI (wt/h2) 0.998 (0.935-1.064) 0.005 0.943 1.000 (.992-1.008) 0.001 0.992 1.000 (.997-1.003) 0.001 0.981 
LVSD; left ventricular fat, BMI, body mass index 
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6.3.4 Cox regression 
In a multi-variable analysis, the strongest predictors of survival were age, NYHA class, 
quality of life, haemoglobin and NT-proBNP. Neither echocardiographic variables nor 
measures of renal function provided additional prognostic information (Table 6.5). The 
strongest echocardiographic predictor of an adverse outcome was the presence of moderate or 
severe mitral regurgitation, followed by left atrial dilatation and only then by the presence of 
LVSD but none entered the multi-variable model. When NT-proBNP was removed from the 
model, the relationship between death and quality of life and with haemoglobin became much 
stronger but echocardiographic measures or renal function still did not enter the model.  The 
presence of AF was a powerful univariate predictor of an adverse outcome, but after 
adjusting for NT-proBNP and, to a lesser extent, other variables tended to be associated with 
better outcomes.  
6.4 Discussion: 
This analysis suggests that screening long-term survivors of myocardial infarction using NT-
proBNP may be a useful method to identify patients with an adverse prognosis in whom a 
more aggressive diagnostic and treatment strategy is justified. Blood for NT-proBNP can be 
taken in the community and by non-specialists and sent using routine transport as for other 
standard blood tests to a central laboratory or measured using a point-of-care device. About 
one third of patients will have an NT-proBNP >50pmol/L, of whom about 42% will die 
within the subsequent 3 years compared to only 7% in those with an NT-proBNP <50pmol/L. 
An NT-proBNP >50pmol/L identified all nine deaths where heart failure (100%) was the 
primary or contributory cause, nine of twelve (75%) sudden deaths and 11 of 16 (69%) non-
cardiovascular deaths.  In the United Kingdom, patients who have had a myocardial 
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infarction are assessed annually thereafter to assess cardiovascular status and risk by their 
family doctor, who will often not have specialist cardiology knowledge or skill. Testing for 
NT-proBNP is simple, relatively inexpensive and identifies an adverse outcome with greater 
precision than more complex and expensive tests, such as echocardiography. Accordingly, it 
might be considered for inclusion as part of this routine assessment. Whether it needs to be 
done annually or less frequently requires further evaluation.  
Several previous reports [65 67 160] have suggested that NT-proBNP lacks sufficient 
sensitivity and specificity for the detection of LVSD to make it a useful clinical tool for 
clinical practice. The problem may lie with the deficiencies of cardiac imaging or in the way 
that it is reported rather than with NT-proBNP. Patients with LVSD and a normal NT-
proBNP had a fairly good prognosis. None died of heart failure in the subsequent three years 
and only one died suddenly four months after the test. This may be because patients who 
have a normal NT-proBNP have less severe LVSD or because the report on the 
echocardiogram was inaccurate and a false-positive result. Conventionally, an elevated NT-
proBNP in the absence of LVSD has been counted as a false positive. However, these 
patients have a poor outcome and the echocardiogram is usually not normal. Many of these 
patients have a dilated left atrium suggesting the presence of left ventricular diastolic 
dysfunction or mitral regurgitation. A prior history of hypertension was more common in 
patients with an elevated NT-proBNP and could be the cause of diastolic LV function. The 
diagnostic strength of NT-proBNP is its ability to identify patients with an adverse outcome 
for a variety of reasons, including both systolic and diastolic left and right ventricular 
dysfunction, atrial fibrillation, valve disease and renal dysfunction. The diagnostic weakness 
of NT-proBNP is its inability to distinguish the reasons why an adverse outcome is likely, 
which requires further investigation. 
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This study is rather small to draw confident conclusions about the ability of NT-proBNP to 
predict the mode of death. However, NT-proBNP appears to be a better predictor of death 
from progressive heart failure than of sudden death as reported previously in a large study 
[161]. It is rare for a patient to die of heart failure within the following few years unless NT-
proBNP is grossly elevated[161]. NT-proBNP also identifies an increased risk of sudden 
death[162] but risk begins to rise when NT-proBNP is only modestly elevated. NT-proBNP 
was also a surprisingly good predictor of non-cardiovascular deaths and again this is 
consistent with reports that NT-proBNP is at least as good at predicting all-cause mortality as 
it is in predicting cardiovascular deaths [162], Patients with cancer or lung disease may be 
more likely to die if they have serious underlying heart disease, whilst lung congestion may 
be a substrate for lung infection. On the other hand, lung disease may cause pulmonary 
hypertension and right ventricular overload[39] and cancers may cause wasting, leading to 
cachexia and cardiac dysfunction [163].  
An increase in NT-proBNP was associated with many adverse prognostic factors and may 
have little to add to them as noted in some other clinical settings[62]. However, NT-proBNP 
is simple to administer, relatively inexpensive and objective. The assay has high precision 
although day-to-day variation reflecting diet and other physiological variations may be 
substantial. NT-proBNP performed better when patients with atrial fibrillation were excluded 
from the model. Other data suggests that the relationships between NT-proBNP, other 
measures of cardiac function and prognosis are disturbed in the presence of atrial fibrillation. 
For a given plasma concentration of NT-proBNP, patients with atrial fibrillation will have 
less evidence of important cardiac dysfunction [164] and a better prognosis [162].  
The prevalence of echocardiographic abnormalities and the risk of death both increase 
progressively as NT-proBNP rises. NT-proBNP is a continuous variable with a wide 
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distribution. The higher the NT-proBNP, the worse the outlook. Any threshold value used to 
identify disease or risk is, to some extent, arbitrary. Accordingly, it may be better to use a 
system of graduated risk rather than a single threshold. For instance, in our clinical practice, 
NT-proBNP <25pmol/L is considered low-risk and requiring no special actions while values 
>50pmol/L are of concern and require investigation. Values between 25-50pmol/L are 
considered a ‘grey-zone’ requiring repeat NT-proBNP evaluation and more intensive control 
of traditional risk-factors rather than referral for further investigation. 
This analysis has many limitations. Many patients died prior to the study. Other studies show 
that NT-proBNP is a powerful marker when measured early after a myocardial infarction [50 
51]. A major limitation of this analysis is that 54% of surviving patients did not attend. 
Mortality in this group was 27%; very similar to that observed in the studied cohort (21%).  
The number of deaths in this analysis is relatively small and therefore we had limited 
statistical power [44 165]. 
6.5 Conclusion: 
In patients who have had a myocardial infarction and survived several years, an elevated NT-
proBNP identifies those with an adverse prognosis in whom investigation and more intensive 
treatment may be justified. Echocardiography provides little or no additional prognostic 
information but may inform therapeutic choices. 
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7 Chapter 7: The Incidence and Outcome of Patients 
Hospitalised for Acute Coronary Syndrome in 2005. The Hull 
Infarction Project. 
7.1 Background 
Although acute coronary syndromes (ACS), including myocardial infarction (MI), are 
common, there is a lack of robust epidemiological data about their incidence [74]. Case 
ascertainment and selection could have a major impact on incidence and outcome statistics. 
This creates difficulty in planning appropriate resources, doubt about the efficacy of coronary 
prevention at a population level and uncertainty about the overall effectiveness of 
management of acute coronary syndromes.   
In late 1998 the United Kingdom launched the Myocardial Infarction National Audit Project 
(MINAP) and required all hospital trusts to report all MIs initially and subsequently a much 
broader range of patients [166]. Between 2000 and 2002, more than 100,000 cases had been 
reported to MINAP [167 168]. These reports suggest that the quality of care for ACS in the 
UK is good or excellent. However, there are deep concerns about the completeness of the 
MINAP returns and case-selection which could distort the true pattern of care. 
We conducted a retrospective audit of all patients coded for MI in our region in 1998. This 
identified 896 patients of whom 562 (63%) developed heart failure and 480 (54%) died 
during approximately six years’ follow-up [107]. We now report a new audit of MIs 
occurring in 2005 from the same region using the same and three additional methods for 
case-ascertainment. This gave us the opportunity of comparing the hospital incidence of MI 
using three different approaches and of making a historical comparison from the same region 
at a time of major changes in treatment and services.  
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7.2 Methods 
7.2.1 Study population 
One hospital group in Hull and the East Riding of Yorkshire (UK) provides all the acute 
cardiac services for about 560,000 people, of whom about 300,000 are aged >35 years, living 
in a geographically distinct part of the United Kingdom. Patients who were transferred from 
another region were excluded from all analyses. The Hull Infarction Project (HIP-2005) 
employed specialist cardiac nurses to try to identify all patients with acute coronary 
syndrome (ACS) admitted during 2005to the acute assessment or cardiac monitoring units 
and other medical wards. Case records were reviewed to verify the medical diagnosis, use of 
loop diuretics, and concentrations of troponin T (TnT), which used a conventional (non high-
sensitivity) assay at this time. Results of imaging tests were obtained whenever available and 
treatment at discharge was recorded. The hospital information department was asked to 
provide all death and discharge data for acute MI and patients reported to MINAP in 2005. 
We also received a report of all positive (>0.03ug/L) troponin T (TnT) tests done by the 
hospital laboratory, the sole provider of the service to the region. Survival status was 
recorded until 31st December 2008.  
7.2.2 HIP-2005 Definitions 
Acute coronary syndrome was defined as a diagnosis made by a cardiologist or, if the TnT 
was elevated, by a cardiac specialist nurse or a non-specialist doctor. ACS was sub-classified 
as an MI or unstable angina by cardiologists. When the cardiologist did not specify, patients 
who had an elevated TnT or ST segment elevation on the electrocardiogram were considered 
to have had a MI and those who did not were reported as unstable angina. Patients with 
sudden death or cardiac arrest that was considered likely to be due to an acute coronary 
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syndrome were included in the survey and considered to have had an MI if they had left 
bundle branch block or ST segment elevation or had a pre-existing increase in TnT. 
Assessments of left ventricular function within one year of admission were recorded. Criteria 
for left ventricular systolic dysfunction were left ventricular ejection fraction (LVEF) < 40 % 
or a qualitative report of moderate or severe left ventricular systolic dysfunction on 
echocardiography, first-pass radionuclide ventriculography, or contrast angiography. TnT 
was defined as positive if >0.03ug/L and strongly positive if >1.0ug/L.  
7.2.3 MINAP criteria: 
MINAP seeks to enrol all patients with symptoms suggestive of an acute coronary syndrome 
admitted to hospital in England and Wales (population about 50 million)[169], although we 
suspect, in practice, that many hospitals report only patients who have been considered for 
thrombolysis or coronary intervention. From January 2004 until March 2005, 88,782 patients 
were reported to have had an MI by MINAP [170] although only 49,116 discharges were 
reported from March 2008 until March 2009 [171]. The discharge diagnosis of ACS is made 
by the medical staff caring for the patient in the light of standard investigations including 
clinical history, ECG and troponin. Patients’ data are entered by clinical audit staff into a 
central database [131 169].  
7.2.4 Hospital Coding System: 
The coding department has specialised coding staff who review and code the case-notes of all 
deaths and discharges regardless of cause, including data from post-mortem examinations. 
The codes are used to generate central returns to the NHS and for reimbursement. Acute MI 
was coded as I21 and complications following acute MI as I23. These codes are recorded on 
an electronic patient administration system.  
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7.2.5 Laboratory-positive troponin T (TnT): 
TnT (Roche Diagnostics) is only measured in a single laboratory in the region. All results are 
stored on an electronic data-base. Values >0.03ug/L are considered positive. 
7.2.6 Statistical Analysis 
Data were entered into a Microsoft Excel database then imported into Access database and 
analysed using SPSS (version 16.0). Categorical data are presented as percentages. 
Continuously distributed data are presented as median and inter-quartile range (IQR). 
Estimating the probability of death at day 30, one year and three years was calculated by 
using moving average estimator curves in patients who had TnT report after dividing them 
into patients with and without a diagnosis of ACS. 
7.3 Results 
7.3.1 Overall Results 
Of 1764 admission identified with ACS by HIP-2005, 33 were excluded from further analysis 
because they had been transferred from another region. This left 1439 unique patients with 
1731 admissions for the main analysis, of which 292 were readmissions within the same year, 
including 148 with one readmission and 55 with multiple readmissions. Of the 1,731 
admissions identified in HIP-2005, 764 (704 patients and 60 readmissions) were classified as 
MI and 967 (735 patients and 232 readmissions) as angina (Figure 7.1a). Of 1,439 patients 
with ACS identified by HIP-2005, there was a prior history of hypertension in 541 (38%), MI 
in 246 (17%) and diabetes in 227 (16%). During the index hospitalization, only about half 
were managed, at least in part, by a consultant cardiologist and only 199 (14%) patients had 
percutaneous transluminal coronary angioplasty (PTCA). 
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Using the hospital information department, only 552 admissions with MI (544 patients and 8 
readmissions) were identified and using MINAP, only 206 admissions (203 patients and 3 
readmissions) for MI. (Figure 7.1b and c). 
 
Figure  7-1Incidence of ACS and myocardial infarction (MI) in (a) HIP, (b) HID and (c) MINAP 
 
 
 
 
 
 
 
 
 
 
Flow diagram showing the incidence of ACS and myocardial infarction (MI) identified by (A) the Hull 
Infarction Project (HIP), (B) the Hospital Information Department (HID), (C) the Myocardial Infarction 
National Audit Project (MINAP) and (D) Laboratory report of troponin T (TnT) during 2005 and sequence of 
mortality until end of 2008. See text for details 
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 Cohort from HIPP ACS Admission 
n=1764 
ACS Admission in 2005 n=1731 
(292 was readmission) 
MI Admission 
(n=764) 
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(n=967) 
Readmission 
(n=232) 
Patients with 1st Admission (n=735) 
12 died during first admission 
Readmission 
(n=60) 
Exclusion 
Patients with 1st Admission (n=704) 
78 died during first admission 
Alive by end of 
2008 (n=501) 
Died by end of 2008 
(n=125) 
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(n=626) 
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(n=723) 
Alive by end of 
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Died by end of 
2008 (n=86) 
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 Cohort from HID-MI Admission 
n=590 
MI Admission in 2005  
n=552 
Other region (n=38) 
Patients with 1st Admission (n=544) 
104 died during first admission 
Exclusions 
Readmission 
(n=8) 
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(n=342) 
Died by end of 2008 
(n=98) 
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 Cohort from MINAP 
n=211 
MI Admission in 2005  
n=206 
Other region (n=5) 
Patients with 1st Admission (n=203) 
10 died during first admission 
Exclusions 
Readmission 
(n=3) 
Alive by end of 2008 
(n=174) 
Died by end of 2008 
(n=19) 
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(n=193) 
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Of the 764 admissions (704 patients) identified by HIP-2005 with MI, 388 (381 patients) 
were also identified by hospital discharge codes and 186 (183 patients) by MINAP. Hospital 
discharge codes identified an additional 164 admissions (163 patients) with MI not identified 
by HIP-2005, of whom 140 patients had an elevated TnT, including 80 who had values 
>1.0ug/L. In addition, five patients were identified as MI by MINAP but not by other 
methods; two of these were identified as angina by HIP-2005, three had a negative troponin 
and two had no record of troponin being measured. Overall, the three methods of surveillance 
identified 933 admissions (872 patients) with MI and 1896 admissions (1,603 patients) with 
ACS (figure 7.2, 7.3a and 3b). 
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2005 (n=856)a   
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2008 (n=563) 
died by end of 
2008 (n=197) 
 
Discharged (n=760) 
Repeated TNT and other 
region (n=621) 
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Figure  7-2Incidence of myocardial infarction in all three data-sets (HIP, HID and MINAP) 
 
Flow diagram showing the incidence of myocardial infarction in all three data-sets (Hull Infarction Project 
(HIP), Hospital Information Department (HID) and the Myocardial Infarction National Audit Project (MINAP)) 
during 2005 and sequence of mortality during index admission, 30 days, one year and until 31 December 2008. 
See text for details. 
  
 
All MI patients identified by HIP, HID 
and MINAP during 2005 n=872  
(from 933 admission for MI) 
Discharged index admission 
n=726 
Died during index admission 
n=146 
Survived index admission until 31 
days from index n=715 
Died between discharge 
and day 30 n=11 (1.3%) 
Died between day 31 and 
one year n=61 
Survived one year after index 
admission n=654 
Died by end of 2008 
n=307 (35.2%) 
Survived until end of 2008 
n=565 (64.8%) 
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Figure  7-3patients with (a) MI and (b) ACS  identified by HIP, HID and MINAP with highest TnT during 
any ACS admission in 2005 
a: 
 
Venn diagram showing patients with MI identified by the Hull Infarction Project (HIP) (n=704), patients with 
MI identified by the Hospital Information Department (HID) (n=544) and patients with MI identified by the 
Myocardial Infarction National Audit Project (MINAP) data (n=203) with highest troponin T (TnT) during any 
acute coronary syndrome admission in 2005, (positive (+ve), >1 and not reported (NR) TnT). 
  
N=5
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TnT+: 8
TnT>1: 6
NR TnT: 1 
N=15
TnT+: 13
TnT>1: 11
NR TnT: 1 
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b: 
 
Venn diagram showing patients with acute coronary syndrome (ACS) identified by HIP (n=1439), patients with 
MI identified by hospital information department (HID) (n=544) and patients with MI who identified by 
MINAP data (n=203) with highest troponin T (TnT) during any acute coronary syndrome admission in 2005. 
(positive (+ve), >1 or not reported (NR) TnT). 
 
 
N=3
TnT+: 0
TnT>1: 0
NR TnT: 1
N=146
TnT+: 126
TnT>1: 68
NR TnT: 18
N=173
TnT+: 170
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NR TnT: 7
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TnT>1: 11
NR TnT: 1
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Table  7-1Patient characteristics recorded during the index admission 
Data are median (inter-quartile range) and number occurring (%) 
Variables  ACS-HIP 
[missing data] 
MI-HIP 
[missing data] 
MI-
HID[missing 
data] 
MI-
MINAP[missing 
data] 
TnT +ve Only 
[missing data] 
Any Case 
[missing data] 
n 1439 704 544 203 823 2,426 
Age (years) 67 (58-77) 69 (59-78) 71 (60-80) 65 (56-73) 77 (69-84) 72 (61-81) 
Age>75-men 181 (21%) 113 (24%) 95 (27%) 18 (13%) 211 (47%) 440 (32%) 
Age>75-women 224 (38%) 117 (49%) 102 (54%) 18 (29%) 250 (67%) 511 (50%) 
Women 591 (41%) 241 (34%) 189 (35%) 63 (31%) 375 (46%) 1029 (42%) 
TnT>0.03ug/L 724 (50%) [34] 678 (98%) [13] 510 (99%) [27] 191 (96%) [4] 823 1698 (71%) [51] 
TnT>1.0 a ug/L 324 (23%)[34] 323 (47%)[13] 335 (65%) [27] 163 (82%) [4] 85 (10%) 491 (21%) [51] 
Loop Diuretic ug/L 305(21%) 162(23%) n 15 (12%) [81] n n 
Aspirin 1027 (71%)[2] 517 (74%)[2] n 144 (97%) [55] n n 
ACE inhibitor 589 (41%)[1] 374 (53%)[1] n 121 (92%) [71] n n 
Angiotension receptor blocker 
(ARB) 
82 (6%)[1] 30 (4%)[1] n 2 (3%) [127] n n 
Beta-blocker 873 (61%)[1] 473 (67%)[1] n 120 (91%) [71] n n 
Aldosterone Antagonist  59 (4%)[1] 37(5%)[1] n 5 (4%) [82] n n 
Statin 979 (68%) 513 (73%) n 132 (95%) [64] n n 
Report on LV Function Available 703 [736] 409 [295] 293 [251] 125 [78] 298 [525] 1055 [1371] 
LVSD 236 (34%) 173 (42%) 142 (48%) 47 (38%) 134 (45%) 401 (38%) 
In-Patient Mortality 87 (6%) 78 (11%) 104 (19%) 10 (5%) 209 (25%) 342 (14%) 
30-day Mortality 96 (7%) 84 (12%) 101 (19%) 12 (6%) 187 (23%) 343 (14%) 
One year Mortality 179 (12%) 134 (19%) 149 (27%) 19 (9%)  334 (41%) 597 (25%) 
Overall Mortality by end of 2008 301 (21%) 203 (29%) 202 (37%) 29 (14%) 472 (57%) 877 (36%) 
Any case, all ACS-HIP (MI and unstable angina in HIP), MI HID, MI MINAP and TnT +ve; ACS, acute coronary syndrome; MI, myocardial 
infarction; HIP, Hull Infarction Project; HID, Hospital Information Department; MINAP, Myocardial Infarction National Audit Project; TnT +ve, 
positive troponin T. Any case means a patient who belonged to any one of the other groups. 
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The laboratory reported 7,945 TnT tests (2,300 with positive TnT) in 5,852 patients during 
2005. After excluding patients from other regions, of 1679 patients with a positive TnT, 823 
patients were not reported as ACS by any of the other three routes of ascertainment. Eighty 
five (10%) of these had values of TnT>1ug/L. These patients were older than other groups 
(Figure 7.1d and Table7.1). 
The characteristics of the patients using each survey method are shown in table 7.1. The 
median age of the patients identified by HIP-2005 with ACS was 67 (interquartile range 
(IQR) 58-77) years, and with MI was 69 (IQR 59-78) years compared to 71 (IQR 60-80),65 
(IQR 56-73) and 77 (IQR 69-84) years identified by HID, by MINAP and by a positive TnT 
only. The proportion of women in each group was 591 (41%), 241 (34%), 189 (35%), 63 
(31%) and 375 (46%) respectively.  
In HIP-2005, ST segment elevation (STEMI) was present in 328 (23%) patients on their first 
admission and an additional 9 patients had STEMI during readmission. Seventy one (5%) 
patients had left bundle branch block (LBBB), of whom 43were diagnosed as angina and 28 
were managed as MI. Thrombolysis was given to 227 of 356 (64%) patients during their first 
admission and an additional 4 patients on readmission. The ‘door to needle’ time was 
available for228admissions and the median time was 30 minutes (IQR 20-63).  This 
compares to 203 patients with STEMI or MI with LBBB identified by Hull MINAP (of 
whom three had a further readmission with STEMI), of whom 197 got thrombolysis with a 
door to needle time of 30 (IQR 20-51) minutes. Similar data were not available for patients 
identified by the hospital information department or laboratory TnT. 
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7.3.2 Mortality according Troponin T (TnT) during first admission in all patients 
identified by HIP-2005, HID, MINAP and Lab positive TnT 
Overall 2,426 patients were identified by HIP-2005, HID, MINAP or a positive TnT as 
potentially having an ACS. Of these, TnT was <0.03ug/L in 708, >0.03 to 1.0ug/L in 1188, 
>1.0 ug/L in 474 and was not done in 56 patients (Figure 7.4). Of 708 patients with 
TnT<0.03ug/L, 84 (12%) had died by 2009 of whom seven (1%) died during the index 
hospitalization and 42 (6%) during the first year. Of 1188 patients with TnT 0.04 to 1.0ug/L, 
582(49%) patients had died by 2009of whom 220 (19%) died during the index hospitalization 
and 393 (49%) during the first year. Of 474 patients with TnT>1.0ug/L, 180 (38%) patients 
died, of whom 86(18%) died during the index hospitalization and 133 (28%) during the first 
year.  
Of 1662 patients with an elevated TnT, only 839 (50%) were diagnosed with ACS by one of 
the survey methods. Of 1547 patients with ACS by at least one survey method, 708 (46%) 
had a negative TnT. There was a dramatic increase in mortality in patients with values of 
TnT>0.03ug/L but mortality was similar regardless of concentration above this level (Figure 
7.5). Patients with a positive TnT who were not identified to have ACS by one of the survey 
methods had a worse prognosis (41%) at one year than those with ACS, whether they were 
TnT positive (23%; p=0.0001) or not (6%; p=0.0001). This was also true at 30 days and at 3 
years (Figure 7.5). 
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Figure  7-4Mortality by end of 2008 from first admission in all patients with ACS 
 
Mortality by end of 2008 from first admission in all patients with ACS identified by HIP, MI identified by HID, 
MINAP and positive Troponin T (TnT) during 2005 according to TnT measured during first admission.  
# note that number may be smaller than for index admission because some people died during an index 
admission that lasted >30 days. 
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n=2426 
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(n=1188) 
TnT negative 
 (n=708) 
TnT not reported 
(n=56) 
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30 day N=9 (1%)# 
Total N=84 (12%) 
Index N=7 (1%) 
One year N=42 (6%) 
180 day N=22 (3%) 
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Total N=31 (55%) 
Index N=29 (52%) 
One year N=29 (52%) 
180 day N=29 (52%) 
30 day N=96 (21%)# 
Total N=180 (38%) 
Index N=86 (18%) 
One year N=133 (28%) 
180 day N=126 (27%) 
30 day N=211 (18%)# 
Total N=582 (49%) 
Index N=220 (19%) 
One year N=393 (33%) 
180 day N=329 (28%) 
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Probability of death within 30-day, one-year and 3-year according to the troponin T level during index 
admission in all patients identified by HIP, HID, MINAP or by positive TnT (n=2426), patients identified as an 
ACS or MI by HIP, HID or MINAP (n=1547) and in patients with no diagnosis of ACS but positive Troponin T 
(TnT) during 2005 (n=823) (56 patients with no report of TnT were excluded).  
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Figure  7-5Probability of death within 30-day, one-year and 3-yearaccording to the troponin T level during index 
admission 
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7.3.3 Loop diuretic and survival subsequent to discharge and by end of 2008 in 
patients with ACS identified by HIP-2005 
Information on diuretic treatment was available in 1439 ACS patients from HIP-2005. Of 703 
patients with TnT<0.03ug/L, 698 survived the index admission of whom 126 (18%)were, and 
572 were not, discharged on a loop diuretic, of whom 34 (27%) and 42 (7%) subsequently 
died. Of 700 patients with TnT>0.03ug/L included in HIP-2005, 633 survived the index 
admission of whom 144(23%) were, and 489(77%) were not, discharged on a loop diuretic, 
of whom 67 (47%) and 69 (14%) subsequently died (Figure 7.6). 
Figure  7-6Survival until end of 2008 in patients with a first admission with ACS identified by HIP 
 
Survival until end of 2008 in patients with a first admission with ACS identified by HIP according to treatment 
with loop diuretic at discharge. Troponin T (TnT) measured during first admission. 
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7.3.4 Loop diuretics and left ventricular function 
Of 1352 patients with ACS identified by HIP-2005 who survived the index admission, no 
record of an assessment of LV function could be identified for 685 (51%) patients from their 
case notes or hospital systems during the subsequent year. Of 667, who had LV function 
assessed, 206 (30%) had LVSD. Mortality was 31% in those with LVSD, 12% in those 
without LVSD and 14% for those who had no reported assessment of LV function. 
7.4 Discussion 
This report demonstrates that the incidence of ACS is highly dependent on the method of 
ascertainment, with a ten-fold difference depending on the criteria applied. Identifying a high 
proportion of those who have ACS or MI is important when assessing therapeutic 
intervention rates and outcomes provided by services. An audit may appear excellent when 
applied to a subset of carefully selected patients but when applied to all those requiring care 
may appear poor. No single survey method identified more than 60% of the total possible 
population with ACS of 2,426 patients. The incidence of MI seems only slightly less 
dependent on the method of ascertainment with a three-fold difference between MINAP and 
HIP-2005 assessments. The high mortality amongst patients with a positive TnT but who 
were not identified by any other survey method gives cause for concern and is the subject of 
further investigation. Clearly, surveys that focus on cardiology wards and interventions are 
likely to miss many patients admitted elsewhere with ACS, especially in high risk groups 
such as older people or those with other important medical co-morbidities.  
Our data from 2005 suggest an annual incidence of MI of 1.56 per thousand population, of 
ACS 2.86 per thousand and of ACS or positive TnT, 4.33 per thousand. In our region, using 
MI identified by hospital discharge statistics alone, the incidence of MI has dropped by 40% 
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from 1.66 per thousand per year in 1998 to 0.97 in 2005. This compares to 64,436 admissions 
in England for acute MI using hospital episode statistics, which gives a rate of 1.29 per 
thousand in 2005 [16].Of these, 49,017 patients were reported as STEMI [172] and 13,489 
with non-STEMI [173], which suggests substantial under-reporting of non-STEMI. These 
incidence rates appear lower than historical reports from the UK [16]. However, the reports 
have often quoted rates excluding younger people from the denominator rather than using the 
whole population. If only people aged >35 years are considered, as has been done 
previously[74], then our local incidence of MI is closer to three per thousand. This is 
remarkably similar to the rate of clinically overt myocardial infarction reported in the 
Hypertension Outcomes Trial (HOT) [174] in 1998. However, these data are also likely to be 
an underestimate of the rate of MI in the community, as up to 30% of people with an MI may 
die before they reach hospital[8 9], and up to 40% of patients do not have symptoms that 
either cause them to seek medical attention or be referred to hospital [10 11 12 174].  
With improvement in the diagnostic tests for MI we may expect that the incidence of MI 
should increase, especially that of non-STEMI that would otherwise be defined as unstable 
angina in the absence of a marker of myocardial damage. In our region, in 2005, the 
diagnosis of MI was based on Troponin T which had a higher sensitivity for diagnosis of MI 
compared to creatine kinase/CK-MB in 1998. A higher sensitivity Troponin-T assay has now 
been introduced will further increase the proportion of ACS that is defined as MI. Assuming 
the incidence of ACS does not change, the incidence of MI will rise. The detection of still 
smaller MIs will also lead to an apparent improvement in prognosis. Only adjustment of risk 
for other prognostic markers will enable detection of any real improvement in outcomes for 
MI. However, high-sensitivity Troponin-T will also increase the number of false-positive test 
results.   Based on hospital discharge statistics alone, there appeared to be a 40% fall in the 
incidence of MI between 1998 and 2005. This might be a true effect and reflect improved 
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management through recommendations for lifestyle changes, better management of 
hypertension, widespread use of statins and appropriate revascularisation procedures [134]. In 
1998, only 45% of MI patients were treated with statins in 1998 compared to 73% and 95% 
in HIP and MINAP data respectively during 2005. Alternatively, it is possible that treatments 
have had a greater impact on the size and severity of MI than on its incidence. Retrospective 
access to plasma from a large, representative cohort of patients with ACS in order to measure 
high-sensitivity Troponin-T would be necessary to investigate this possibility further. 
Ultimately, lack of rigorous case-ascertainment and consistent diagnostic criteria thwart the 
accurate description of the incidence of MI and whether it has changed. However, there 
seems little doubt that the age-adjusted prognosis of MI has improved dramatically in the last 
decade, provided the patients is referred to and reaches hospital. 
About half of patients with a positive TnT were not identified as having ACS by any of the 
survey methods. There are reasons other than ACS for elevation in TnT, including strenuous 
exercise, heart failure, trauma, renal failure, sepsis, pulmonary embolism and myocarditis 
[175 176]. Undoubtedly, some of our patients with elevated TnT that were not identified in 
our surveys will not have had ACS. However, it is also likely that the diagnosis of ACS was 
missed in some cases and uncertain in others. For instance, in patients with heart failure, TnT 
is often elevated, especially although not exclusively during acute exacerbations [177]. Post-
mortem data suggests a substantial rate of sub-clinical myocardial infarction in patients with 
heart failure dying suddenly or from progressive deterioration [81 82]. The high mortality 
rate amongst patients with elevated TnT who were not identified with ACS may well indicate 
a group of patients with high rates of heart and renal failure. This requires further exploration 
of patient characteristics and the contribution of myocardial damage to the elevated troponin 
and poor outcome. 
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In contrast to a previous report[178], on a much smaller patient population, we found that 
three month mortality was similarly high in patients with modest or substantial increases in 
TnT. Our hospital policy is to conduct, for most patients, a single TnT measurement at least 
12 hours after the onset of symptoms. Single measurements may be a poor guide to the extent 
of myocardial damage. Alternatively, even modest increases in TnT may indicate the 
presence of unstable plaque and the threat of further events that provoke arrhythmias or cause 
substantial cardiac damage.  
The outcome from myocardial infarction in our unselected population remains very different 
from that reported amongst patients in randomised controlled trials of ACS. The exclusion of 
high-risk, elderly patients with multiple co-morbidities from trials probably accounts for most 
of the disparity. However, failure to refer patients for cardiology advice and failure of 
cardiologists to undertake timely intervention may also contribute to poor outcomes. 
However, in-patient mortality for MI has dropped from 22% in 1998, a mortality that was 
consistent with the international GRACE score, to 11% in 2005, although some of the 
difference might be accounted for by differences in survey method. Use of more sensitive 
assays and new diagnostic criteria may increase the incidence of MI by detecting small 
infarcts that, in turn, may lead to an apparent decrease in the incidence of heart failure and of 
mortality after MI. Patients with small MIs have a low incidence of heart failure and a good 
prognosis. Improved detection and treatment of small MIs may reduce the rate of recurrent 
events and delay or prevent the development of heart failure in the longer term. However, in 
the short- to medium-term, the incidence and of heart failure and prognosis will be driven by 
patients who have sustained a large MI and if such cases are not prevented or managed 
effectively, the incidence of heart failure in the community may be little affected. Moreover, 
if patients with extensive MI who would have died of shock or heart failure on the index 
admission are managed well, they are highly likely to be discharged with or soon develop 
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chronic heart failure. Good management of MI could thus increase the incidence and 
prevalence of heart failure at the same time as improving prognosis.  
Since this survey, a regional primary angioplasty service has been implemented for STEMI 
that may improve outcomes. However, standards of care appear much worse as case 
ascertainment increases, which is probably true of any hospital practice. As noted in the 
present study and previous studies here [107] and elsewhere [179], it is patients who develop 
clinical evidence of heart failure who fare particularly badly. Heart failure precedes the 
majority of deaths after myocardial infarction [180]. 
 
7.5 Conclusion 
The incidences of ACS and MI are highly dependent on the method of case ascertainment but 
incidence rates of patients hospitalised with MI appear to have fallen in the last decade. 
Failure to identify older, high-risk patients leads to over-optimistic estimations about the 
prognosis of ACS, underestimation of the resources needed to manage it and misleading 
perceptions about the adequacy of care that may lead to complacency. TnT and use of 
diuretics appear simple clinical markers of prognosis. Even slight elevation in TnT indicates a 
poor outcome whether or not a patient is diagnosed with ACS. 
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Appendices 
1. Consultant Letter 
University headed paper 
Dear Dr ………Trust Consultant …. 
I am a research fellow working for Professor John Cleland in the Academic Department of 
Cardiology of the University of Hull, based at Hull & East Yorkshire Hospitals Trust.  I am 
working on a research project studying the occurrence of heart failure in patients who 
suffered an MI in 1998 and to investigate the predictive capacity of N-terminal B Natriuretic 
Peptide (NT-BNP) in heart failure. 
I am seeking your agreement and help in recruiting patients who, following the occurrence of 
an MI in 1998, either were either admitted under your care or are currently under your care.  
In line with Caldicott principles, the first contact with these individuals should be from the 
clinician who either cared for them at the time of the infarct or are currently caring for them.  
The patients (see attached list) were identified to me by the Information Department.  Should 
you approve that your patients can participate in this study, I would be most grateful if you 
would sign the attached template letter.  I will then make copies of the template letter, add to 
the copies the name and address of each patient and arrange for the letters to be sent to them.  
If you have any objections please notify Professor Cleland in writing. 
Circulatory levels of NT-BNP are known to increase when heart function is impaired.  By 
measuring the level of NT-BNP in patients with suspected heart failure, it may be possible to 
filter-out patients who do not require further assessment, thereby reducing hospital waiting 
times for echocardiography and specialist referral.  It may therefore be possible for us to 
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assess heart function using just a blood test.  However, the amount of NT-BNP in the blood is 
also increased if kidney function is impaired and as such it is not yet clear whether this test 
alone can be used to distinguish between heart and kidney problems.  It is therefore possible 
that measuring NT-BNP levels in combination with a test for kidney function may be very 
useful indeed. 
This study requires the patient to visit the Department of Academic Cardiology, Hull Royal 
Infirmary, for blood tests (including NT-BNP and renal function (urea)).  Patients will be 
reimbursed travel expenses or provided with transport to the Department.  If the level of NT-
BNP is high, they will be asked to return for further tests for heart failure including an ECG 
and an echocardiogram.  They may also be asked to wear a 24 hour ambulatory ECG.  The 
patient may also be invited to participate if they have a normal level of NT-BNP in order to 
act a control group. 
I would be grateful if you would indicate whether you would like to be informed of patients’ 
test results. 
You will be informed should any patient agree to participate. 
Thank you for your consideration, 
Yours sincerely, 
 
Dr A Torabi  
Research Fellow in Cardiology 
Dept of Academic Cardiology  
Floor 3, Haughton Building 
Hull Royal Infirmary 
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Anlaby Road 
Hull, HU3 2JZ 
Phone 01482 675016. 
Cc Patient’s GP 
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2.Consultant letter to patient 
 
 
Dear…………. 
I am writing to invite you to take part in a research study.  The study is being carried out, by 
the Department of Cardiology, the University of Hull, based at Hull & East Yorkshire 
Hospitals Trust.  As well as being a research department, the Unit also runs cardiology clinics 
as part of the NHS program to provide care for heart patients in Hull and East Riding.  You 
have been contacted because you were in the care of a consultant at this hospital with a heart 
attack in 1998. 
What is this study about? 
We are currently inviting people who had a heart attack in 1998 to volunteer to take part in a 
research study that we hope will help doctors to find a simpler way to check for heart 
damage.  
The current way that doctors check for heart damage is expensive and time consuming We 
would like to test a new, quick and inexpensive blood test that measures a substance present 
in our blood, called N-terminal brain natriuretic peptide (or more simply, NT-BNP).  More 
NT-BNP is thought to be in our blood when the heart has not made a full recovery. 
It is hoped that this simple blood test will enable doctors to detect and treat heart problems 
earlier than is currently possible.  It will also help the NHS to use its resources more 
effectively because the test may help GPs to decide which patients are more likely to need 
assessment by a hospital specialist. 
 
What does taking part involve? 
If you decide that you would like to take part (or you would like more information) about the 
study we ask that you contact us on the telephone number at the end of this letter to arrange a 
date to visit us.  During your visit to us, we will discuss the study with you in more detail and 
you will be given time to decide if you would like to take part. You can discuss taking part 
with family, friends or even your GP.  If you do agree to take part, we will ask you to do the 
following: 
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- provide a sample of blood to allow the level of NT-BNP and some other routine 
blood tests to be measured. 
- have some further tests, such as an Echocardiogram (to look at the heart beating, a 
bit like the scan used to look at babies during pregnancy) and an 
Electrocardiogram, or ECG (to look at how your heart is performing). 
- you may also be asked to wear a smaller walkman-like version of the ECG, called an 
Ambulatory ECG, to record your heart’s performance for 24 hours.  This will be 
attached to you by sticky tape.  You will be asked to wear it when you go home and 
to return it to us the following day. 
 
Please remember, your participation in this study is voluntary, and your care in the NHS will 
not be affected if you do not decide to take part.  Your local doctor has been informed about 
this study.  If you agree to take part, your doctor will be informed of that decision too. 
 
What do I do now? 
 
If you would like to take part in this study please telephone our reception on: 
01482 624073 
You can also call this number if you feel that you might like to take part, but you need to 
know more about the study before you decide what to do. Dr Azam Torabi, the study’s 
researcher, will be pleased to discuss the study with you. 
Yours sincerely, 
 
Prof JGF Cleland, or Drs Alamgir, Caplin or Kaye 
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3. Patient Information Leaflet 
 
A Study to Assess the Use of NT-BNP 
as a Marker of Cardiac Dysfunction in Post-MI Patients 
You are invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with others if you 
wish.  Ask us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not to take part. 
 
Thank you for reading this. 
 
About NT-BNP 
We have known about the existence of Coronary Artery Disease for many years. We know 
that people with Coronary Artery Disease are more likely to develop heart problems. 
Improvements in modern medicine have improved the treatment of heart disease, but, 
unfortunately, some people still develop these problems. Detecting these problems early will 
alert your doctor so that treatment can be discussed with you that may stop or slow down 
their development. 
 
It has recently been discovered that the level of a substance produced in blood - called “N-
terminal B NatriureticPeptide” or NT-BNP for short -increased when heart function was 
impaired.This discovery may allow us to assess heart function as well as kidney function by a 
simple blood test.  At the moment, however, assessing heart function is much more complex 
and requires special heart scans. However, the amount of NT-BNP in the blood is also 
increased if kidney function is impaired. Therefore, it is not yet clear whether this test alone 
can be used to distinguish between heart and kidney problems. It is therefore possible that 
NT-BNP combined with a simple test for kidney function may be very useful indeed.   
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In order to resolve these uncertainties, we wish to measure NT-BNP along with 
routine tests for heart and kidney function in about 700 people with Coronary Artery 
Disease.  
We are receiving some support for the study from a company called Roche 
Diagnostics, who are developing the kit to measure NT-BNP. The company will have 
access to the data we acquire, but only in an anonymised form.  
 
Study Requirements 
If you agree to take part, we will invite you to the hospital for approximately 11/2 
hours. We will take blood from you for measuring NT-BNP and to check your kidney 
function. 
We will ask you a standard set of questions that we ask all patients who attend our 
special clinics for heart problems.  
You will be asked to blow into a machine so that we can ensure that any 
breathlessness you might have is not due to lung problems.  
Special heart tests include: 
• anelectrocardiogram (ECG) This measures small electrical signals from 
your heart muscle using wires attached to your chest, arms and legs by sticky 
tape. 
• possibly a 24 hour ambulatory ECG. This takes about half an hour. We may 
then attach you to a 24 hour ECG tape machine (a bit like a ‘Walkman’) using 
wires and sticky tape and you will go home. You will return 24 hours later to 
have the tape removed or we can arrange for the tape to be picked up. 
• anechocardiogram (ECHO) This uses sound waves to build a picture of 
your heart moving inside your chest (a bit like the scan used to look at babies 
during pregnancy). You will be asked to lie on your side on a couch in a 
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darkened room. Some warm jelly will be put on your chest and a plastic 
probe pressed against your skin. 
 
What are the potential risks and inconveniences for me? 
There are no potential risks to you if you take part in this study. You will be required 
to visit our Department to give a blood sample and undergo some tests as described 
above.  You may experience some bruising as a result of giving the blood. 
If we do identify important heart or kidney problems, the results will be discussed 
with you and your GP and the best available advice and treatment offered. Your GP 
will be informed of your participation in this study. 
 
Your Rights 
You are under no obligation to take part in the study. You may withdraw at any time. 
If you withdraw it will in no way affect your future care. 
All blood samples will be stored securely with in the Department for an indefinite 
period.  They will be anonymised so that only staff working within the Department 
can trace the samples directly to you.  All computerised data will be anonymised in 
the same manner and stored on password-protected computers within the Trust.  
Some data will be shared with Roche in order that they can develop their NT-BNP 
assay, but your confidentiality will be kept at all times.  We may use the blood 
samples for other heart failure related studies but we will obtain your consent before 
we do this. 
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If you have decided to take part in the study, you will be asked to sign a consent 
form, a copy of which will be given to you.  You will also be asked to sign a second 
consent form to join another study being run in this clinic called the Heart Care 
Study.  The Heart Care Study is a large study that looks at the health of the heart 
during regular visits to the department to the clinic.  If you agree to take part in the 
Heart Care Study, you will be asked to visit the clinic on average three times a year 
and it will also allow us to use the results of your tests in both studies. 
You are under no obligation to take part in the second study and your healthcare will 
not be affected by your decision. 
More details about the Heart Care Study are available upon arrival at the clinic, or 
alternatively can be sent to you upon request. 
 
If you would like more information or would like to speak to someone please contact: 
Dr Azam Torabi, Research Fellow in Cardiology, Academic Department of 
Cardiology, 3rd Floor Haughton Building, Hull Royal Infirmary, Anlaby Road HULL 
HU3 2JZ. Telephone 01482 675016. 
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4.Patient Consent Form 
Consent Form 
 
A Study to Assess the Use of NT-BNP 
as a Marker of Cardiac Dysfunction after a 
Heart Attack (MI) 
(The Post-MI NT-BNP Study) 
 
Name of Researcher: Dr Azam Torabi,  
Academic Cardiology, Hull Royal Infirmary 
Telephone 01482 675016 
 
1. I confirm that I have read and understood the information sheet dated  
20 April 2004  (version 4.0) for the above study and have been given a  
copy to keep.  I have had the opportunity to ask questions and understand that  
my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, and without my medical care or legal rights being affected. 
 
2. I give permission for my medical records to be looked at and information 
taken from them to be analysed in strict confidence by the team. 
Subsequent data collected will be kept anonymous and can be used for 
scientific publications. 
 
3. I understand that the medical information collected may be shared with  
Roche (who make the NT-BNP measurement kits) anonymously so that  
it will not be possible for Roche to identify me personally. 
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4. I agree that the anonymised data and samples obtained from me during 
this study may be used in future heart care related studies. 
 
5. I understand that information on me will be stored on a secure  
computer and that analyses will be conducted confidentially. 
This information may be used for scientific publications but my identitywill remain 
anonymous 
 
6. I agree to take part in the above study. 
 
__________________________ ______________  __________________ 
Name of Patient   Date    Signature 
 
__________________________ ______________  __________________ 
Name of Person taking consent Date    Signature 
 
__________________________ ______________  __________________ 
Researcher    Date    Signature 
 
 
1 for patient; 1 for researcher; 1 to be with hospital notes 
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5. Gp letter 
Dear Dr …………. 
Re: <<patient name, DOB, address, unit number>>. 
Your patient has attended the Department of Academic Cardiology and provided an informed 
consent to participate in the Post MI Study and Heart Care Study  
The Post MI Study involves investigating the occurrence and current status of heart failure in 
all patients who suffered an MI in 1998 and also attended Hull and East Yorkshire hospitals. 
Prior to contacting the patient, permission of the Consultant Cardiologists to contact the 
patient was obtained. 
The tests involved include blood tests (haemoglobin, urea & electrolytes and NT-BNP – a 
marker of cardiac dysfunction) an ECG, an echocardiogram and possibly a 24-hour tape. 
As per the normal practice of this Department’s Heart Care Study, a QED report is enclosed 
for your information. 
Should you wish for further information, please contact me on the number below. 
Yours sincerely, 
Dr Azam Torabi 
Research Fellow in Cardiology 
Dept of Academic Cardiology  
Floor 3 Haughton Building, 
Hull Royal Infirmary 
Anlaby Road 
Hull 
HU3 2JZ 
Telephone 01482 675016 
 
